

From: [Safronet, David \(PHAC/ASPC\)](#)
Sent: 2018-05-30 10:58 AM
To: [Qiu, Xiangguo \(PHAC/ASPC\)](#)
Cc: [Drebot, Mike \(PHAC/ASPC\)](#)
Subject: Re: Nipha and Ebola viruses requested by China CL4 lab

We would need a letter from their BSO to confirm they can accept and safely handle these viruses. Personally I don't believe in MTAs for these materials but we would need to look into Agency regulations.

Dave

[Sent from my BlackBerry 10 smartphone on the Rogers network.](#)

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: Wednesday, May 30, 2018 9:27 AM
To: Safronet, David (PHAC/ASPC)
Cc: Drebot, Mike (PHAC/ASPC)
Subject: Nipha and Ebola viruses requested by China CL4 lab

Hi Dave,

The CL4 of China from Wuhan has contacted me for possibility to receive Nipha and Ebola viruses from us. If possible, what paper work needs to be done beside the import permit from them and export permit from us? MTA?

Pls advise!

Thanks!

Qiu

From: 3rd party
Sent: 2018-07-10 11:50 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: 3rd party
3rd party [He, Shihua](#)
(PHAC/ASPC)
Subject: Re: RE: Re: request letter of EBOV & NiV

Dear Dr. Qiu,

We will deal with it strictly as you wish. I'm sorry for the trouble caused you because I didn't quite catch your meaning before!

Tomorrow we will draft a new agreement "between scientists", if you have more specific requirements for these viruses, please feel free to tell me, we will keep your request together on the terms of the new agreement.

Best wishes,

3rd

-----原始邮件-----

发件人:"Qiu, Xiangguo (PHAC/ASPC)"

发送时间:2018-07-10 21:34:18 (星期二)

收件人: 3rd party

3rd party, "He, Shihua
(PHAC/ASPC)"

主题: RE: Re: request letter of EBOV & NiV

Dear 3rd party

I just went through the draft MTA your Institute initiated.

I am afraid I can't sign it as I don't have the authority, even our Chief of Special Pathogens can't sign it as it is still formal MTA and none of the scientists is entitled to sign. It has to be go through our IP office.

I am sorry for this situation but there is really not much I can do on our side with the MTA. Hope there is another way around.

Best,

Qiu

Xiangguo Qiu, M.D

Head, Vaccine Development & Antiviral Therapy

Special Pathogens Program
National Microbiology Laboratory
Public Health Agency of Canada
1015 Arlington Street H2410
Winnipeg, MB R3E 3R2
Adjunct Professor
Dept. of Medical Microbiology
University of Manitoba
Ph: 1-204-789-5097 (lab)
1-204-784-7548(O)
Fax: 1-204-789-2140
email: xianguo.qiu@canada.ca

From: 3rd party [REDACTED]
Sent: 2018-07-10 6:11 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: 3rd party [REDACTED] He, Shihua (PHAC/ASPC)
Subject: Re: Re: request letter of EBOV & NiV

Dear Dr. Qiu,

Thank you again for your strongly support!

According to the content of the communication this morning, please check the attached MTA we have drafted.

After you confirm the content, would you please sign and send it back to us before July 12th? Thank you!

Please feel free to contact us if you have any questions.

Best wishes,

3rd party [REDACTED]

[REDACTED]
Wuhan Institute of Virology, Chinese Academy of Sciences
Xiao Hong Shan 44,
430071 Wuhan, Hubei

P.R. China

Tel/Fax: 3rd party

发件人 : [Qiu, Xiangguo \(PHAC/ASPC\)](#)

发送时间 : 2018-07-09 20:52

收件人 : 3rd party

抄送 : 3rd party [He, Shihua \(PHAC/ASPC\)](#)

主题 : Re: 回复: 回复: request letter of EBOV & NiV

Dear 3rd party,

The MTA will be initiated by our IP office. I will check with them and try my best to push. But again, MTA usually takes quite long time in our agency. I can't guarantee the MTA will be ready by Thursday. Sorry about this.

Again, generally speaking, MTA usually is requested by the Institute which provides the materials, I don't understand why MTA is has be in place in this case if PHAC doesn't request it? Most of these viruses are from outbreak isolates and technically no one owns the IP.

Best,

Qiu

Sent from my BlackBerry 10 smartphone on the Rogers network.

From: 3rd party

Sent: Monday, July 9, 2018 2:49 AM

To: Qiu, Xiangguo (PHAC/ASPC)

Cc: 3rd party

Subject: 回复: 回复: request letter of EBOV & NiV

Dear Dr. Qiu,

In order to promote the import of pathogens, the leaders of our institute will have a coordination meeting with the entry-exit inspection and quarantine department next week to negotiate on the import of highly pathogenic pathogens. Therefore, we need to complete the submission of the EBOV and NiV import application materials as soon as possible this week to enter the list of consultations.

The most important materials of the online declaration is MTA, if the other materials need more time, could you please prepare MTA first and send it to us before July

12th?

If there is anything we can do, please feel free to contact us.

Looking forward to your reply!

Best wishes,

3rd
party

Wuhan Institute of Virology, Chinese Academy of Sciences

Xiao Hong Shan 44,

430071 Wuhan, Hubei

P.R. China

Tel/Fax: 3rd party

Email: 3rd party

发件人 : 3rd party

发送时间 : 2018-07-04 10:33

收件人 : xiangguo.qiu

抄送 : 3rd party

主题 : 回复: RE: request letter of EBOV & NiV

Dear Dr. Qiu,

Thank you very much for this useful information. The PDF version of request letter and biological safety laboratory assurance are attached.

According to requirements of the Entry-Exit Inspection and Quarantine Bureau in China, the materials we still need to submit are as follows:

1. MTA;

2. Descriptive materials of the virus strains, including the biological characteristics, sterilization, inactivation methods and effectiveness. The quickest way to prepare this material is that you can provide relevant articles with the required information instead, and I will prepare the descriptive materials.

3. Test report. Please see the attached template for your reference.

If you have any questions in preparing these materials, please feel free to contact us.

Best wishes,

3rd
party

Wuhan Institute of Virology, Chinese Academy of Sciences

Xiao Hong Shan 44,

430071 Wuhan, Hubei

P.R. China

Tel/Fax: (3rd party)

发件人 : [Qiu, Xiangguo \(PHAC/ASPC\)](#)

发送时间 : 2018-07-04 05:58

收件人 : 3rd party

抄送 : 3rd party

主题 : RE: request letter of EBOV & NiV

Dear 3rd party,

The letters look good to me. Pls can you send it as PDF file and send it to me again? The person who is in charge on our side is on vacation this week and hopefully we can start the paper work next week.

Attached is our CL4 annually recertification for this year and let me know if you need anything else.

Best regards,

Qiu

Xiangguo Qiu, M.D

Head, Vaccine Development & Antiviral Therapy

Special Pathogens Program

National Microbiology Laboratory

Public Health Agency of Canada

1015 Arlington Street H2410

Winnipeg, MB R3E 3R2

Adjunct Professor

Dept. of Medical Microbiology

University of Manitoba

Ph:1-204-789-5097 (lab)

1-204-784-7548(O)

Fax: 1-204-789-2140

email: xianguo.qiu@canada.ca

From: 3rd party [REDACTED]

Sent: 2018-06-28 5:40 AM

To: Qiu, Xiangguo (PHAC/ASPC)

Cc: 3rd party [REDACTED]

Subject: request letter of EBOV & NiV

邱教授：

您好！

关于EBOV和NiV的引进，非常感谢您一直以来为我们提供的大力支持和帮助！

按照我们之前沟通的内容，我单位已经按照之前商量的事项拟好了request letter和生物安全声明，电子版请见附件，请您审阅。不知是否满足贵单位的要求？

如有问题或者还有任何我们可以做的，敬请随时联系！

祝好

3rd [REDACTED]

3rd party [REDACTED]

Wuhan Institute of Virology, Chinese Academy of Sciences

Xiao Hong Shan 44,

430071 Wuhan, Hubei

P.R. China

Tel/Fax: 3rd party [REDACTED]

[REDACTED]

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-09-10 2:36 PM
To: [Drew, Tracy \(PHAC/ASPC\)](#)
Cc: [Safronetz, David \(PHAC/ASPC\)](#); [Leung, Anders \(PHAC/ASPC\)](#)
Subject: viruses to be exported to China
Attachments: Certification of Biological Safety Laboratory Assurance-20180628.pdf; request letter-20180628.pdf

Follow Up Flag: Follow up
Flag Status: Completed

Hi Tracy,

Pls see attached for the request letter from Wuhan Institute of Virology, Chinese Academy of Sciences and let me know if there are any concerns/questions.

Dave, we had discussed this some time ago and you are agreed to send the viruses once all the documents are in place.

Thanks!

Qiu

From: [Safronetz, David \(PHAC/ASPC\)](#)
Sent: 2018-09-14 6:18 PM
To: [Richards, Hannah \(PHAC/ASPC\)](#); [Robertson, Catherine \(PHAC/ASPC\)](#)
Cc: [Drebot, Mike \(PHAC/ASPC\)](#); [Guercio, Steven \(PHAC/ASPC\)](#); [Gilmour-lit, Matthew \(PHAC/ASPC\)](#)
Subject: Re: viruses to be exported to China

Sounds like a plan. Let's meet up on Monday morning. I doubt any of the internal paper work has been started yet.

Dave

Sent from my Samsung Galaxy smartphone.

----- Original message -----

From: "Richards, Hannah (PHAC/ASPC)"
Date: 2018-09-14 3:44 PM (GMT-06:00)
To: "Robertson, Catherine (PHAC/ASPC)"
Cc: "Safronetz, David (PHAC/ASPC)" , "Drebot, Mike (PHAC/ASPC)" , "Guercio, Steven (PHAC/ASPC)" , "Gilmour, Matthew (PHAC/ASPC)"
Subject: RE: viruses to be exported to China

Hi Dave

I will touch base with you early next week to see what stage the paperwork was at for Tracy's side of this process - I can then better track the related TA and associated paperwork and then follow up on my end with documentation that might already be in process.

In the interim, can you send me the original attachment/application from Qiu (as indicated at the start of this email chain) as a starting point for me to review. Do you know if a transfer application (SES-F-052) was already submitted for processing?

From there, I will work with your section and the requesting lab, as well as reach out the key personnel for MTAs/MoUs, as required.

Thanks very much!

Have a lovely weekend.

Hannah

Hannah Richards

A/Safety Officer

National Microbiology Laboratory | Laboratoire national de microbiologie

Public Health Agency of Canada | Agence de la santé publique du Canada

1015 Arlington Street

Winnipeg, Canada R3E 3R2

hannah.richards@canada.ca

Telephone | Téléphone 204-789-5005

Government of Canada | Gouvernement du Canada

From: Robertson, Catherine (PHAC/ASPC)

Sent: 2018-09-14 3:24 PM

To: Richards, Hannah (PHAC/ASPC)

Cc: Safronetz, David (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Guercio, Steven (PHAC/ASPC);

Gilmour, Matthew (PHAC/ASPC)

Subject: Fw: viruses to be exported to China

Hi dave,

Hannah is acting for Tracy and will help in getting the paperwork in place. Hannah acted for Allan last time so she is aware of the transfer approval process. Please contact Hannah directly,

Cathy

Sent from my BlackBerry 10 smartphone on the Bell network.

From: Safronetz, David (PHAC/ASPC)

Sent: Friday, September 14, 2018 9:59 AM

To: Gilmour, Matthew (PHAC/ASPC); Robertson, Catherine (PHAC/ASPC)

Cc: Drebot, Mike (PHAC/ASPC); Guercio, Steven (PHAC/ASPC)

Subject: Re: viruses to be exported to China

We would of course not send anything out without appropriate paper work, MTAs, certifications , letters from BSOs etc. They are requesting material from us due to collaboration with dr. Qiu.

Historically it's also been easier to obtain material from us as opposed to US labs. I don't think other , closer labs have the ability to ship these materials. We can certainly ask about their stocks and see if we can get some.

Dave

Sent from my Samsung Galaxy smartphone.

----- Original message -----

From: "Gilmour, Matthew (PHAC/ASPC)"

Date: 2018-09-14 9:17 AM (GMT-06:00)

To: "Safronetz, David (PHAC/ASPC)" , "Robertson, Catherine (PHAC/ASPC)"

Cc: "Drebot, Mike (PHAC/ASPC)" , "Guercio, Steven (PHAC/ASPC)"

Subject: RE: viruses to be exported to China

Hi Dave,

I have some concerns here.

- No certifications are provided, they simply cite they have them.
- What is the nature of the work, and why are our materials required? (ie. these are surely available from other, more local labs).
- MTA's would be required, not generic 'guarantees' on their storage and usage.
- Are there materials that they have that we would benefit from receiving? Other VHF? High path flu?
- Good to know that you trust this group. How did we get connected with them?

Matt

From: Safronetz, David (PHAC/ASPC)

Sent: 2018-09-12 2:13 PM

To: Robertson, Catherine (PHAC/ASPC)

Cc: Drebot, Mike (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)

Subject: FW: viruses to be exported to China

Hi Cathy,

We haven't heard back from Tracey regarding this. Is there any issues from your perspective to send out these isolates? I trust the lab and would be personally fine to sign off for SP.

Dave

From: Qiu, Xiangguo (PHAC/ASPC)

Sent: 2018-09-10 2:36 PM

To: Drew, Tracy (PHAC/ASPC)

Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)

Subject: viruses to be exported to China

Hi Tracy,

Pls see attached for the request letter from Wuhan Institute of Virology, Chinese Academy of Sciences and let me know if there are any concerns/questions.

Dave, we had discussed this some time ago and you are agreed to send the viruses once all the documents are in place.

Thanks!

Qiu

From: [Robertson, Catherine \(PHAC/ASPC\)](#)
Sent: 2018-09-20 4:09 PM
To: [Richards, Hannah \(PHAC/ASPC\)](#); [Drew, Tracy \(PHAC/ASPC\)](#)
Cc: [Safronetz, David \(PHAC/ASPC\)](#)
Subject: FW: viruses to be exported to China
Attachments: Certification of Biological Safety Laboratory Assurance-20180628.pdf; request letter-20180628.pdf

Follow Up Flag: Follow up
Flag Status: Completed

Hi Ladies,

I'm not sure if you are are of this request from Dave. I may have asked you this already but I've **personal info** Can someone please contact Dave to follow up and see what he needs form us?

Thanks,

cAthy

Catherine Robertson
 Director, Biorisk and Occupational Safety Services
 Public Health Agency of Canada
 National Microbiology Laboratory
 1015 Arlington Street
 Winnipeg
 Manitoba R3E 3P6
 Tel: 204 789-6079 (office)
 204-229-8275 (cellphone)
 Fax: 204 789-2069
 e-mail: catherine.robertson@canada.ca

From: Safronetz, David (PHAC/ASPC)
Sent: 2018-09-12 2:13 PM
To: Robertson, Catherine (PHAC/ASPC)
Cc: Drebot, Mike (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)
Subject: FW: viruses to be exported to China

Hi Cathy,

We haven't heard back from Tracey regarding this. Is there any issues from your perspective top send out these isolates? I trust the lab and would be personally fine to sign off for SP.

Dave

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-09-10 2:36 PM
To: Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Subject: viruses to be exported to China

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-10-25 5:23 PM
To: [Leung, Anders \(PHAC/ASPC\)](#); [Drew, Tracy \(PHAC/ASPC\)](#)
Cc: [Safronetz, David \(PHAC/ASPC\)](#)
Subject: RE: viruses to be exported to China
Attachments: NML transfer application for pathogens and toxins-WIV-20181018.pdf

Hi all,

Pls see attached for the signed form and returned by our Chinese colleagues .

Thanks!

Qiu

From: Leung, Anders (PHAC/ASPC)
Sent: 2018-10-25 10:57 AM
To: Drew, Tracy (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Hi Tracy,

We have the forms filled out, we are just waiting for signatures from the China BSOs.

Thanks!
Anders

From: Drew, Tracy (PHAC/ASPC)
Sent: 2018-10-25 9:24 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Morning Qiu,

Are you still planning on sending samples to China. If so, please fill out the SES-F-052 form (attached), and return it back to me.

Thank you

Tracy Drew
Safety Officer
1-204-789-7638/1-204-784-5986
Winnipeg, Manitoba, Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-10-06 9:54 AM
To: Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC); Krishnan, Jay (PHAC/ASPC); Robertson, Catherine (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Hi Tracy,

Thanks for the following up. We will drop the form off once it is completed!

Best,

Qiu

From: Drew, Tracy (PHAC/ASPC)
Sent: 2018-10-01 11:12 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Morning Qiu,

Just touching base on the China shipment. Once the SES-F-052 form has been completed, please drop it off via email or in person.

Thanks

Tracy Drew
Safety Officer
1-204-789-7638/1-204-784-5986
Winnipeg, Manitoba, Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de

l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

From: Drew, Tracy (PHAC/ASPC)
Sent: 2018-09-21 11:01 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC); Richards, Hannah (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Morning Qiu

Sorry for the delay. **personal info**

Thank for you providing the letter that the lab is in fact able to handle the pathogen in question. We still need to complete the transfer form, SES-F-52A (attached to this email).

Please drop off the form when it is completed,
Thanks

Tracy Drew
Safety Officer
1-204-789-7638/1-204-784-5986
Winnipeg, Manitoba, Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-09-10 2:36 PM
To: Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Subject: viruses to be exported to China

Hi Tracy,

Pls see attached for the request letter from Wuhan Institute of Virology, Chinese Academy of Sciences and let me know if there are any concerns/questions.
Dave, we had discussed this some time ago and you are agreed to send the viruses once all the documents are in place.

Thanks!

Qiu

From: [Safronetz, David \(PHAC/ASPC\)](#)
Sent: 2018-09-21 9:14 AM
To: [Richards, Hannah \(PHAC/ASPC\)](#); [Robertson, Catherine \(PHAC/ASPC\)](#); [Drew, Tracy \(PHAC/ASPC\)](#)
Subject: Re: viruses to be exported to China

Follow Up Flag: Follow up
Flag Status: Completed

I don't think there is a huge urgency on this shipment been a bit a a crazy week for me **pers**
onal
 will be back in the lab next Friday.

Dave

Sent from my Samsung Galaxy smartphone.

----- Original message -----

From: "Richards, Hannah (PHAC/ASPC)"
Date: 2018-09-21 9:08 AM (GMT-06:00)
To: "Robertson, Catherine (PHAC/ASPC)" , "Drew, Tracy (PHAC/ASPC)"
Cc: "Safronetz, David (PHAC/ASPC)"
Subject: RE: viruses to be exported to China

Hi Cathy,

Just trying to connect with Dave to be brought up to speed; we have been missing each other this week.

Will try to touch base next week, or if Tracy is back, I will leave it in her hands ☺

Cheers

Hannah

Hannah Richards

A/Safety Officer

National Microbiology Laboratory | Laboratoire national de microbiologie

Public Health Agency of Canada | Agence de la santé publique du Canada

1015 Arlington Street

Winnipeg, Canada R3E 3R2

hannah.richards@canada.ca

Telephone | Téléphone 204-789-5005

Government of Canada | Gouvernement du Canada

From: Robertson, Catherine (PHAC/ASPC)
Sent: 2018-09-20 4:09 PM
To: Richards, Hannah (PHAC/ASPC); Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC)
Subject: FW: viruses to be exported to China

Hi Ladies,

I'm not sure if you are are of this request from Dave. I may have asked you this already but I've **personal info**. Can someone please contact Dave to follow up and see what he needs form us?

Thanks,

cAthy

Catherine Robertson

Director, Biorisk and Occupational Safety Services
Public Health Agency of Canada
National Microbiology Laboratory
1015 Arlington Street
Winnipeg
Manitoba R3E 3P6
Tel: 204 789-6079 (office)
204-229-8275 (cellphone)
Fax: 204 789-2069
e-mail: catherine.robertson@canada.ca

From: Safronetz, David (PHAC/ASPC)

Sent: 2018-09-12 2:13 PM

To: Robertson, Catherine (PHAC/ASPC)

Cc: Drebot, Mike (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)

Subject: FW: viruses to be exported to China

Hi Cathy,

We haven't heard back from Tracey regarding this. Is there any issues from your perspective to send out these isolates? I trust the lab and would be personally fine to sign off for SP.

Dave

From: Qiu, Xiangguo (PHAC/ASPC)

Sent: 2018-09-10 2:36 PM

To: Drew, Tracy (PHAC/ASPC)

Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)

Subject: viruses to be exported to China

Hi Tracy,

Pls see attached for the request letter from Wuhan Institute of Virology, Chinese Academy of Sciences and let me know if there are any concerns/questions.

Dave, we had discussed this some time ago and you are agreed to send the viruses once all the documents are in place.

Thanks!

Qiu

Capes, Jennifer (PHAC/ASPC)

From: [third party](#)
Sent: 2018-10-15 10:41 PM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: [third party](#)
Subject: RE: [third party](#) || DG Shipment to Wuhan Institute of Virology

Follow Up Flag: Follow up
Flag Status: Flagged

Hekki Xiang,

Thank you for your feedback.

Please confirm shipment dims to determine packaging required.

Regards,

[third party](#)
[Redacted]
[Redacted]
[Redacted]

[Redacted]
[Redacted]
[Redacted]
[Redacted]

[Redacted]
[Redacted]
[Redacted]

[Redacted]
[Redacted]
[Redacted]
[Redacted]

[Redacted]
[Redacted]

From: Qiu, Xiangguo (PHAC/ASPC) [mailto:xiangguo.qiu@canada.ca]
Sent: 15 October 2018 10:49
To: [third party](#)
Cc: [third party](#)
Subject: RE: [third party](#) || DG Shipment to Wuhan Institute of Virology

Dear [third party](#),

Thanks for the following up and sorry for the delayed reply.

We don't have an exact date yet at this points as some of the paper work (import permit and export permit, etc). Once we got all the documents ready, I will give you the date for shipment.

*required temperature: -160oC(ship on dry ice)

*needed supplies (box, data loggers, dry ice): yes to all.

Best regards,

Xiangguo Qiu, M.D
Head, Vaccine Development & Antiviral Therapy
Special Pathogens Program
National Microbiology Laboratory
Public Health Agency of Canada
1015 Arlington Street H2410
Winnipeg, MB R3E 3R2

Adjunct Professor
Dept. of Medical Microbiology
University of Manitoba
Ph:1-204-789-5097 (lab)
1-204-784-7548(O)
Fax: 1-204-789-2140
email: xiangguo.qiu@canada.ca

From: third party
Sent: 2018-10-15 7:33 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: third party
Subject: RE: third party || DG Shipment to Wuhan Institute of Virology

Hello,

Please advise when the samples will be ready for pick –up and if you need any supplies from Word Courier. Thank you.

Regards,

third
part
y

[Redacted signature block]

third party

third party [redacted]
[redacted]

[redacted]
[redacted]
[redacted]
[redacted]
[redacted]

[redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]

[redacted]
[redacted]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

From: third party [redacted]
Sent: 09 October 2018 07:59
To: 'xianguo.qiu@canada.ca'
Cc: third [redacted]
Subject: RE: third party || DG Shipment to Wuhan Institute of Virology

Hello,

I would like to follow up on this shipment. Thank you

Regards,

third [redacted]

third party [redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]
[redacted]

third party

From: **third party**
Sent: 30 September 2018 13:13
To: 'xiangguo.qiu@canada.ca'
Cc: **third**
Subject: **third party** | | DG Shipment to Wuhan Institute of Virology

Hello,

We received a shipment request for an Ebola virus shipment from your location going to Wuhan Institute of Virology in China. Please provide the paperwork and permit for this shipment and confirm the following--

- *ready date/ time
- *required temperature
- *needed supplies (box, data loggers, dry ice)

Thanks,

third

Title: NML Transfer Application for Pathogens and Toxins
Date Issued: 2017-02-08

Form #: SES-F-052A-8

TRANSFEROR			
Section Head/ Designate:	David Safronetz		Contact Person: Xiangguo Qiu
NML Location:	<input checked="" type="checkbox"/> CSCHAH 1015 Arlington St, Winnipeg, MB, R3E 3R2	<input type="checkbox"/> JCWIDRC 745 Logan Ave, Winnipeg, MB, R3E 3L5	
	<input type="checkbox"/> Guelph 110 Stone Rd West, Guelph, ON, N1G 3W4	<input type="checkbox"/> St. Hyacinthe 3400 boul Casavant Ouest, St. Hyacinthe, QC, J2S 8E3	
	<input type="checkbox"/> Lethbridge 225089 Township Road 9-1, Lethbridge, AB, T1J 3Z4	<input type="checkbox"/> Other: Click here to enter text.	
	Department/Unit: Special Pathogens Program		Telephone: 204-784-7548
Origin of Material	<input checked="" type="checkbox"/> Domestic <input checked="" type="checkbox"/> Imported	Import Permit or Transfer Letter No.: P14-3865 (Makona), P05670 (MA-Zebov) P-05100 (ass. Ebola), P15000 (Bebov), P05978 (Hendra), P05671 (Nipah)	
Risk Group / Material (select all that apply)	<input type="checkbox"/> RG2	<input type="checkbox"/> RG3	<input checked="" type="checkbox"/> RG4 <input type="checkbox"/> SSBA <input type="checkbox"/> Prions
Pathogen/Toxin and description of material(s)* to be transferred:	Ebola and Henipah viruses		

RECIPIENT LABORATORY			
Recipient Name:	third party		Biosafety Officer (BSO): third party
BSO Email:	third party		BSO Telephone No: +third party
Organization Name:	Chinese Academy of Sciences		
Department:	Wuhan Institute of Virology		
Street Address:	Xiao Hong Shan No.44		
City:	Wuhan	Prov/State:	Hubei
		Country:	China
Postal/Zip Code:	430071	Telephone:	third party
		Fax:	+third party
For Canadian Labs: Room number(s) where Prions, RG3, RG4 or SSBA material will be used or stored:		Click here to enter text.	
Work Intent:	Stock virus culturing		
<input type="checkbox"/>	Canadian Laboratory	<input type="checkbox"/> CL2 <input type="checkbox"/> CL2+ <input type="checkbox"/> CL3 <input type="checkbox"/> CL4	PHAC Licence No.: Click here to enter text. Expiry Date: Click here to enter text. <input type="checkbox"/> Exempt***
<input checked="" type="checkbox"/>	International Laboratory**	<p>Include one or more of the following documentation</p> <input checked="" type="checkbox"/> Recipient Import Permit <input checked="" type="checkbox"/> Laboratory Certification Letter <input checked="" type="checkbox"/> Documentation from Institute Director or Biosafety Officer indicating they meet the biosafety and biosecurity requirements to work safely with the exported material.	

* Examples of materials include (but are not exclusive): cultures, various infected specimens (serum, blood, tissue, etc), toxins, etc.

** For international laboratories: an import permit, certification letter, or documentation from the institute's Director or Biosafety Officer indicating they meet the biosafety and biosecurity requirements to work safely with the exported material is required.

*** Canadian laboratories receiving proficiency panels with RG2 or RG3 samples that mimic primary specimens for instrument calibration, performance determination of a laboratory's tests or measurements, and/or monitoring a laboratory's continuing performance may be exempt from PHAC licencing requirements.

Recipient acknowledgement:

- PHAC makes no representations and gives no warranties of any nature, expressed or implied, with respect to the Materials.
- The Material shall be used only on the Recipient's premises and under suitable containment conditions to the Recipient.

 Recipient's BSO / Director/ Licence Holder Signature	2018-10-18 _____ Date (YYYY-MM-DD)	_____ Transferor Signature	_____ Date (YYYY-MM-DD)
	2018-10-18 _____ Date (YYYY-MM-DD)	_____ Transferring BSO (or designate) Signature	_____ Date (YYYY-MM-DD)

Capes, Jennifer (PHAC/ASPC)

From: [redacted]
Sent: 2018-10-18 11:25 PM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: [redacted]
Subject: Re: RE: request letter of EBOV & NiV
Attachments: NML transfer application for pathogens and toxins-WIV-20181018.pdf

Follow Up Flag: Follow up
Flag Status: Flagged

Dear Dr. Qiu,
 Please find and check the attached transfer application. If you have any questions, please feel free to contact us.

Thank you again for all your great support and help during this time.

Best wishes,

[redacted]
 party

[redacted]
 Wuhan Institute of Virology, Chinese Academy of Sciences
 Xiao Hong Shan 44,
 430071 Wuhan, Hubei
 P.R. China
 Tel/Fax: [redacted]

From: [Qiu, Xiangguo \(PHAC/ASPC\)](#)
Date: 2018-07-10 21:34
To: [redacted]
CC: [redacted] [He, Shihua \(PHAC/ASPC\)](#)
Subject: RE: Re: request letter of EBOV & NiV

Dear [redacted],

I just went through the draft MTA your Institute initiated.

I am afraid I can't sign it as I don't have the authority, even our Chief of Special Pathogens can't sign it as it is still formal MTA and none of the scientists is entitled to sign. It has to be go through our IP office.

I am sorry for this situation but there is really not much I can do on our side with the MTA. Hope there is another way around.

Best,

Qiu

Xiangguo Qiu, M.D
Head, Vaccine Development & Antiviral Therapy
Special Pathogens Program
National Microbiology Laboratory
Public Health Agency of Canada
1015 Arlington Street H2410
Winnipeg, MB R3E 3R2

Adjunct Professor
Dept. of Medical Microbiology
University of Manitoba
Ph:1-204-789-5097 (lab)
1-204-784-7548(O)
Fax: 1-204-789-2140
email: xiangguo.qiu@canada.ca

From: third party
Sent: 2018-07-10 6:11 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: third party; He, Shihua (PHAC/ASPC)
Subject: Re: Re: request letter of EBOV & NiV

Dear Dr. Qiu,

Thank you again for your strongly support!

According to the content of the communication this morning, please check the attached MTA we have drafted.

After you confirm the content, would you please sign and send it back to us before July 12th? Thank you!

Please feel free to contact us if you have any questions.

Best wishes,

third
party

Wuhan Institute of Virology, Chinese Academy of Sciences
Xiao Hong Shan 44,
430071 Wuhan, Hubei
P.R. China
Tel/Fax: third party

发件人: [Qiu, Xiangguo \(PHAC/ASPC\)](#)

发送时间: 2018-07-09 20:52

收件人: [third party](#)

[He, Shihua \(PHAC/ASPC\)](#)

主题: Re: 回复: 回复: request letter of EBOV & NiV

Dear [third party](#),

The MTA will be initiated by our IP office. I will check with them and try my best to push. But again, MTA usually takes quite long time in our agency. I can't guarantee the MTA will be ready by Thursday. Sorry about this.

Again, generally speaking, MTA usually is requested by the Institute which provides the materials, I don't understand why MTA is has be in place in this case if PHAC doesn't request it? Most of these viruses are from outbreak isolates and technically no one owns the IP.

Best,

Qiu

Sent from my BlackBerry 10 smartphone on the Rogers network.

From: [third party](#)

Sent: Monday, July 9, 2018 2:49 AM

To: Qiu, Xiangguo (PHAC/ASPC)

Cc: [third party](#)

Subject: 回复: 回复: request letter of EBOV & NiV

Dear Dr. Qiu,

In order to promote the import of pathogens, the leaders of our institute will have a coordination meeting with the entry-exit inspection and quarantine department next week to negotiate on the import of highly pathogenic pathogens. Therefore, we need to complete the submission of the EBOV and NiV import application materials as soon as possible this week to enter the list of consultations.

The most important materials of the online declaration is MTA, if the other materials need more time, could you please prepare MTA first and send it to us before July 12th?

If there is anything we can do, please feel free to contact us.

Looking forward to your reply!

Best wishes,

[third party](#)

[redacted]

Wuhan Institute of Virology, Chinese Academy of Sciences
Xiao Hong Shan 44,
430071 Wuhan, Hubei
P.R. China
Tel/Fax: [redacted]

发件人: [redacted]

发送时间: 2018-07-04 10:33

收件人: xiangguo.qiu

抄送: [redacted]

主题: 回复: RE: request letter of EBOV & NiV

Dear Dr. Qiu,

Thank you very much for this useful information. The PDF version of request letter and biological safety laboratory assurance are attached.

According to requirements of the Entry-Exit Inspection and Quarantine Bureau in China, the materials we still need to submit are as follows:

1. MTA;

2. Descriptive materials of the virus strains, including the biological characteristics, sterilization, inactivation methods and effectiveness. The quickest way to prepare this material is that you can provide relevant articles with the required information instead, and I will prepare the descriptive materials.

3. Test report. Please see the attached template for your reference.

If you have any questions in preparing these materials, please feel free to contact us.

Best wishes,

[redacted]
party

[redacted]
Wuhan Institute of Virology, Chinese Academy of Sciences
Xiao Hong Shan 44,
430071 Wuhan, Hubei
P.R. China
Tel/Fax: [redacted]

发件人: [Qiu, Xiangguo \(PHAC/ASPC\)](mailto:Qiu, Xiangguo (PHAC/ASPC))

发送时间: 2018-07-04 05:58

收件人: [redacted]

抄送: [third party]
主题: RE: request letter of EBOV & NiV

Dear [third],

The letters look good to me. Pls can you send it as PDF file and send it to me again? The person who is in charge on our side is on vacation this week and hopefully we can start the paper work next week.

Attached is our CL4 annually recertification for this year and let me know if you need anything else.

Best regards,

Qiu

Xiangguo Qiu, M.D
Head, Vaccine Development & Antiviral Therapy
Special Pathogens Program
National Microbiology Laboratory
Public Health Agency of Canada
1015 Arlington Street H2410
Winnipeg, MB R3E 3R2

Adjunct Professor
Dept. of Medical Microbiology
University of Manitoba
Ph:1-204-789-5097 (lab)
1-204-784-7548(O)
Fax: 1-204-789-2140
email: xiangguo.qiu@canada.ca

From: [third party]
Sent: 2018-06-28 5:40 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: [third party]
Subject: request letter of EBOV & NiV

邱教授:

您好!

关于EBOV和NiV的引进, 非常感谢您一直以来为我们提供的大力支持和帮助!

按照我们之前沟通的内容, 我单位已经按照之前商量的事项拟好了request letter 和生物安全声明, 电子版请见附件, 请您审阅。不知是否满足贵单位的要求?

如有问题或者还有任何我们可以做的, 敬请随时联系!

祝好

third
part
y

Wuhan Institute of Virology, Chinese Academy of Sciences
Xiao Hong Shan 44,
430071 Wuhan, Hubei
P.R. China
Tel/Fax: third party

From: [Leung, Anders \(PHAC/ASPC\)](#)
Sent: 2018-10-29 4:27 PM
To: [Drew, Tracy \(PHAC/ASPC\)](#); Qiu, Xiangguo (PHAC/ASPC)
Cc: [Safronetz, David \(PHAC/ASPC\)](#); [Drebot, Mike \(PHAC/ASPC\)](#)
Subject: RE: viruses to be exported to China
Attachments: NML-TA-18-0480 Signed.pdf

Here is a copy of the final signed TA for everyone's record. Qiu when do you expect to ship these viruses?

From: Drew, Tracy (PHAC/ASPC)
Sent: 2018-10-29 8:08 AM
To: Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Drebot, Mike (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Good morning

Here is the processed TA. Please have Mike sign the document, provide me back signed copy, and you are good to go.

Thanks

Tracy Drew
Safety Officer
1-204-789-7638/1-204-784-5986
Winnipeg, Manitoba, Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

From: Leung, Anders (PHAC/ASPC)
Sent: 2018-10-26 5:29 PM
To: Qiu, Xiangguo (PHAC/ASPC); Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC)
Subject: RE: viruses to be exported to China

All done! Dave did it this morning.

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-10-26 5:17 PM
To: Drew, Tracy (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC)
Subject: Re: viruses to be exported to China

Hi Anders,

Pls can you have Dave signed and forward to Tracy?

Thanks!

Qiu

Sent from my BlackBerry 10 smartphone on the Bell network.

From: Drew, Tracy (PHAC/ASPC)
Sent: Friday, October 26, 2018 8:37 PM
To: Qiu, Xiangguo (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Morning,

As Dave is the one responsible for the transfer, we still require his signature as the transferor.
Please have Dave sign and return it me.

Thanks

Tracy Drew
Safety Officer
1-204-789-7638/1-204-784-5986
Winnipeg, Manitoba, Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-10-25 5:23 PM
To: Leung, Anders (PHAC/ASPC); Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Hi all,

Pls see attached for the signed form and returned by our Chinese colleagues .

Thanks!

Qiu

From: Leung, Anders (PHAC/ASPC)
Sent: 2018-10-25 10:57 AM
To: Drew, Tracy (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Hi Tracy,

We have the forms filled out, we are just waiting for signatures from the China BSOs.

Thanks!
Anders

From: Drew, Tracy (PHAC/ASPC)
Sent: 2018-10-25 9:24 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Morning Qiu,

Are you still planning on sending samples to China. If so, please fill out the SES-F-052 form (attached), and return it back to me.

Thank you

Tracy Drew
Safety Officer
1-204-789-7638/1-204-784-5986
Winnipeg, Manitoba, Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-10-06 9:54 AM
To: Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC); Krishnan, Jay (PHAC/ASPC); Robertson, Catherine (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Hi Tracy,

Thanks for the following up. We will drop the form off once it is completed!

Best,

Qiu

From: Drew, Tracy (PHAC/ASPC)
Sent: 2018-10-01 11:12 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Morning Qiu,

Just touching base on the China shipment. Once the SES-F-052 form has been completed, please drop it off via email or in person.

Thanks

Tracy Drew
Safety Officer
1-204-789-7638/1-204-784-5986
Winnipeg, Manitoba, Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

From: Drew, Tracy (PHAC/ASPC)
Sent: 2018-09-21 11:01 AM
To: Qiu, Xiangguo (PHAC/ASPC)

Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC); Richards, Hannah (PHAC/ASPC)
Subject: RE: viruses to be exported to China

Morning Qiu

Sorry for the delay. **personal info**

Thank you providing the letter that the lab is in fact able to handle the pathogen in question. We still need to complete the transfer form, SES-F-52A (attached to this email).

Please drop off the form when it is completed,
Thanks

Tracy Drew
Safety Officer
1-204-789-7638/1-204-784-5986
Winnipeg, Manitoba, Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-09-10 2:36 PM
To: Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Subject: viruses to be exported to China

Hi Tracy,

Pls see attached for the request letter from Wuhan Institute of Virology, Chinese Academy of Sciences and let me know if there are any concerns/questions.
Dave, we had discussed this some time ago and you are agreed to send the viruses once all the documents are in place.

Thanks!

Qiu

From: [Leung, Anders \(PHAC/ASPC\)](#)
Sent: 2018-11-01 10:21 AM
To: [Drew, Tracy_\(PHAC/ASPC\)](#)
Cc: Qiu, Xiangguo (PHAC/ASPC); [Safronetz, David \(PHAC/ASPC\)](#);
[Drebot, Mike \(PHAC/ASPC\)](#)
Subject: Transfer Doc for China Shipment
Attachments: NML-TA-18-0480 Signed.pdf

Hi Tracy,

There seems to be a difference in the shipping address for the lab, on the application we stated it should be;

Wuhan Institute of Virology
Xiao Hong Shan No.44
Wuhan, Hubei, China
430071

But the permit states a different address in Beijing.

Sorry for not noticing this earlier.

Thanks!

Anders Leung
National Microbiology Laboratory | Laboratoire national de microbiologie
Public Health Agency of Canada | Agence de la santé publique du Canada
Canadian Science Centre for Human and Animal Health | Centre scientifique canadien de la santé
humaine et animale
Winnipeg, Canada R3E 3R2
anders.leung@canada.ca
Telephone | Téléphone 204-789-7665 / Facsimile | Télécopieur 204-789-2140
Government of Canada | Gouvernement du Canada

Capes, Jennifer (PHAC/ASPC)

From: 3rd party
Sent: 2019-03-19 12:48 AM
To: Leung, Anders (PHAC/ASPC)
Cc: Qiu, Xiangguo (PHAC/ASPC)
Subject: 回复: Re: T0-Taking the Delivery-0311

Dear Anders,

Ok, I understand now, thank you very much for your patience!

Best wishes,

3rd
party

██████████

----- 原始邮件 -----

主题 : RE: Re: T0-Taking the Delivery-0311

发件人 : "Leung, Anders (PHAC/ASPC)"

收件人 : 3rd party

抄送 : "Qiu, Xiangguo (PHAC/ASPC)"

Hi 3rd
party

The overpack box should support 15 kg of dry ice, I don't think we need to ask 3rd party to add another package of dry ice just that they should top off if necessary. Just a question about all these shipping regulation questions, you do realize that all of this will be completed on our side so you don't have to worry about all the packaging, notifications, etc. right?

Anders

From: 3rd party
Sent: 2019-03-16 8:45 PM
To: Leung, Anders (PHAC/ASPC)
Cc: Qiu, Xiangguo (PHAC/ASPC)
Subject: Re: Re: T0-Taking the Delivery-0311

Dear Anders,

Thank you for your information.

According to the link you recommended before , we should use the UN2814 package of STP-310 series this time.

Sorry, since I have not operated this package before, I would like to confirm again whether the package of this size (outer diameter 11 5/8 x 10 x 8 ") can carry 15KG of dry ice. And besides this package, do I need to ask 3rd party [REDACTED] to add another dry ice package (such as GDI15 series)?

Best wishes,

3rd [REDACTED]

3rd party [REDACTED]

Wuhan Institute of Virology, Chinese Academy of Sciences

Xiao Hong Shan 44,

430071 Wuhan, Hubei

P.R. China

Tel/Fax: 3rd party [REDACTED]

From: [Leung, Anders \(PHAC/ASPC\)](#)

Date: 2019-03-17 02:41

To: 3rd [REDACTED]

CC: [Qiu, Xiangguo \(PHAC/ASPC\)](#)

Subject: Re: T0-Taking the Delivery-0311

Hi 3rd [REDACTED],

My best guess would be 15 kg of dry ice. Normally 3rd party [REDACTED] will top up the dry ice if necessary on route to the final destination.

Anders

Sent from my BlackBerry 10 smartphone on the Bell network.

From: 3rd

Sent: Saturday, March 16, 2019 10:09 AM

To: Leung, Anders (PHAC/ASPC)

Cc: Qiu, Xiangguo (PHAC/ASPC)

Subject: Re: RE: T0-Taking the Delivery-0311

Dear Anders,

Sorry for the late reply!

Thank you so much for taking your precious time to make such meticulous changes to our documents!

In addition, we have two more questions:

How many kilograms of dry ice is needed for this package? What is the total weight of the package?

Thank you!

Best wishes,

3rd

-----原始邮件-----

发件人:"Leung, Anders (PHAC/ASPC)" <anders.leung@canada.ca>

发送时间:2019-03-15 05:51:45 (星期五)

收件人: "Qiu, Xiangguo (PHAC/ASPC)" <xiangguo.qiu@canada.ca>, "3rd party"

抄送:

主题: RE: T0-Taking the Delivery-0311

Hi,

Generally the instructions will work for this shipment and the shipping packaging is appropriate for CL-4 shipments but I made a few changes and deleted a few parts that don't really apply to the shipment. In regards to the video and photos for the packaging of the shipment this is not possible nor allowed according to PHAC policies so you will have to remove all references to the photos and videos. There also seems to be a bit of miscommunication to how the passaging of the sample to 3rd party is so I removed a lot of the parts where the carrier picks up the package from PHAC. Also this shipment is unique as the package will be sent to CFIA for storage as our lab is shutdown for maintenance but the shipment will be transferred back to PHAC for the shipment to 3rd party so I would leave those instructions out.

Thanks!

Anders

From: Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>

Sent: 2019-03-12 9:44 AM

To: Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; 3rd party

Subject: FW: T0-Taking the Delivery-0311

Hi Anders,

Pls see attached and edits where you see fit.

Thanks!

Qiu

From: 3rd party
Sent: 2019-03-11 10:49 PM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: 3r
Subject: T0-Taking the Delivery-0311

Dear Qiu,

The General Administration of Customs of China requires that the entire transportation process plan should be reviewed before it can be implemented. Among them, the transportation work in the PHAC section is set as the first step of the workflow (T0).

Please see the attachment is a draft work plan that according to our own understanding and speculation.

Please check its compliance and feasibility. If there is anything wrong, please modify and point it out. Since the lack of time, we would appreciate your feedback within 2 days.

Once again, we would like to express our heartfelt thanks to you for your great support to our work!!

Best wishes,

3rd
party

Wuhan Institute of Virology, Chinese Academy of Sciences
Xiao Hong Shan 44,
430071 Wuhan, Hubei
P.R. China
Tel/Fax: 3rd party

11 pages of previous document fully redacted due to security

Capes, Jennifer (PHAC/ASPC)

From: third party [redacted]
Sent: 2019-03-19 2:43 PM
To: Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); third party [redacted]
Cc: third party [redacted]
Subject: RE: PI620 certificate/ Job third party [redacted] / Wuhan Institute of Virology

Thanks Andres,

We have provided this information to third party [redacted] and will advise if this certificate is mandatory.

Regards

third party [redacted]

[redacted]
[redacted]
[redacted]
[redacted]

third party [redacted]

[redacted]
[redacted]
[redacted]
[redacted]

[redacted]
[redacted]
[redacted]
[redacted]

[redacted]
[redacted]
[redacted]
[redacted]
[redacted]

[redacted]

[redacted]

From: Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]
Sent: 19 March 2019 12:31
To: Qiu, Xiangguo (PHAC/ASPC); third party [redacted]
Cc: third party [redacted]
Subject: RE: PI620 certificate/ Job third party [redacted] / Wuhan Institute of Virology

Hi,

Again we've shipped many CL-4 pathogens and certificates were never necessary as long as we used the proper Packing Instructions as per international transport regulations. Contact with the manufacturer would be necessary if you need these certificates.

Anders

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2019-03-19 10:12 AM
To: Leung, Anders (PHAC/ASPC) ; **third party**
Subject: FW: PI620 certificate/ Job **third** Wuhan Institute of Virology

Anders,
Pls take look. I thought we discussed it before with **third** and it's not necessary.

Thanks!

Qiu

From: **third party**
Sent: 2019-03-18 8:33 PM
To: Qiu, Xiangguo (PHAC/ASPC); **third**
Subject: PI620 certificate/ Job **third** / Wuhan Institute of Virology

Hello,
It's possible to provide us a PI620 certificate approval for this shipment to Wuhan Institute of Virology.
See attached for a temple.

Regards,
third party

[Redacted]
[Redacted]
[Redacted]
[Redacted]

[Redacted]
[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]
[Redacted]

[Redacted]
[Redacted]
[Redacted]

5 pages of previous document fully redacted due to third party information

MEDIA LINES

ISSUE: On June ##, 2019, the Public Health Agency of Canada launched an administrative investigation into possible policy breaches by two employees working at the National Microbiology Laboratory in Winnipeg, Manitoba. **personal info**
personal info

KEY MESSAGES:

- The Public Health Agency of Canada takes the integrity of the scientific research conducted at the National Microbiology Laboratory very seriously.
- For privacy reasons, we cannot comment further on this matter.
- There is no risk to the health and safety of Canadians.

If pressed on the investigation (only if investigation details are released by either employee)

- An investigation is underway at the National Microbiology Laboratory.
- As the investigation is ongoing, we cannot comment further at this time.
- The Agency is taking the necessary steps to resolve the matter.

QUESTIONS AND ANSWERS:

Q1. What are the allegations against the employees?

For privacy reasons, we cannot comment.

Q2. Is there a risk to Canadians since the employees worked at the National Microbiology Laboratory?

No, there is no risk to the health and safety of Canadians.

personal information

For privacy reasons, we cannot comment.

Q4. When did the alleged incident(s) occur?

As the matter is ongoing, we cannot comment further at this time.

personal information

As the matter is ongoing, we cannot comment further at this time.

Q6. How does this affect the employees' relationship or status with any universities they were working with and outside collaborators?

For privacy reasons, we cannot comment.

Q7. Are the police involved?

As the matter is ongoing, we cannot comment further at this time.

Q8. When will the investigation be completed?

We are taking steps to ensure due process is followed. The matter will be concluded as expeditiously as possible.

MEDIA LINES


Administrative Investigation at the National Microbiology Laboratory

ISSUE: On July 5, 2019, the Public Health Agency of Canada launched an administrative investigation into possible policy breaches by two scientists working at the National Microbiology Laboratory in Winnipeg, Manitoba.

KEY MESSAGES:

- Canada's National Microbiology Laboratory (NML) is known worldwide for its scientific expertise and contributions to global health.
- That is why the Public Health Agency of Canada takes the NML's supporting policies and procedures very seriously.
- For privacy reasons, we cannot comment further on this matter.
- There is no risk to the health and safety of Canadians.

personal info



Key Messages:

- Canada's National Microbiology Laboratory (NML) is known around the world for its scientific excellence and contributions to global health.
- We can assure Canadians that there is absolutely no risk to the Canadian public and that the work of the NML continues in support of the health and safety of all Canadians.
- The NML's greatest assets are the world-class scientists who work in the facility—we value the exceptional role they play in protecting the health of Canadians.
- For privacy reasons, we cannot comment on measures that may be taken regarding any employee.

Scenario: Administrative Investigation

The media become aware of an administrative investigation at the NML and ask questions.

Key Messages:

- Canada's National Microbiology Laboratory (NML) is known around the world for its scientific excellence and contributions to global health.
- We can assure Canadians that there is no risk to the public and that the work of the NML continues in support of the health and safety of all Canadians.
- Its greatest assets are the world-class scientists who work in the facility—we value the exceptional role they play in protecting the health of Canadians.
- We can confirm that an administrative investigation is underway at the NML.
- For privacy reasons, we cannot comment further.
- The Agency is taking the necessary steps to resolve the matter as expeditiously as possible.

Scenario: Level 4 Lab and the Health and Safety of Canadians

Media are reporting that one or both scientists work in Canada's only level 4 lab at the National Microbiology Laboratory, and have access to infectious agents (e.g., Ebola, Lassa fever), stoking fears among Canadians, partners and other levels of government.

Key Messages:

- Canada's National Microbiology Laboratory (NML) is known around the world for its scientific excellence.
- We can assure Canadians that there is no risk to the public and that the work of the NML continues in support of the health and safety of all Canadians.
- Safety and security are paramount at the NML, and the lab continues to meet or exceed all national and international standards for containment laboratories.
- The lab is licensed under the *Human Pathogens and Toxins Act* and its regulations to carry out controlled activities with human pathogens and toxins.
- Infectious pathogens are stored and handled in the highest level of biocontainment labs according to the strictest standards for safety and security.

- Protocols followed by the NML are based on international standards developed by the World Health Organization as well as on the Canadian Biosafety Standards.

personal info

Key Messages:

- PHAC values diversity and is firmly committed to having a workplace that is inclusive and reflective of Canadian society.
- PHAC scientists are committed to scientific excellence and work closely with scientists across Canada and around the world, including with scientists in China.
- PHAC values this collaboration, and the fundamental role it plays in protecting the health of Canadians.
- All employees are expected to adhere to policies, protocols and practices governing the protection and security of Government of Canada property, including the Values and Ethics Code for the Public Sector.

If pressed on whether there is a link to challenges in Canada-China relations

- The Government of Canada is treating this as a standalone issue.

Scenario: Potential Loss of Intellectual Property

Media raise questions in relation to allegations that both scientists may have been sharing unauthorized information with organizations abroad without proper collaboration agreements in place.

Key Messages:

- All employees of the Government of Canada are expected to adhere to the Values and Ethics Code for the Public Sector.
- The Public Health Agency of Canada (PHAC) is committed to protecting the information and assets of the Government of Canada.

- The Government of Canada and PHAC have measures in place to safeguard intellectual property, including the *Public Servants Inventions Act* and the PHAC Policy on Intellectual Property.
- The Government of Canada and PHAC have policies and standards to help keep our systems and data secure, such as the Policy on Government Security. For example, monitoring is carried out to detect and respond to security incidents.

Scenario: Delay in Taking Action

PHAC is criticized for the length of time it took to examine the matter and to take action once concerns came to light.

Key Messages:

- We took the necessary steps to ensure due process was followed.

Scenario: Risks Related to Ebola

The scientific community rallies around one of the scientists because of her world-renowned work on Ebola. High-profile figures criticize PHAC publicly for having the scientist at home when there is an ongoing outbreak of Ebola in the Democratic Republic of the Congo.

Key Messages:

- Canada has a long history of leadership and collaboration on the world stage.
- The Public Health Agency of Canada (PHAC) will continue to work with our international partners to protect the health of our citizens and people around the world.
- In collaboration with international partners, PHAC continues to closely monitor the Ebola outbreak in the Democratic Republic of the Congo.
- PHAC's contribution to addressing Ebola goes beyond any one individual.

QUESTIONS AND ANSWERS:

Q1. What prompted PHAC to initiate an administrative investigation?

As the matter is being examined, we cannot comment further at this time.

Q2. What are the allegations against the scientists?

For privacy reasons, we cannot comment.

Q3. Is there a risk to Canadians since the scientists worked at the National Microbiology Laboratory (NML)?

No, there is no risk to the health and safety of Canadians. The NML is licensed under the *Human Pathogens and Toxins Act* and its regulations to carry out controlled activities with human pathogens and toxins. Infectious pathogens are stored and handled in the highest level of biocontainment labs according to the strictest standards for safety and security.

personal info

For privacy reasons, we cannot comment on measures that may be taken regarding any employee.

Q5. When did the alleged incident(s) occur?

As the matter is being examined, we cannot comment further at this time.

personal info

As the matter is being examined, we cannot comment further at this time.

Q7. How does this affect the scientists' relationship or status with any universities they were working with and outside collaborators?

For privacy reasons, we cannot comment.

Q8. When will the investigation be completed?

We are taking steps to ensure due process is followed. The matter will be concluded as expeditiously as possible.

Q9: What is the difference between a Fact Finding exercise and an Administrative Investigation?

A Fact Finding is an initial assessment that is undertaken once allegations are first brought to management's attention. An administrative investigation is a formal process of assessing allegations.

Q10. Is this another example of the Government muzzling scientists?

The Government of Canada firmly stands behind the principle that scientists can discuss their important work with each other, with the media and with Canadians. In 2017, the Government made a commitment to scientific integrity through a Memorandum of Agreement that encourages scientists and researchers to speak openly about their scientific work without undue interference.

Q11. How long have you known there was an issue?

As the matter is being examined, we cannot comment further at this time.

Q12. Who is undertaking the investigation? Is this something that security services are involved in?

The Public Health Agency of Canada is the lead on the administrative investigation, and is reaching out to external parties as required.

Q13. Has this happened before and what did you do about it?

As the matter is being examined, we cannot comment further at this time.

Q14. Have you referred this to security agencies?

PHAC has advised the RCMP of possible policy breaches. As the matter is being examined, we cannot comment further at this time.

Q15. Is this espionage?

As the matter is being examined, we cannot comment further at this time.

Q16. What kinds of security clearances are required at the NML and how are they granted?

A Secret level clearance is required to work at the NML. In addition, for employees working with human pathogens and toxins, a clearance under the *Human Pathogens and Toxins Act* (HPTA) is also required.

A Secret clearance is granted by filling out the appropriate forms, which are sent to RCMP and CSIS for their respective assessment. If any adverse information is uncovered, it is shared with the department to determine if it poses a risk to the Department.

For the HPTA clearance, it is a similar process but goes above and beyond where Law Enforcement Records Checks are conducted. The findings are reviewed at the Interdepartmental Security Advisory Forum (ISAF). The ISAF is responsible to provide a recommendation to grant or not to grant a HPTA clearance to the President of the Public Health Agency of Canada.

Q17. What has changed since one of the scientists received an award for her work on Ebola?

As the matter is being examined, we cannot comment further at this time.

MINISTERIAL MEDIA LINES

Administrative Investigation at the National Microbiology Laboratory

ISSUE: On July 5, 2019, the Public Health Agency of Canada launched an administrative investigation into possible policy breaches by two scientists working at its National Microbiology Laboratory in Winnipeg, Manitoba.

MINISTERIAL KEY MESSAGES:

- I am aware that there is a matter under review at the National Microbiology Laboratory.
- I can assure Canadians that there is absolutely no risk to the Canadian public and that the work of the NML continues in support of the health and safety of all Canadians.
- Canada's National Microbiology Laboratory is known around the world for its scientific excellence and contributions to global health.
- For privacy reasons, I cannot comment further.
- Further questions should be directed to the Public Health Agency of Canada.

Media responses on the NML

July 12 2019 to April 19, 2021

July 12,13, 15, 2019

Stephanie Tsicos, CTV /Caitlyn Gowriluk, Winnipeg Free Press/Austin Siragusa, Global News/Kelly Malone, Canadian Press/ Jill Macyshon, CTV Winnipeg/Kristy Kirkup, Canadian Press/ Leslie Young, Global News/Gabrielle Marchand, Global News/Kim MacRael, Wall Street Journal/Moira Warburton, Reuters/ Rebekah Riess, CNN/New York Times

Response (the same answer was delivered regardless of the question):

We are looking into an administrative matter at the National Microbiology Laboratory (NML) and are taking steps to resolve it expeditiously. On May 24, 2019, The Public Health Agency of Canada has advised the RCMP of possible policy breaches. There is no employee from the NML under arrest or confined to their home.

We can assure Canadians that there is no risk to the public and that the work of the NML continues in support of the health and safety of all Canadians.

For privacy reasons, we will not comment further.

July 30, 2019 - Dylan Robertson, Winnipeg Free Press

Q1. We have enough corroboration to report on a Level 4 pathogens being sent to China earlier this year, despite the lack of a Material Transfer Agreement.]

To advance scientific work worldwide, the National Microbiology Laboratory (NML) routinely shares samples of pathogens and toxins with partner laboratories in Canada and in other countries. These transfers follow strict protocols, including requirements under the [Human Pathogens and Toxins Act](#) (HPTA), the [Transportation of Dangerous Goods Act](#), the [Canadian Biosafety Standard](#) and Standard Operating Procedures of the NML. All transfers of Risk Group 4 samples follow strict transportation requirements and are authorized by senior officials at the lab. The NML also tracks and keeps electronic records of all shipments of samples in accordance with the HPTA.

On the specific shipment to China earlier this year, we can confirm that we have all records pertaining to the shipment, and that all protocols were followed as directed by the above Acts and Standards.

Q2. How is the investigation proceeding; has Xiangguo Qui been arrested?

The Public Health Agency of Canada continues to look into an administrative matter at the NML and we cannot comment further. We can assure Canadians that there is no risk to the public and that the work of the NML continues in support of the health and safety of all Canadians.

July 31, 2019 - Karen Pauls, CBC

Q1. I understand Canada is not allowed to send anything to other countries or labs without the IP office negotiating and having a material transfer agreement in place - to protect the Crown's intellectual property rights should the material being sent lead to any kind of notable discovery. Can you confirm if there is one between the Special Pathogens program and the Chinese government and/or the Chinese Academy of Sciences? Is it illegal to ship pathogens without it?

Q2. What and how much virus was sent? (This will be on the TDG - transportation of dangerous goods paperwork)

To advance scientific work worldwide, the National Microbiology Laboratory (NML) routinely shares samples of pathogens and toxins with partner laboratories in Canada and in other countries. These transfers follow strict protocols, including requirements under the Human Pathogens and Toxins Act<<https://laws-lois.justice.gc.ca/eng/acts/h-5.67/>> (HPTA), the Transportation of Dangerous Goods Act<<https://lois-laws.justice.gc.ca/eng/acts/T-19.01/>>, the Canadian Biosafety Standard<<https://www.canada.ca/en/public-health/services/canadian-biosafety-standards-guidelines/second-edition.html>> and Standard Operating Procedures of the NML. All transfers of Risk Group 4 samples follow strict transportation requirements and are authorized by senior officials at the lab and the NML tracks and keeps electronic records of all shipments of samples in accordance with the HPTA. Agreements for the transfer of materials are determined on a case-by-case basis.

On the specific shipments to China earlier this year, we can confirm that we have all records pertaining to the shipment, and that all protocols were followed as directed by the above Acts and Standards. The shipment to China earlier this year contained Ebola and Henipah viruses.

August 1, 2019 - Tom Blackwell, National Post

Q1. Can you confirm that this occurred?

To advance scientific work worldwide, the National Microbiology Laboratory (NML) routinely shares samples of pathogens and toxins with partner laboratories in Canada and in other countries. These transfers follow strict protocols, including requirements under the Human Pathogens and Toxins Act<<https://laws-lois.justice.gc.ca/eng/acts/h-5.67/>> (HPTA), the Transportation of Dangerous Goods Act<<https://lois-laws.justice.gc.ca/eng/acts/T-19.01/>>, the Canadian Biosafety Standard<<https://www.canada.ca/en/public-health/services/canadian-biosafety-standards-guidelines/second-edition.html>> and Standard Operating Procedures of the NML. All transfers of Risk Group 4 samples follow strict transportation requirements and are authorized by senior officials at the lab and the NML tracks and keeps electronic records of all shipments of samples in accordance with the HPTA.

On the specific shipment to China earlier this year, we can confirm that we have all records pertaining to the shipment, and that all protocols were followed as directed by the above Acts and Standards.

Q2. And was this related to the matter that was passed on to the RCMP for investigation? I find that there is a lot of information out there that is perhaps telling part of the story, but not the whole story, which I think is very confusing for the public and shrouding this whole situation in unnecessary mystery. Anything that can shed more light on it would be helpful!

The Public Health Agency of Canada continues to look into an administrative matter at the NML and we cannot comment further. We can assure Canadians that there is no risk to the public and that the work of the NML continues in support of the health and safety of all Canadians.

January 27, 2020 – Ming Pao

I am Liang Feng with Mingpao Saturday Magazine of Mingpao Newspaper Canada Ltd.

I want to get updated information about Ms. Xiang Guo Qiu, a scientist at the Canadian National Microbiology Laboratory in Winnipeg. Ms. Qiu and her husband Keding Cheng were seceded out of the lab in July 2019 and under investigation.

Ms. Qiu visited Wuhan National Biosafety lab at least 5 times before last year.

Rumor say Ms. Qiu's case related to Wuhan coronavirus broke out in China.

- where is Ms. Qiu and her husband?
- Can she still be able to work at Canada National Lab as before?

This is misinformation and there is no factual basis for claims being made on social media. For privacy reasons, we will not comment further.

April 14 – CBC Karen Pauls

Our last response stands. To respect privacy, no further details on the individuals will be disclosed.

April 15 – Globe and Mail

Last year, scientist Xiangguo Qiu was removed from her duties at the Canadian National Microbiology Laboratory.

My questions: Has Ms. Qiu been reinstated to those duties? Has her husband, Keding Cheng, resumed his relationship with the laboratory?

For privacy reasons, we will not comment further.

April 20 – National Post – Tom Blackwell

Because of her visits to Wuhan and other reasons, there is tremendous public interest now in the case Xiangguo Qiu and her husband Keding Cheng, who were removed from the NML last year. I feel that there needs to be some update on that, if only to squelch the widespread, largely uninformed speculation about the case. I had a couple of questions:

Has PHAC's inquiry into the alleged administrative issues around these two been completed? If so, what was the result?

Are Qiu and Cheng back at work at the NML?

Was any impropriety identified in the transport of Ebola and henipavirus samples to China? Can you explain the results of that inquiry?

In response to a request from the Institute for viral samples of Ebola and Henipah viruses, the Public Health Agency of Canada sent samples for the purpose of scientific research in 2019. The National Microbiology Laboratory (NML) shares samples with other public health laboratories—as they do with the NML—to contribute to the advancement of science. Transfers are subject to strict protocols, including requirements under *the Human Pathogen and Toxins Act*, the *Transportation of Dangerous Goods Act*, the Canadian Biosafety Standard, and standard operating procedures of the NML.

The NML also provides training to international laboratory professionals, and has previously trained scientists from many countries including China.

As for your questions regarding Dr. Qiu and Cheng. For privacy reasons, we will not comment on individual employees.

Any speculation about the role of the Public Health Agency of Canada (PHAC)'s scientists in the emergence of the novel coronavirus has no factual basis.

----No offense, but I don't think you answered a single one of my questions!

As I understand from information you provided me last year, the export of those samples was the subject of an inquiry by PHAC, and obviously is a matter of some public interest. Can you just say what was the outcome of that inquiry? Or if there was no inquiry and it was all a routine matter, please indicate that?

I would ask the same regarding the inquiry into administrative issues you referenced last year. Has that been completed and, if so, what was the outcome?

Re. Dr. Qiu and Mr. Cheng, I'm not asking for any private information about them, simply whether they are on the job now as employees of PHAC, or not.

I agree with you about the COVID-19 virus and PHAC scientists; that is pure fantasy. But I can say from the many emails I receive about this and posts I see on social media, these other matters, with their connection to the WIV lab in Wuhan, have led to much speculation, most of it groundless I'm sure.

I think the only way to end that conjecture is to illuminate what has actually happened with this matter. I don't think you can expect the public to just forget this ever happened.

Re. the queries that Andre was handling, I assume I should follow up with him about those?

I'll follow up again on your question regarding the inquiry/administrative matter.

As for employee status, we will not comment on the status of individual employees.

I'll be in touch with you tomorrow.

For privacy reasons, we will not comment further.

April 22, 2020 – CBC Karen Pauls

Sorry for not getting back to you sooner. We respectfully decline the request for an interview. Any speculation about the role of the Public Health Agency of Canada’s scientists in the emergence of the novel coronavirus has no factual basis.

May 1, 2020 – CBC Karen Pauls

Q. Can you give me an update on the investigation into the possible administrative breach, what you’ve discovered so far, and the status of the scientists involved?

The administrative review remains underway. We cannot provide further details.

Q. Also, have there been/are there any bat studies going on at NML? Was Qiu involved in any bat research?

Scientists at the National Microbiology Laboratory have not been involved in research involving bats, beyond a 2012 investigation in the Democratic Republic of the Congo that sampled wildlife species, including bats, to test for pathogens, including the Ebola virus.

May 6, 2020 – National Post Tom Blackwell

Q1. Has Health Canada or PHAC had any dealings with the WIV lab? Has HC or PHAC had or currently have any concerns about the safety of the research being done there?

In response to a request from the Institute for viral samples of Ebola and Henipah viruses, the Public Health Agency of Canada sent samples for the purpose of scientific research in 2019. The National Microbiology Laboratory (NML) routinely shares samples with other public health laboratories—as they do with the NML—to contribute to the advancement of science. Transfers follow strict protocols, including requirements under *the Human Pathogen and Toxins Act*, *the Transportation of Dangerous Goods Act*, the Canadian Biosafety Standard, and standard operating procedures of the NML.

The NML also routinely provides training to international laboratory professionals, and has previously trained scientists from many countries including China.

If Pressed

For privacy reasons, we will not comment on private circumstances of individual employees

Any speculation about the role of the Public Health Agency of Canada (PHAC)’s scientists in the emergence of the novel coronavirus has no factual basis.

FOLLOW UPS

NATIONAL POST + CBC QUESTION re Administrative Matter

Q1. What was the outcome of the inquiry last year into “administrative” or policy matters at the NML, associated with the removal of the two researchers from the lab? (National Post)

Q. Can you give me an update on the investigation into the possible administrative breach, what you've discovered so far, and the status of the scientists involved? (CBC)

The administrative review remains underway. We cannot provide further details.

CBC QUESTION re. Bat studies:

Also, have there been/are there any bat studies going on at NML? Was Qiu involved in any bat research?

Scientists at the National Microbiology Laboratory have not been involved in research involving bats, beyond a 2012 investigation in the Democratic Republic of the Congo that sampled wildlife species, including bats, to test for pathogens, including the Ebola virus.

NATIONAL POST FOLLOW UP re. Wuhan Institute of Virology:

Q2. Has PHAC or Health Canada had any concerns about bio-safety at the Wuhan Institute of Virology BSL-4 lab, along the lines apparently expressed in a U.S. diplomatic cable in 2018, reported on here?

The Public Health Agency of Canada does not have any information on biosafety concerns in regards to this institute.

June 11, 2020 – Karen Pauls - CBC

PHAC-A-2019-000061/AB

Q1. We are finally getting details on the list of pathogens sent - on the first page and also on p. 153. It looks like much more was shipped than we were originally led to believe - 30 vials. While they are all under the Ebola umbrella, they are all different viruses. I'm also told you only need a small volume, 10 microlitres to infect cells to grow more virus and make your own stock. Each vial has 500 microlitres. So one vial could be used to make infect 50 new cell cultures, within which the virus itself is multiplying. *Why did NML send so much?**

This shipment included 15 strains of virus. It is standard practice to ship two vials of each strain in case the receiving lab encounters problems growing the virus from the stock. This second vial is provided to reduce the need for multiple Risk Group 4 (RG4) shipments.

The aliquot volume of 250-500 µL is the standard storage condition for virus stocks. It is not standard practice to thaw virus stocks to change the amount of virus being shipped since this increases manipulation of the sample and can compromise the stock quality. The Special Pathogens Standard Operating Procedure SP-CL4-PR-004-1, “Preparation of Working Virus Stocks for CL4,” provides the following directive: “8.17. g. Dispense the desired volume (aliquots of 250 µL and 500 µL are preferred).”

Q2. *Where was this shipment of Ebola and Henipah virus sent to? I understand the third-party issue, but in September 2018, the head of the lab, Matthew Gilmour, expressed some concerns about the paperwork, the nature of the work and why the NML's materials were required, that MTA's would be required, not generic 'guarantees' on the storage and usage. He also said, "Good to know that you trust this group. How did we get connected with them?"**

Part of the response from David Safronetz was: "I trust the lab and would be personally fine to sign off for SP."

At one point, Mike Drebot also asks to what agency or institution are they going? He loops in Matt and Steve.

If the Chinese lab involved was public or university-connected, surely Matthew Gilmour would know about it and wouldn't have to ask what it was.

Sending level-4 pathogens outside recognized research labs is concerning, especially in these times. I think there is a case to be made for identifying the lab in question. I think it's in the public's best interest to know this.

As reported in a [National Post](#) article on May 5, 2020, in response to a request from the Wuhan Institute of Virology for viral samples of Ebola and Henipah viruses, the Public Health Agency of Canada (PHAC) sent samples for the purpose of scientific research in 2019. The NML routinely shares samples with other public health laboratories—as they do with the NML—to contribute to the advancement of science. Transfers follow strict protocols, including requirements under the *Human Pathogens and Toxins Act* (HPTA), the *Transportation of Dangerous Goods Act*, the Canadian Biosafety Standard, and standard operating procedures of the NML.

Q3. Apr 3 - p 146 After the shipment, there are questions from Ottawa about what was sent, where it was sent, was there proper paperwork. "We didn't do anything wrong.. just that because of the nature of the pathogens and where it was going they (the higher ups in PHAC) wanted to know if we did our due diligence." Was Ottawa sufficiently informed about this shipment?

The process for shipments of RG4 pathogens is outlined under the Emergency Response Assistance Plan (ERAP) process. Following the NML's notification of the Health Portfolio Operations Centre (HPOC) in Ottawa, as is noted on page 144, the HPOC advised the Centre for Biosecurity (CB). CB is the regulatory authority responsible the HPTA and its regulations. Consistent with its regulatory role, the CB contacted the NML to confirm that all required documentation was completed and procedures followed. This was confirmed, as outlined in page 146.

Q4. The first requests for this shipment date back to September 2018 - six months before it actually happened. How unusual is that?

This is not unusual. It reflects the time required for documentation, verification of permits, approvals and establishing appropriate shipping and logistics arrangements to transfer an RG4 pathogen according to the requirements of the HPTA and Transport Canada's *Transportation of Dangerous Goods Act*.

Q5. Jay Krishnan asks about the phrase "the crown doesn't regulate the crown" from Foreign Affairs - what is this and what does this mean? Why is it necessary?

This phrase indicates that PHAC is not regulated by Global Affairs Canada under the *Export and Import Permits Act*. With respect to the shipment of pathogens to institutions outside Canada, the NML must comply with all applicable requirements of the HPTA, the *Transportation of Dangerous Goods Act*, and the Canadian Biosafety Standard.

Q6. Did NML get any payment or viruses in return from this agency? if so, what?

No payment nor viruses were received in return.

Q7. What paperwork is required in a shipment like this? was it all provided?

All required documentation according to the provisions of the HPTA was in place.

Under the HPTA, the NML requires the requesting laboratory to provide:

- Laboratory certification (if the country has a certification scheme);

- Import permit (if the requesting country issues such permits. Not all countries issue import permits); and/or
- Letter from Director of Laboratory or Biosafety Officer of the institute attesting that the laboratory meets the containment requirements for safely working with a particular risk group of pathogens (if the country does not have a certification scheme).

Shipment of pathogens requires:

- NML transfer application/authorization and NML shipment requisition (both internal documents); and
- ERAP notification (for RG4 samples) and Transportation of Dangerous Goods documentation which includes shippers' declaration, waybill and list of pathogens in package (both as per Transport Canada).

Q8. How unusual is the request by China for photos/video of the pickup process?

The request for photos or video was made by the shipping company. PHAC cannot comment on the commercial practices and requirements of third party companies.

A-2019-000602/AB2

Q9. *My very first request about this case generated a lot of urgent responses internally - high impact/high complexity. e.g. John Taylor, A/director investigations and regional security management was involved, PCO comms - lots of sharing of media lines between departments. Why was security management involved when I was told it was not a national security issue?**

Security management was involved as they were the contract authority for the fact finding and subsequent administrative investigation reports.

Q10. Why were people like Sandra Entwistle, departmental security officer communicating with RCMP about this? Was that political interference?

Actions taken by a departmental official do not constitute political interference. As part of her regular duties, the departmental security officer communicates regularly with Government of Canada security partners.

Q11. Was the PMO contacted about this story? What were the instructions? Please provide a definition for "administrative matter"

Neither the Public Health Agency of Canada nor Health Canada contacted the Prime Minister's Office. An "administrative matter" generally refers to an issue that is linked to administrative policies and procedures.

Q12. What is the difference between a fact-finding mission and an administrative investigation?

A fact-finding exercise is the precursor to a formal administrative investigation. A fact-finding exercise gathers and documents information pertaining to an issue to determine whether the facts warrant the initiation of an in-depth investigation to determine or confirm what occurred, the factors that contributed to the issue being investigated and whether it constitutes misconduct. The purpose of an administrative investigation is to establish whether an employee's behaviour or actions were inappropriate and culpable, and whether the actions constitute misconduct that might warrant the imposition of corrective measures. An investigation is therefore a means of establishing factual and documented findings.

Q13. p. 193 you prepared some media lines about the values and ethics code and measures in place to safeguard....? What?

Media lines are prepared in anticipation of questions that may arise. Administrative investigations often generate questions related to values and ethics.

Q14. * Is this case connected in any way to Xiangguo Qiu's shipment of Ebola and Henipah to an unknown agency in China several months earlier, in March 2019? I know there were questions raised by Ottawa at the time - did those concerns lead to this investigation?**

The administrative investigation is not related to the shipment of virus samples to China. Samples were provided in accordance with policies and procedures required under the HPTA.

Q15. *I was told at the time you were taking steps to resolve this as expeditiously as possible. It's been almost a year. What have you done in the last year and what is the status of this case?**

Administrative investigations are impartial, thorough and in-depth. They are also procedurally fair and respect the rights of individuals. The investigation has not yet concluded.

**Q16: Was this package sent to the Chinese military - is NML is doing Ebola studies in collaboration with the Academy of Military Medical Sciences in China?
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384060/>**

No shipments were made to the Chinese Academy of Military Medical Sciences. NML scientists participated in the research study, referenced above, along with other academic institutions. This study is a part of the laboratory's Ebola research program and, in this case, contributed to the assessment of potentially life-saving Ebola treatments. The NML is committed to global public health efforts to find effective vaccines and treatments for infectious diseases.

June 22, 2020 – Winnipeg Free Press – Dylan Robertson

Q1. Is it accurate that The administrative investigation is not related to the shipment of virus samples to China?

The administrative investigation is not related to the shipment of virus samples to China. Samples were provided in accordance with policies and procedures required under the *Human Pathogens and Toxins Act* (HPTA).

Q2. Is it accurate that viral samples of Ebola and Henipah were sent in response to a request from the Wuhan Institute of Virology for those samples?

Q4. Is it accurate that the National Microbiology Lab routinely shares samples with other public health labs?

As reported in a [National Post article](#) on May 5, 2020, in response to a request from the Wuhan Institute of Virology for viral samples of Ebola and Henipah viruses, the Public Health Agency of Canada (PHAC) sent samples for the purpose of scientific research in 2019. The NML routinely shares samples with other public health laboratories—as they do with the NML—to contribute to the advancement of science. Transfers follow strict protocols, including requirements under the HPTA, the *Transportation of Dangerous Goods Act*, the Canadian Biosafety Standard, and standard operating procedures of the NML.

Q3. Is it accurate that PHAC is taking steps to resolve this case as quickly as possible and that administrative investigations are impartial, thorough and in-depth. They are also procedurally fair and respect the rights of individuals?

Administrative investigations are impartial, thorough and in-depth. They are also procedurally fair and respect the rights of individuals. The investigation has not yet concluded.

More broadly (please answer these later as they may require some looking into) about the Ebola/Henipah shipment:

Q5. Please comment on the apparent confusion over how to package the samples and the contention that NML staff originally did not safety package these viruses or decontaminate it. CBC claims "it appears the NML's shipper initially planned to send the viruses in inappropriate packaging and only changed it when the clients in China flagged the problem."

Q6. What has changed in PHAC protocol since the package was sent? It appears there was confusion between Tunney's Pasture and Winnipeg over where the package was going, what was in it, and whether it had the proper paperwork.

The process for shipments of RG4 pathogens is outlined under the Emergency Response Assistance Plan (ERAP) process. Following the NML's notification of the Health Portfolio Operations Centre (HPOC) in Ottawa, the HPOC advised the Centre for Biosecurity (CB). CB is the regulatory authority responsible for the HPTA and its regulations. Consistent with its regulatory role, the CB contacted the NML to confirm that all required documentation was completed and procedures followed.

The shipping 'mistake' that was referred to in the [article published by the CBC on June 14](#), makes reference to a typo on the type of packaging, and it was fixed before anything had been shipped.

Five weeks before the shipment date (March 29, 2019), there was an e-mail exchange between Special Pathogens (SP) and World Courier Toronto (YYZ-Ops). Following this email, World Courier Toronto had been in touch with the Wuhan Institute of Virology that had pointed out the typo (from February 20, 2019). When World Courier Toronto informed SP shipper of the correction, it was noted by our staff member that a typo had occurred in the original email. This email correspondence occurred five weeks before the shipment date (March 29, 2019). The shipment of samples was carried out in full compliance with regulations under the *Human Pathogens and Toxins Act* that ensure the safe transport of material.

The transfer of Risk Group 4 (RG4) materials is a highly complex process that involves multiple checks and balances within the laboratory to prevent errors from occurring. To support this endeavour, in January 2017, a standard operating procedure (SOP) titled "Procedure for transferring Risk Group 4 Pathogens" was established (SP-CL4-PR-003-3). This document outlines step-by-step procedures that must be followed when shipping an RG4 pathogen and the numerous stakeholders that are engaged in the process.

Furthermore, a chain of custody form has been established to document each step in the transfer procedure (SP-CL4-PR-F-003-3). Oversight is provided at numerous levels to ensure compliance with Transport of Dangerous Goods (TDG) and the *Human Pathogens and Toxins Act* (HPTA).

7) Was there a Material Transfer Agreement for the shipment, or not? The ATIP documents suggest there wasn't an MTA. I reported there wasn't one [in August 2019](#). That month, the National Post [has PHAC saying](#) that "Contrary to a recent news report, all appropriate precautions, including protections for the government's intellectual property, were taken before the viruses were shipped, spokesman Eric Morrissette said."

It was determined that a Material Transfer Agreement (MTA) was not required for the sharing of these samples given that the purpose was to facilitate research to benefit human health and advance scientific enquiry on preventing and treating infectious diseases. In this case, and for this purpose, there was no desire to put constraints on appropriate scientific use.

The shipment of samples was carried out in full compliance with regulations under the *Human Pathogens and Toxins Act* that ensure the safe transport of material.

The NML has assessed its procedures with respect to case-by-case decisions on the requirement for MTAs. In the interests of assuring clarity and removing any ambiguity on the use of MTAs, the NML has instituted the requirement for MTAs whenever RG-3 or RG-4 samples are shared.

Q8. Does PHAC do any gain-of-function experiments? Are there any parameters such as limiting which viruses can undergo gain-of-function experiments such as by BSL?

The research performed at the NML is always done in pursuit of the betterment of public health, both within Canada and as part of global health initiatives. For example, as part of the development of the life-saving VSV-Ebola vaccine, the NML adapted the vaccine in order to test its efficacy in pre-clinical research studies. The NML complies with all regulations administered and enforced by the Public Health Agency of Canada's Centre for Biosecurity (CB) pertaining to the planning and conduct of research that may result in dual use. Specifically, a risk assessment is mandatory for any activities with a new or emerging pathogen, any major changes to existing techniques or any work with animal models. This risk assessment determines whether any potential exists for dual use within the work being done. If the potential exists, the risk assessment must be reviewed by the Institutional Biosafety Committee (IBC), which is mandated to decide whether the research project will go ahead. All IBC assessments are conducted independently from the scientists associated with these research projects.

Q9. Are gain-of-function experiments banned in Canada?

Gain-of-function experiments can be a critical step in the development of life-saving therapeutics and vaccines. Therefore, gain-of-function experiments are not banned in Canada; however, they are heavily regulated to ensure that the benefits outweigh the risks and that any resulting risks are mitigated. PHAC's CB administers and enforces regulations under the HPTA. All research within Canada with the potential for dual use including gain-of-function research falls under these regulations. In addition to requiring a licence to manipulate pathogens and toxins, all research facilities performing research on pathogens must submit a plan for administrative oversight that demonstrates how institutions identify, assess and manage research activities with dual-use potential. A licence will not be granted to any institution unless this plan is approved by the CB.

The NML requires completion of a risk assessment prior to proceeding with any work involving a new or emerging pathogen, any major changes to existing techniques or any work with animal models. This risk assessment process determines whether any potential exists for dual use within the work being proposed. Should this potential exist, the risk assessment must be reviewed by the Institutional Biosafety Committee, which is mandated to determine whether the research project will go ahead.



SP-CL4-PR-003-3.pdf



SP-CL4-PR-F-003-3.p

df

August 31, 2020 – Karen Pauls - CBC

Q. I'd also like to get an update on the search for a new boss.

The Public Health Agency of Canada (PHAC) has initiated the recruitment process to hire the next Scientific Director General of the National Microbiology Laboratory (NML). This position is critical to Canada's capacity to protect Canadians from infectious disease threats and to respond effectively to disease outbreaks and emergency situations. The NML's leading edge scientific expertise is a national asset that extends to global efforts to detect and respond to existing and new pathogens that threaten the

health of populations. As the COVID-19 pandemic demonstrates, the national laboratory is at the centre of Canada's scientific response that includes detection and characterization of SARS-CoV-2 using genomic technology; collaboration in vaccine development; and the development, standardization and validation of diagnostic tests used by clinicians to support patient care.

The leader of the NML has a prominent role in Canada's scientific, clinical and public health communities and in major international initiatives. To support our objective to recruit a renowned scientific leader, an external Recruitment Panel was established in June 2020, chaired by Dr. Lorne Tyrrell, an eminent virologist at the University of Alberta.

The focus of the first phase of the Panel's work was to define the requirements of the position based on the leadership role of the NML and its essential relationships with academia, industry, and public health laboratory systems both domestically and globally.

We are now moving into the recruitment phase which will entail wide advertisement of this leadership opportunity, nationally and internationally, along with targeted recruitment measures to attract the most highly qualified candidates.

Q. Are there any developments in the case of Xiangguo Qiu and Keding Cheng? Are they still on paid leave? Are they doing any research at all?

For privacy reasons, we will not comment further.

October 15, 2020 - Medscape (Allison Shelley)

Q1. I am a journalist reporting for Medscape Medical News and I have been following the ZMapp work of Dr. Xiangguo Qiu and her subsequent removal from the National Microbiology Laboratory in Winnipeg and RCMP investigation. As conspiracy theories over infectious diseases grip international communities, I wanted to circle back at this time for an update on this important Canada and China controversy. Is your team able to offer an update on the status of Dr. Xiangguo Qiu's case and employment status?

Any speculation about the role of Public Health Agency of Canada scientists in the emergence of the novel coronavirus has no factual basis. For privacy reasons, we will not comment on the administrative matter nor on personal circumstances of individual employees.

FOLLOW UP

Thanks Eric for your note and compassionate approach. The optics of a rising-star Governor General Award decorated scientist studying RNA viruses who is then unceremoniously escorted from her desk along with her Chinese team under RCMP investigation and never heard from again are not good.

I hear what you are saying about unfounded speculation over a naturally-occurring biohazard and employment privacy concerns and I respect that. On my new beat, I have renewed interest in the security of our national laboratory and hub for our country's national response to the largest pandemic of our time that is documented to have begun in China.

Dr. Xiangguo Qiu's reputation and case has called good work into question and some transparency will be needed. I've reached out to the RCMP about the police involvement and I'm wondering if your team might be able to share other information for Canadians in the days ahead?

For privacy reasons, we will not comment further.

January 19, 2021 – Elaine Dewar – Freelance Author

Full response sent on February 5, 2021

PART I (Sent to Media Relations directly)

Q1. I would like to confirm that the Public Health Agency of Canada has let go Keding Cheng and Dr. Xiangguo Qiu from their jobs at the National Microbiology Laboratory. This must have happened quite recently as I called asking for Qiu only a few weeks ago and she still had a voice mail message on the Laboratory's system. I would appreciate if you would tell me exactly when this happened, why this happened and whether or not charges have been laid by the RCMP.

Q2. I also need to confirm some facts with regard to when both of them began work with National Microbiology Laboratory and the various titles they have held while employed there. Is it possible for you to confirm that they both began to work at the Laboratory on or around 2003? Or was that only Xiangguo Qiu? Can you tell me when exactly Keding Cheng began to work directly under Xiangguo Qiu in the Special Pathogens Program? It looks to me as if they began to work closely together in late 2018 or 2019. I would appreciate it if you could give me the dates upon which they first entered employment at the Laboratory, their titles over the years, and the years in which those titles changed. I would also appreciate if you could tell me when they were granted security clearances to work at the Lab and whether they were landed immigrants or Canadian citizens at that time.

Q3. As I'm sure you are aware, Xiangguo Qiu's name was prominent in some of those theories. I am trying to explain to readers who they are, when they came to the NML, the kind of work they did there. Does that help you? And can you give me a timeline please?

Q4. Finally, I am unable to find a record that Dr. Xiangguo Qui was awarded a doctorate from the University of Manitoba. I am aware that both she and her husband hold MSc degrees but not doctorates. Is that correct?

The two scientists are no longer employed by the Public Health Agency of Canada as of January 20, 2021. We cannot disclose additional information nor comment further for reasons of confidentiality.

Please refer to the RCMP for questions on the status of their investigation.

PART II (Sent to Logan Banadyga)

Q4. I am interested to know when this non human primate study was begun. I see the original publication with the great results on macaques was published in 2019. was the work on this paper done in 2019?

The nonhuman primate experiment that is the focus of the mBio paper was completed in 2017. Subsequent sample analyses, as well as follow-up in vitro and in vivo (ferret) experiments were primarily performed in 2018 and 2019.

NOTE FOR BACKGROUND ONLY – NOT PART OF THE MEDIA RESPONSE : Qiu is listed as a corresponding author on both the mBio paper and the Nature Communications paper (PMID: 30631063) that preceded it. Her @canada.ca email address is listed on both papers.

Q5. And can you give me an email address for the last author (Dr. Qiu)?

We cannot disclose personal email addresses.

PART III (Sent to Media Relations for Mike Drebot)

Q6. I would like to speak to Mike Drobot directly. I want to ask Mike Drobot about what was required for people to qualify for security clearances in the early days at NML, that is, the period from 2000 when it opened until the end of 2006. He was there from 1998 and would be best positioned to answer that question.

The Public Health Agency of Canada politely declines the request for interview.

February 5, 2021 - CBC Karen Pauls

I am seeking confirmation that Xiangguo Qiu and Keding Cheng have been fired from the National Microbiology Lab and PHAC.

I have three sources telling me staff was told at a meeting of the special pathogens unit yesterday.

Can you please confirm that?

Can you also give me an update on the investigation into the possible administrative breach, what you've discovered so far, and the status of the scientists involved?

Note from reporter: We have enough independent corroboration to publish it in the morning, but I would prefer to get an official comment from you first.

Response:

The two scientists are no longer employed by the Public Health Agency of Canada as of January 20, 2021.

We cannot disclose additional information nor comment further for reasons of confidentiality.

FOLLOW UP

Does this have anything to do with the possible policy breach and administrative matter?

Does this conclude the internal review?

Are any charges being laid?

We cannot disclose additional information nor comment further for reasons of confidentiality.

Please refer to the RCMP for questions on the status of their investigation.

February 8, 2021 – Winnipeg Free Press – Dylan Robertson

1) I would like you to send me the statement sent to CBC about the National Microbiology Lab; in the past you have asked me to instead list specific questions, and so please include: the date Xiangguo Qiu and Keding Cheng had their employment with PHAC terminated; why PHAC is not saying the cause of this (was it directly related to the "administrative" issue or "policy breach")?

2) Why did these two stay on the payroll for 18 months until they were sacked?

3) Does PHAC have any response to the criticism that the lack of information around this situation is encouraging conspiracy theories?

The two scientists are no longer employed by the Public Health Agency of Canada as of January 20, 2021.

We cannot disclose additional information nor comment further for reasons of confidentiality.

March 4, 2021 – Global News – Sam Cooper

Could I please get an update on the QIU case? Is PHAC looking at changing oversight of staff based on this case? What is QIU's status?

Did PHAC not find it odd that the China side seemed pressureful about getting these materials from Canada? Did this pressure, or a lack of diligence from PHAC, contribute to dangerous transportation of these materials? Is it usual for PHAC staff to tell others “the Crown doesn’t regulate the Crown” when looking at issues of expediting movement or shipment of materials China has requested from Canada?

The two scientists are no longer employed by the Public Health Agency of Canada as of January 20, 2021.

We cannot disclose additional information nor comment further for reasons of confidentiality.

March 23, 2020 – G&M Steven Chase

Q1. Can you tell me when they were fired?

Q2. Why were they fired?

Q3. Were they fired because of the shipment of virus samples to China?

The two scientists are no longer employed by the Public Health Agency of Canada as of January 20, 2021. We cannot disclose additional information nor comment further for privacy reasons and confidentiality.

Q4. Is the investigation by PHAC/National Microbiology Lab over?

Yes, our review has been completed.

Q5. Are they still in Canada?

For privacy reasons, we are not able to respond to this question.

Q6. Are they Canadian citizens or Permanent Residents?

For privacy reasons, we cannot confirm the individual status of an employee, however we can say that they had to be eligible to legally work in Canada when they worked at the National Microbiology Laboratory.

Q7. Why did Iain Stewart refuse to tell MPs (Monday night at committee) the reason for these employees’ termination?

At this time we are seeking advice on what additional information can be disclosed, bearing in mind national security and privacy reasons, and a response will be provided to the Committee before (or by) the indicated deadline.

From: [Gilmour, Matthew \(PHAC/ASPC\)](#)
Sent: 2019-07-31 10:35 PM
To: Morrissette, Eric (HC/SC)
Cc: [Guercio, Steven \(PHAC/ASPC\)](#); [Elmslie, Kim \(PHAC/ASPC\)](#); [Hartigan, Maureen \(PHAC/ASPC\)](#)
Subject: Fwd: ERAP Notification 2019-02 - Shipment Ready for Departure

Hi Eric

This thread not only confirms the March 31 departure, but is a also good example of the scope of communication involved in the ERAP process (incl. prov and airport authorities). We can add more on ERAP tomorrow if this a valuable line to go down.

Matt

(via mobile)

Begin forwarded message:

From: "OCNML DIR / LNMCO (PHAC/ASPC)" <PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA>
Date: March 31, 2019 at 3:08:18 PM CDT
To: "Gilmour, Matthew (PHAC/ASPC)" <matthew.gilmour@canada.ca>, "Guercio, Steven (PHAC/ASPC)" <steven.guercio@canada.ca>, "Drebot, Mike (PHAC/ASPC)" <mike.drebot@canada.ca>, NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.aspc@canada.ca>, "CSCHAH SES (PHAC/ASPC)" <phac.cschah.ses.aspc@canada.ca>, "OCNML Logistics / Logistique LNMCO (PHAC/ASPC)" <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>, "OCNML Support / Soutien LNMCO (PHAC/ASPC)" <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>, "**personal information**" <**personal information**>, "PHAC.F OC_NML_OCD_Group F.ASPC" <OC_NML_OCD_Group@canada.ca>, "NML Specimen Receiving (PHAC/ASPC)" <phac.nml.specimen.receiving.aspc@canada.ca>, "guelph, erap (PHAC/ASPC)" <phac.erap-guelph.aspc@canada.ca>, "**personal information**" <**personal information**>
Cc: "HPOC-COPS, PHAC-ASPC (PHAC/ASPC)" <phac-aspc.hpoc-cops@canada.ca>
Subject: Re: ERAP Notification 2019-02 - Shipment Ready for Departure

Please be advised that the RG4 shipment has departed Toronto for Beijing on flight AC031.

ERAP teams can now stand down.

Sent from my BlackBerry 10 smartphone on the Bell network.

From: OCNML DIR / LNMCO (PHAC/ASPC)

Sent: Friday, March 29, 2019 6:16 PM

To: Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); **personal information**; PHAC.F OC_NML_OCD_Group F.ASPC; NML Specimen Receiving (PHAC/ASPC); guelph, erap (PHAC/ASPC); **personal information**

Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC); **personal information**

Cc: HPOC-COPS, PHAC-ASPC (PHAC/ASPC)

Subject: Re: ERAP Notification 2019-02 - Shipment Ready for Departure

The RG4 shipment is scheduled to depart Toronto for Beijing on Air Canada Flight AC 031 on March 31 at 14:45 EDT.

The Air Canada Cargo air waybill tracking number for this shipment is **third party**.

Sent from my BlackBerry 10 smartphone on the Bell network.

From: OCNML DIR / LNMCO (PHAC/ASPC)

Sent: Friday, March 29, 2019 3:38 PM

To: OCNML DIR / LNMCO (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); **personal information**; 'oc_nml_ocd_group@phac-aspc.gc.ca'; NML Specimen Receiving (PHAC/ASPC); 'erap.guelph@canada.ca'; **personal information**

Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC); **personal information**

Cc: HPOC-COPS, PHAC-ASPC (PHAC/ASPC)

Subject: ERAP Notification 2019-02 - Shipment Ready for Departure

The Risk Group 4 shipment has been picked up by **third party** from the NML in Winnipeg.

The tracking number for this shipment is **3rd**. This shipment is en-route to China via Toronto.

Please note - once this shipment departs from the airport in Toronto, ERAP teams can stand down.

Operations Centre Director

National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch

Canadian Science Centre for Human and Animal Health

Public Health Agency of Canada - Government of Canada

Telephone (866)262-8433

******new e-mail** PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

Directeur du centre des opérations

Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses

Centre scientifique canadien de la santé humaine et animale

Agence de la santé publique du Canada

Téléphone (866)262-8433

**** **nouveau courriel** PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

1015 Arlington Street, Emergency Operations Centre

Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.

 cid:image001.png@01D34279.EE0CF920

From: Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

Sent: 2019-03-29 8:03 AM

To: Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.asp.aspc@canada.ca>; CSCHAH SES (PHAC/ASPC) <phac.cschah.ses.aspc@canada.ca>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>;

personal information [REDACTED];

'oc_nml_ocd_group@phac-aspc.gc.ca' <oc_nml_ocd_group@phac-aspc.gc.ca>; NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>;

erap.guelph@canada.ca; **personal information** [REDACTED]

Cc: HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>

Subject: ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment will be routed through Toronto and is scheduled to depart from the NML in Winnipeg today between 13:30-14:00. Further details will be provided when available.

Operations Centre Director

National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch

Canadian Science Centre for Human and Animal Health

Public Health Agency of Canada - Government of Canada

Telephone (866)262-8433

******new e-mail** PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

Directeur du centre des opérations

Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses

Centre scientifique canadien de la santé humaine et animale

Agence de la santé publique du Canada

Téléphone (866)262-8433

**** **nouveau courriel** PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

1015 Arlington Street, Emergency Operations Centre

Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu

cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.

cid:image001.png@01D34279.EE0CF920

From: Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)
Sent: 2019-03-28 9:34 AM
To: OCNML DIR / LNMCO (PHAC/ASPC) <PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA>; Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nlm.sp-lnm.asp.aspc@canada.ca>; CSCHAH SES (PHAC/ASPC) <phac.cschah.ses.aspc@canada.ca>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>; **personal information**; 'oc_nml_ocd_group@phac-aspc.gc.ca' <oc_nml_ocd_group@phac-aspc.gc.ca>; NML Specimen Receiving (PHAC/ASPC) <phac.nlm.specimen.receiving.aspc@canada.ca>
Cc: HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>
Subject: ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29th. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood

Operations Centre Director

National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch

Canadian Science Centre for Human and Animal Health

Public Health Agency of Canada - Government of Canada

Telephone (866)262-8433

******new e-mail** PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

Directeur du centre des opérations

Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses

Centre scientifique canadien de la santé humaine et animale

Agence de la santé publique du Canada

Téléphone (866)262-8433

**** **nouveau courriel** PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

1015 Arlington Street, Emergency Operations Centre

Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.

cid:image001.png@01D34279.EE0CF920

From: Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)
Sent: 2019-03-27 1:31 PM
To: Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Drebot, Mike (PHAC/ASPC)

<mike.drebot@canada.ca>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.aspc@canada.ca>; CSCHAH SES (PHAC/ASPC) <phac.cschah.ses.aspc@canada.ca>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>; **personal information**; oc_nml_ocd_group@phac-aspc.gc.ca; NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>
Cc: HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>

Subject: ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28th. The shipment will be transported by **3rd party** to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director

National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch

Canadian Science Centre for Human and Animal Health

Public Health Agency of Canada - Government of Canada

Telephone (866)262-8433

******new e-mail** PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

Directeur du centre des opérations

Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses

Centre scientifique canadien de la santé humaine et animale

Agence de la santé publique du Canada

Téléphone (866)262-8433

**** **nouveau courriel** PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

1015 Arlington Street, Emergency Operations Centre

Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.

 [cid:image001.png@01D34279.EE0CF920](#)

Capes, Jennifer (PHAC/ASPC)

From: Guercio, Steven (PHAC/ASPC)
Sent: 2019-07-31 4:12 PM
To: Magro, Sabrina (HC/SC)
Cc: MacKenzie, Sara (HC/SC); Gilmour, Matthew (PHAC/ASPC); Hollington, Jennifer (HC/SC); Morrissette, Eric (HC/SC); Hartigan, Maureen (PHAC/ASPC); Payette, Louise (HC/SC); Killen, Marita (PHAC/ASPC)
Subject: RE:
Attachments: MED-F-13A.pdf

Here is the form.

From: Guercio, Steven (PHAC/ASPC)
Sent: 2019-07-31 3:02 PM
To: Magro, Sabrina (HC/SC)
Cc: MacKenzie, Sara (HC/SC); Gilmour, Matthew (PHAC/ASPC); Hollington, Jennifer (HC/SC); Morrissette, Eric (HC/SC); Hartigan, Maureen (PHAC/ASPC); Payette, Louise (HC/SC); Killen, Marita (PHAC/ASPC)
Subject: FW:

From: Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>
Sent: 2019-07-30 2:58 PM
To: Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>
Subject:

This is from the ERAP database that the OC is keeping now.

Shipment #	Tracking#	Courier	Date Shipment Initiated (yyyy-mm-dd)	Date ERAP Initiated (yyyy-mm-dd)	Date Shipped (yyyy-mm-dd)	Date Completed (yyyy-mm-dd)	# Days (Duration)	Incoming/Outgoing	Consignor	Consignee	Pathogen	Comments
2019-02	3rd party		2019-03-27	2019-03-29	2019-03-29	2019-04-01	3	Outgoing	Xiangguo Qiu	personal Chinese Academy of Sciences - Wuhan Institute of Virology Xiao Hong Shan No.44 Wuhan, Hubei, China, 430071	Ebola & Henipah Virus	Left Toronto (Canadian air space) on March 31, 2019

In the CBS, it references HPTR 4(1) in TABLE 1-2.

<https://www.canada.ca/en/public-health/services/canadian-biosafety-standards-guidelines/second-edition.html#4.1>

- persons exporting human pathogens and toxins outside of Canada must take reasonable care to satisfy themselves that the intended recipient will

Public Health
Agency of CanadaAgence de la santé
publique du Canada

Internal Use Only

**ALL FIELDS IN RED
BOXES ARE REQUIRED**

NML Shipping Requisition

Requested Ship Date: (YYYY-MM-DD)

Originator Information:

Name: **Department:**
Room Number: **Telephone Number:**

Person Responsible: *Please check box if same as Originator*

Name: **Title:**
Room Number: **Telephone Number:**

NOTE: Person Responsible must have knowledge and expertise related to contents and would be contacted in case of emergency relating to the shipment

Recipient: CL2 Laboratory CL3 Laboratory CL4 Laboratory Domestic International
 * PHAC License No. "Domestic shipments only"
Note: Refer to item 3.4 of SES-WI-068

Receiving Lab Name: **Name of Receiver:**
Address: **City:**
Prov./State: **Country:** **Postal/Zip Code:**
Telephone Number: **Email:**

Preferred Courier: **Originator Acting as Courier**
Account Number:

Description of Material: *Please select all that apply*

RG2 RG3 RG4 Bacteria Virus Prion Non-infectious

Antibody Antigen Blood Product Cells
 Culture Nucleic Acids Recombinant Material Tissue
 Toxins Other

Chemical Radiological Proficiency Panel

Origin of Biological Pathogen or Toxin: Domestic International
Obtain CFIA Transfer Permit and/or Complete SES-F-052A
Note: Refer to SES-WI-052

Complete inventory of items being shipped: *Please attach list if require additional space*

Include any and all chemical solutions, their concentration as well as related MSDS from the manufacturer or MSDS Online Database

Technical Name	Quantity/Volume per Primary Container	Number of Primary Containers
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>

1. Has your supervisor been notified and agreed to the outgoing shipment? YES NO
2. For biological pathogens or toxins; a CFIA Permit or NML Transfer Authorization is required? YES (please attach) NO
(See SES-WI-068 for information)
3. Are other special permits required? YES (please attach) NO
(See SES-WI-068 for information)
4. Is the material being sent under (as part of) an agreement? YES (please attach) NO
(If unsure, please contact the Office of Business Development and Intellectual Property at Ext. 2120)
5. Is a commercial invoice or B13A required? YES (please attach) NO
(If unsure, please contact Shipping and Receiving at Ext. 2046)
6. Special handling Instructions?
 Dry Ice Cold Packs Room Temp. Other:
7. For items from CL3 and CL4: Please describe the method of physical or chemical treatment used to decontaminate the inside and outside of the sealed container (Provide SOP number if applicable)

Other comments or important information:

Originator signature (not required if emailed)

Date (YYYY-MM-DD)

ALL SPECIMENS MUST BE IN SPECIMEN SHIPPING ROOM (R1130) BY NOON

All biological material sent via Specimen Shipping must:

- Be in appropriate leak-proof primary containers. Example, O-ring cryovials, tubes must be wrapped with Parafilm
- Include an inventory list and all required documentation.
- * PHAC License No. is required for "Domestic shipments only"

Completed Shipping Requisitions Required:

48 hours for Domestic shipment
 5 business days for International shipments
 5 business days for Proficiency Panels

Room Temp: Thursday at noon
 Dry Ice: Wednesday at noon
 Cold Pack: Thursday at noon

Cut off for shipping specimens:

Within the City: Daily by 2 pm
 Domestic: International:
 Dry Ice: Monday at noon
 Cold Pack: Tuesday at noon

In case of an emergency shipment, please contact Ext. 6091 and we will do our best to accommodate.

Please use "EMAIL" button to send COMPLETED FORM TO SPECIMEN SHIPPING if you wish to use their service for packaging and labelling.

If you have any questions in regard to shipping specimens, please contact Specimen Shipping at EXT. 6091/6096 or via email at nml.specimen.receiving@phac-aspc.gc.ca

Important Disclaimers:

Please note that obtaining transfer letters or any other special permits will be responsibility of the Originator.

A copy of the Shipping Requisition must be left with Specimen Shipping or Shipping and Receiving for ALL shipments regardless of if the originator is acting as the courier

FINAL January 22, 2021

PROTECTED B

MEDIA LINES

Employment status of two National Microbiology Laboratory scientists

BACKGROUND

In June 2019, the Public Health Agency of Canada (PHAC) launched a review into the conduct of two scientists (Drs. Qiu and Cheng) of the National Microbiology Laboratory (NML) with respect to their adherence to various Government of Canada and departmental policies.

The launch of the review of an administrative matter garnered significant media attention with NML employees speaking anonymously to the media about not only the implicated scientists but also about the culture at the NML. Several reporters follow-up regularly for updates.

personal info

[REDACTED]

personal info

[REDACTED]

The following media lines will be used reactively for media calls only once it is confirmed that the two individuals receive the letters.

Note that a separate RCMP investigation is still underway.

KEY MESSAGES

- The review has been completed.
- We can assure Canadians that their health and safety is not compromised and that the National Microbiology Laboratory continues to play a critical role in protecting the health and safety of Canadians.
- We cannot disclose additional information nor comment further for privacy reasons and confidentiality.

If asked about the status of the employees

- The two scientists are no longer employed by the Public Health Agency of Canada as of January 20, 2021.
- We cannot comment further.

FINAL January 22, 2021

PROTECTED B

If asked about the length of time the matter was under review

- The Public Health Agency of Canada worked expeditiously while respecting the principles of procedural fairness and ensuring appropriate due diligence.

QUESTIONS AND ANSWERS

Q1. Are security partners involved?

It is normal procedure for the Agency to consult with security partners as required. It would be inappropriate to comment any further given privacy and other considerations.

Q2. Is there a link between the scientists and China and did that lead to them no longer being employed by PHAC?

We cannot disclose specific information nor comment further.

Q3. Is there a risk to national security?

The Government of Canada takes any threat to Canada's national security seriously and works with federal partners to keep Canadians safe. As you can expect, we do not publicly comment, or confirm or deny the specifics of investigations, operational interests, methodologies or activities.

Q4. Is the NML currently collaborating with China on any scientific research? Will Canada continue to collaborate and share scientific information with China?

There are no current collaborations between the NML and labs/institutions in China. Canada's National Microbiology Laboratory is known around the world for its scientific excellence and contributions to global health. PHAC engages in important scientific research relationships to advance public health research and science aimed at improving public health. Collaborations with labs outside of Canada is critical to advance public health research into infectious diseases.

Q5. Is the RCMP investigation complete? Why is it taking so long? Have charges been laid?

Refer to the RCMP.



INQUIRY OF MINISTRY DEMANDE DE RENSEIGNEMENT AU GOUVERNEMENT

PREPARE IN ENGLISH AND FRENCH MARKING "ORIGINAL TEXT" OR "TRANSLATION"
PRÉPARER EN ANGLAIS ET EN FRANÇAIS EN INDIQUANT "TEXTE ORIGINAL" OU "TRADUCTION"

QUESTION NO./N° DE LA QUESTION Q-533	BY / DE Mrs. Jansen (Cloverdale—Langley City)	DATE June 15, 2020
---	--	-----------------------

Reply by the Minister of Health
Réponse de la ministre de la Santé

Signed by Mr. Darren Fisher

PRINT NAME OF SIGNATORY
INSCRIRE LE NOM DU SIGNATAIRE

SIGNATURE
MINISTER OR PARLIAMENTARY SECRETARY
MINISTRE OU SECRÉTAIRE PARLEMENTAIRE

QUESTION

With regard to the transfer of Ebola and Henipah viruses from the National Microbiology Lab (NML) to persons, laboratories, and institutions in China: (a) who in China requested the transfer; (b) other than the Wuhan Institute of Virology (WIV), which laboratories in China requested the transfer; (c) for the answers in (a) and (b) which are affiliated with the military of China; (d) on what date was the WIV's request for the transfer received by the NML; (e) what scientific research was proposed, or what other scientific rationale was put forth, by the WIV or the NML scientists to justify the transfer of Ebola and Henipah viruses; — **See full text of the question attached.**

REPLY / RÉPONSE

ORIGINAL TEXT
TEXTE ORIGINAL

TRANSLATION
TRADUCTION

Public Health Agency of Canada

- (a) The Director of National Biosafety Laboratory, Wuhan Institute of Virology.
- (b) Only the WIV requested the transfer.
- (c) N/A.
- (d) June 28, 2018.
- (e) Research on infectious immunological mechanisms, antivirals and virus-cell interactions of the Ebola virus (EBOV) and the Nipah virus (NiV).
- (f) 12 strains of EBOV and 3 strains of NiV were authorized for transfer.
- (g) For shipping purposes, a nominal monetary value of \$75.00 was assigned to the samples. It was never intended to be an invoice for payment and no payment was received.
- (h) No compensation was received.
- (i) No. The National Microbiology Laboratory (NML) complies with all applicable requirements of the *Human Pathogens and Toxins Act* (HPTA), the *Transportation of Dangerous Goods Act* (TDGA), and the Canadian Biosafety Standard when sharing samples of pathogens and toxins with partner laboratories in Canada and in other countries.
- (j) There were no conditions on the transfer of the material to WIV. The NML ensured all applicable requirements of the HPTA, the TDGA and the Canadian Biosafety Standard were followed.
- (k) The NML received a letter from the Director of the National Biosafety Laboratory (WIV), outlining the intent to study these viruses under their National Key Research and Development Plan. The intended areas of study were infectious immunological mechanisms, antivirals and virus-cell interactions of EBOV and NiV. The Director also guaranteed in his signed attestation letter that the viruses will only be used for research purposes. The virus samples were not transferred to any other institutions as outlined in part (b).

- 2 -

The NML is required, as per the *Human Pathogens and Toxins Regulations* (HPTR), to receive, from any laboratory requesting pathogens, proof that they have the containment level of laboratory required for handling that pathogen. In this case, the Biosafety Officer at the WIV provided an official written statement (as specified in the HPTR) outlining the WIV facility had the appropriate containment for the pathogens being shipped.

- (l) The Government of Canada does not have jurisdiction to audit and inspect laboratories in other countries. The NML is required, as per the HPTR, to receive, from any laboratory requesting pathogens, proof that they have the containment level of laboratory required for handling that pathogen. This is in the form of a certification or license from a regulatory body in that country or, in countries who do not have such schemes, an attestation from a Biosafety Officer in the facility stating that the laboratory meets the necessary containment level. In this case, the Biosafety Officer at the WIV provided an official written statement (as specified in the HPTR) outlining the WIV facility had the appropriate containment for the pathogens being shipped.
- (m) See the previous response to part (l).
- (n) No follow up was required, as per question (b) there were no other institutions.
- (o) It was determined that intellectual property protections were not required for the sharing of these samples given that the purpose was to facilitate research to benefit human health and advance scientific enquiry on preventing and treating infectious diseases.
- (p) The NML has a variety of EBOV strains stored in the Containment Level 4 (CL4) of the NML. This shipment contained samples representative of approximately 60% of the EBOV strains housed in the CL4. Two vials per strain were shipped which represents less than 1% of the total EBOV housed in the CL4.
- (q) There are six papers (including the one referenced in this part) listed with at least one author with Special Pathogens affiliation and one author with an affiliation to the military of China. They are:
- *A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses;*
 - *Identification of a clinical compound losmapimod that blocks Lassa virus entry;*
 - *Tangeretin, an extract from Citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever;*
 - *Equine immunoglobulin F(ab')₂ fragments protect mice from Rift Valley fever virus infection;*
 - *Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection;* and
 - *Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.*

There are no unpublished studies that we are aware of that were performed with scientists affiliated with the military of China.

- (r) There are no current collaborations at the NML with the WIV, China's Academy of Military Medical Sciences, or other parts of China's military establishment.
- (s) There was a typo that occurred in an email on February 5, 2019, between Special Pathogens and World Courier Toronto. This email correspondence occurred five weeks before the shipment date (March 29, 2019). Material was shipped using the correct packaging.
- (t) No error was made – see the previous response to part (s).
- (u) These comments relate to the administrative process associated with transit through Toronto. The process for shipment through Vancouver is simpler.
- (v) On March 29, 2019, the risk group 4 (RG4) shipment was scheduled to depart from the NML in Winnipeg between 13:30-14:00 EDT. No flight number was provided.

On March 31, 2019, the RG4 shipment had departed Toronto for Beijing on flight AC031.

On April 1, 2019, PHAC was notified that the package had arrived safely in Wuhan.

- 3 -

- (w) It is the responsibility of the courier, as the NML does not control what airlines and airports are used to ship the samples.
- (x) The other names listed are different strains of EBOV and NiV. No other viruses were shipped.
- (y) No other viruses have been sought by or transferred to the WIV.
- (z) All transfers of RG4 samples follow strict transportation requirements and are authorized by senior NML officials. The NML tracks and keeps electronic records of all shipments of samples in accordance with the HPTA and the HPTR.

On the specific shipment to China, PHAC confirmed that all protocols were followed as directed by legislation and Standards.

- (aa) Documents provided through the Access to Information Act (ATIA) were processed in accordance with the ATIA.
- (bb) In Canada, PHAC administers the HPTA and the HPTR.

Global Affairs Canada (GAC) has oversight on export of any controlled materials, including risk group 3 and RG4 pathogens, under the *Export and Import Permits Act* (EIPA). Under the EIPA, anyone (unless otherwise excluded, such as Crown organizations) wishing to export any materials included on the Export Control List or to a country included in the Area Control List must first receive a Permit to Export from GAC.

As per standard practice in consultation with GAC, the NML is not required to obtain an export permit.

References:

HPTA and HPTR

<https://laws.justice.gc.ca/eng/acts/H-5.67/>

<https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/licensing-program.html>

EIPA

<https://laws-lois.justice.gc.ca/eng/acts/e-19/>

<https://www.international.gc.ca/controls-controles/index.aspx?lang=eng>

- (cc) Canada does have a legal framework for this. See the response for (bb) above.
- (dd) With respect to the transfer to the WIV, the NML complied with all applicable requirements of the HPTA, the TDGA, and the Canadian Biosafety Standard.

The NML is authorized and licensed under the HPTA and the TDGA to ship RG4 pathogens. When shipping RG4 pathogens, the NML is required to submit an Emergency Response Assistance Plan to Transport Canada. For the shipment to WIV, all TDGA documentation was submitted correctly. See also (l) above.

- (ee) See the response to part (bb) above.
- (ff) See the previous response to part (l).
- (gg) There have been no requests from the NML for material from the WIV.

- 4 -

Q-533² — June 15, 2020 — Mrs. Jansen (Cloverdale—Langley City) — With regard to the transfer of Ebola and Henipah viruses from the National Microbiology Lab (NML) to persons, laboratories, and institutions in China: (a) who in China requested the transfer; (b) other than the Wuhan Institute of Virology (WIV), which laboratories in China requested the transfer; (c) for the answers in (a) and (b) which are affiliated with the military of China; (d) on what date was the WIV's request for the transfer received by the NML; (e) what scientific research was proposed, or what other scientific rationale was put forth, by the WIV or the NML scientists to justify the transfer of Ebola and Henipah viruses; (f) what materials were authorized for transfer pursuant to Transfer Authorization NML-TA-18-0480, dated October 29, 2018; (g) did the NML receive payment of \$75, per its commercial invoice of March 27, 2019, for the transfer, and on what date was payment received; (h) what consideration or compensation was received from China in exchange for providing this material, broken down by amount or details of the consideration or compensation received by each recipient organization; (i) has the government requested China to destroy or return the viruses and, if not, why; (j) did Canada include, as a term of the transfer, a prohibition on the WIV further transferring the viruses with others inside or outside China, except with Canada's consent; (k) what due diligence did the NML perform to ensure that the WIV and other institutions referred to in (b) would not make use of the transferred viruses for military research or uses; (l) what inspections or audits did the NML perform of the WIV and other institutions referred to in (b) to ensure that they were able to handle the transferred viruses safely and without diversion to military research or uses; (m) what were the findings of the inspections or audits referred to in (l), in summary; (n) after the transfer, what follow-up has Canada conducted with the institutions referred to in (b) to ensure that the only research being performed with the transferred viruses is that which was disclosed at the time of the request for the transfer; (o) what intellectual property protections did Canada set in place before sending the transferred viruses to the persons and institutions referred to in (a) and (b); (p) of the Ebola virus strains sent to the WIV, what percentages of the NML's total Ebola collection and Ebola collection authorized for sharing is represented by the material transferred; (q) other than the study entitled "Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease", which other published or unpublished studies did the NML scientists perform with scientists affiliated with the military of China; (r) which other studies are the NML scientists currently performing with scientists affiliated with the WIV, China's Academy of Military Medical Sciences, or other parts of China's military establishment; (s) what is the reason that Anders Leung of the NML attempted to send the transferred viruses in incorrect packaging (type PI650), and only changed its packaging to the correct standard (type PI620) after being questioned by the Chinese on February 20, 2019; (t) has the NML conducted an audit of the error of using unsafe packaging to transfer the viruses, and what in summary were its conclusions; (u) what is the reason that Allan Lau and Heidi Wood of the NML wrote on March 28, 2019, that they were "really hoping that this [the transferred viruses] goes through Vancouver" instead of Toronto on Air Canada, and "Fingers crossed!" for this specific routing; (v) what is the complete flight itinerary, including airlines and connecting airports, for the transfer; (w) were all airlines and airports on the flight itinerary informed by the NML that Ebola and Henipah viruses would be in their custody; (x) with reference to the email of Marie Gharib of the NML on March 27, 2019, other than Ebola and Henipah viruses, which other pathogens were requested by the WIV; (y) since the date of the request for transfer, other than Ebola and Henipah viruses, which other pathogens has the NML transferred or sought to transfer to the WIV; (z) did the NML inform Canada's security establishment, including the RCMP, the Canadian Security Intelligence Service, the Communication Security Establishment, or other such entity, of the transfer before it occurred, and, if not, why not; (aa) what is the reason that the Public Health Agency of Canada (PHAC) redacted the name of the transfer recipient from documents disclosed to the Canadian Broadcasting Corporation (CBC) under the Access to Information Act, when the PHAC later willingly disclosed that information to the CBC; (bb) does Canada have any policy prohibiting the export of risk group 3 and 4 pathogens to countries, such as China, that conduct gain-of-function experiments, and in summary what is that policy; (cc) if Canada does not have any policy referred to in (bb), why not; (dd) what is the reason that did the NML or individual employees sought and obtained no permits or authorizations under the Human Pathogens and Toxins Act, the Transportation of Dangerous Goods Act, the Export Control Act, or related legislation prior to the transfer; (ee) what legal controls prevent the NML or other government laboratories sending group 3 or 4 pathogens to laboratories associated with foreign militaries or laboratories that conduct gain-of-function experiments; (ff) with respect to the September 14, 2018, email of Matthew Gilmour, in which he writes that "no certifications [were] provided [by the WIV], they simply cite they have them", why did the NML proceed to transfer Ebola and Henipah viruses without proof of certification to handle them safely; and (gg) with respect to the September 14, 2018, email of Matthew Gilmour, in which he asked "Are there materials that [WIV] have that we would benefit from receiving? Other VHF? High path flu?", did the NML request these or any other materials in exchange for the transfer, and did the NML receive them?



Government
of Canada

Gouvernement
du Canada



INQUIRY OF MINISTRY DEMANDE DE RENSEIGNEMENT AU GOUVERNEMENT

PREPARE IN ENGLISH AND FRENCH MARKING "ORIGINAL TEXT" OR "TRANSLATION"
PRÉPARER EN ANGLAIS ET EN FRANÇAIS EN INDIQUANT "TEXTE ORIGINAL" OU "TRADUCTION"

QUESTION NO./N° DE LA QUESTION Q-534	BY / DE Mrs. Jansen (Cloverdale—Langley City)	DATE June 15, 2020
---	--	-----------------------

Reply by the Minister of Health
Réponse de la ministre de la Santé

Signed by Mr. Darren Fisher



PRINT NAME OF SIGNATORY
INSCRIRE LE NOM DU SIGNATAIRE

SIGNATURE
MINISTER OR PARLIAMENTARY SECRETARY
MINISTRE OU SECRÉTAIRE PARLEMENTAIRE

QUESTION

With regard to both the administrative and RCMP investigations of the National Microbiology Lab (NML), Xiangguo Qiu, and Keding Cheng: (a) with respect to the decision of the NML and the RCMP to remove Dr. Qiu and Dr. Cheng from the NML facilities on July 5, 2019, what is the cause of delay that has prevented that the NML and the RCMP investigations concluding; (b) in light of a statement by the Public Health Agency of Canada (PHAC) to the Canadian Broadcasting Corporation (CBC) which was reported on June 14, 2020, and which stated, "the administrative investigation of [Dr. Qiu or Dr. Cheng] is not related to the shipment of virus samples to China", what are these two scientists being investigated for; (c) did Canada receive information from foreign law enforcement or intelligence agencies which led to the investigations against Dr. Qiu or Dr. Cheng, and, in summary, what was alleged; (d) which other individuals apart from Dr. Qiu or Dr. Cheng are implicated in the investigations; (e) are Dr. Qiu or Dr. Cheng still in Canada; (f) are Dr. Qiu or Dr. Cheng cooperating with law enforcement in the investigations; (g) are Dr. Qiu or Dr. Cheng on paid leave, unpaid leave, or terminated from the NML; (h) what connection is there between the investigations of Dr. Qiu or Dr. Cheng and the investigation by the United States National Institutes of Health which has resulted in 54 scientists losing their jobs mainly due to receiving foreign funding from China, as reported by the journal Science on June 12, 2020; (i) does the government possess information that Dr. Qiu or Dr. Cheng solicited or received funding from a Chinese institution, and, in summary what is that information; and (j) when are the investigations expected to conclude, and will their findings be made public?

REPLY / RÉPONSE

ORIGINAL TEXT
TEXTE ORIGINAL



TRANSLATION
TRADUCTION



Public Health Agency of Canada

- (a) Due process is being followed in the execution of this administrative investigation.
- (b) An administrative investigation pertaining to possible policy breaches is underway.
- (c) The Public Health Agency of Canada (PHAC) has no knowledge pertaining to this.
- (d) The information requested is considered personal information and is subject to the *Privacy Act*. Therefore PHAC will not comment on details pertaining to individual employees.
- (e) The information requested is considered personal information and is subject to the *Privacy Act*. Therefore PHAC will not comment on details pertaining to individual employees.
- (f) The information requested is considered personal information and is subject to the *Privacy Act*. Therefore PHAC will not comment on details pertaining to individual employees.
- (g) The information requested is considered personal information and is subject to the *Privacy Act*. Therefore PHAC will not comment on details pertaining to individual employees.
- (h) There is no connection.
- (i) Funding has not been solicited or received by the National Microbiology Laboratory from any Chinese institution.
- (j) Conclusion of the investigations depend on the completion of due process.



INQUIRY OF MINISTRY DEMANDE DE RENSEIGNEMENT AU GOUVERNEMENT

PREPARE IN ENGLISH AND FRENCH MARKING "ORIGINAL TEXT" OR "TRANSLATION"
PRÉPARER EN ANGLAIS ET EN FRANÇAIS EN INDIQUANT "TEXTE ORIGINAL" OU "TRADUCTION"

QUESTION NO./N° DE LA QUESTION Q-534	BY / DE Mme Jansen (Cloverdale—Langley City)	DATE Le 21 mai 2020
---	---	------------------------

Reply by the Minister of Health
Réponse de la ministre de la Santé

Signé par M. Darren Fisher

PRINT NAME OF SIGNATORY
INSCRIRE LE NOM DU SIGNATAIRE



SIGNATURE
MINISTER OR PARLIAMENTARY SECRETARY
MINISTRE OU SECRÉTAIRE PARLEMENTAIRE

QUESTION

En ce qui concerne l'enquête administrative et l'enquête de la GRC portant sur le Laboratoire national de microbiologie (LNM), Xiangguo Qiu et Keding Cheng : a) pour ce qui est de la décision qu'ont prise le LNM et la GRC de retirer Mme Qiu et M. Cheng des installations du LNM le 5 juillet 2019, quelle est la cause du retard ayant empêché les enquêtes du LNM et de la GRC de se conclure; b) selon la déclaration de l'Agence de la santé publique du Canada dont la CBC a parlé le 14 juin 2020, « l'enquête administrative sur Mme Qiu et M. Cheng ne se rapporte pas à l'envoi d'échantillons de virus en Chine », pour quel motif ces deux chercheurs font-ils alors l'objet d'enquêtes; c) les enquêtes sur Mme Qiu et M. Cheng découlent-elles de renseignements fournis au Canada par les forces de l'ordre ou les services de renseignements d'autres pays et, si oui, que disaient ces renseignements, en gros; d) en plus de Mme Qiu et de M. Cheng, sur quelles autres personnes portent les enquêtes; e) Mme Qiu et M. Cheng sont-ils toujours au Canada; f) Mme Qiu et M. Cheng coopèrent-ils avec les forces de l'ordre pendant les enquêtes; g) Mme Qiu et M. Cheng sont-ils en congé payé, en congé non payé ou ont-ils été licenciés du LNM; h) quels sont les liens entre les enquêtes dont font l'objet Mme Qiu et M. Cheng et l'enquête des National Institutes of Health des États-Unis à l'issue de laquelle 54 chercheurs ont perdu leur emploi, principalement pour avoir reçu du financement étranger de la Chine (revue Science, 12 juin 2020); i) le gouvernement détient-il des renseignements selon lesquels Mme Qiu et M. Cheng auraient sollicité ou obtenu des fonds d'une institution chinoise, et que disent ces renseignements, en gros; j) quand les enquêtes devraient-elles se terminer et les conclusions de ces enquêtes seront-elles rendues publiques?

REPLY / RÉPONSE

ORIGINAL TEXT
TEXTE ORIGINAL

TRANSLATION
TRADUCTION

Agence de la santé publique du Canada

- a) Nous suivons une procédure régulière dans l'exécution de cette enquête administrative.
- b) Une enquête administrative concernant d'éventuelles violations de la politique est en cours.
- c) L'Agence de la santé publique du Canada (ASPC) n'a aucune connaissance à ce sujet.
- d) Les informations demandées sont considérées comme des informations personnelles et sont soumises à la *Loi sur la protection des renseignements personnels*. Par conséquent, nous ne commenterons pas ces détails des employés individuels.
- e) Les informations demandées sont considérées comme des informations personnelles et sont soumises à la *Loi sur la protection des renseignements personnels*. Par conséquent, nous ne commenterons pas ces détails des employés individuels.
- f) Les informations demandées sont considérées comme des informations personnelles et sont soumises à la *Loi sur la protection des renseignements personnels*. Par conséquent, nous ne commenterons pas ces détails des employés individuels.
- g) Les informations demandées sont considérées comme des informations personnelles et sont soumises à la *Loi sur la protection des renseignements personnels*. Par conséquent, nous ne commenterons pas ces détails des employés individuels.
- h) Elles ne sont pas liées.

- 2 -

- i) Aucun financement n'a été sollicité ni reçu par le Laboratoire national de microbiologie d'aucune institution chinoise.
- j) La conclusion des enquêtes dépend de l'achèvement de la procédure régulière.

COVID-19 – NML INVESTIGATION (NP/CBC)

- In 2019, the National Microbiology Lab shared lab samples with the Wuhan Institute of Virology
- The NML **routinely** shares samples with other laboratories, to help advance the international community's knowledge of certain illnesses
- These shipments **are not related** to the outbreak of COVID-19 or research into the pandemic

If pressed:

- There is **no connection** between the National Microbiology Lab and the outbreak of COVID-19

If pressed on safety

- These transfers **follow strict protocols**.
- Any transfer must meet requirements of several different Canadian laws and regulations, as well as standard operating procedures of the NML.
- **All safety protocols were followed.**

If pressed on investigation into researchers

- The administrative investigation is not related to the shipment of virus samples to China
- As this is an ongoing investigation, I cannot comment further.

If pressed on sample sharing

- The National Microbiology Lab routinely shares samples with other public health laboratories—as they do with the NML—to contribute to the advancement of science.
- The NML routinely provides training to international laboratory professionals, and has previously trained scientists from many countries, including China.

Anticipatory Questions: SOCI Appearance June 26, 2020

Physical Distancing Measures (HPOC)

1. In light of the large anti-black racism protests happening across the world and in Canada, has PHAC changed its recommendations on physical distancing to allow other large events?

- No, the Public Health Agency of Canada has not changed its recommendations on physical distancing. The pandemic is still not over, and there continues to be a risk of contracting COVID-19. The Agency is working on developing risk mitigation tools for situations where abiding by public health measures is challenging or not possible.
- The Agency has published a Risk Mitigation Tool Events for Gatherings and Events operating during COVID-19. This tool provides practical advice on ensuring that gatherings and events operate in the safest way possible, thus preventing and limiting COVID-19 spread.
- It is recommended that Canadians wear a non-medical mask when physical distancing is not possible.
- Canadians who have attended a large social gathering are advised to self-monitor for symptoms for 14 days and to contact their provincial or territorial public health authority on when to seek testing.
- If people develop any symptoms, it is important that they immediately isolate, contact their local public health authority and follow their advice.

Other considerations:

- It is also important to note that for some people wearing a non-medical mask or cloth face covering is NOT recommended, including young children under the age of 2 years or anyone who has trouble breathing, is unconscious, incapacitated or otherwise unable to remove the mask on their own.

2. While many jurisdictions in the world, including some in Canada, have changed their physical distance guidelines away from a strict 2m distance, why has PHAC not also updated its advice?

- Current evidence indicates the virus that causes COVID-19 is mainly spread by droplets produced by an infected person through coughing and sneezing. This is why physical distancing is an essential public health control measure.
- Public Health Agency of Canada guidance should be read in conjunction with relevant provincial, territorial, and local legislation, regulations and policies.
- Refer to answer for Q1 for physical distancing measures.

PPE and Procurement

3. How does PHAC test PPE once it's arrived in Canada? What does it do with PPE that doesn't meet its standards?

- PPE and medical supplies received by the Public Health Agency of Canada, whether procured internationally or domestically, are verified to meet the technical specifications for healthcare settings for COVID-19 prior to distribution to provinces and territories. This process is supported by testing capacity within the Nation Research Council.
- For example, a KN95 respirator undergoes visual inspection to verify for defects in design and construction, and is tested to confirm performance expectations. Surgical masks undergo a fluid resistance test.
- Supplies that do not meet specifications are subsequently assessed for potential use in non-healthcare settings.
- Test results are also used to inform future procurements. Public Services and Procurement Canada and the Agency work with suppliers to address issues at the source or avoid purchasing from unreliable suppliers in the future once issues are identified.

Contract Tracing (HPOC)

4. Is the government planning to use an app for the purposes of contact tracing? Has the Privacy Commissioner been consulted on the development of this app? How will the privacy of Canadians be safeguarded with this app?

- The Prime Minister announced on June 18th that a national exposure notification app, called COVID Alert, is in development, using exposure notification technology designed by Google and Apple.
- The federal government is collaborating with the Province of Ontario and leveraging their expertise to develop a national app, based on the COVID Shield model, which was developed by a group of volunteers from Shopify. Ontario is expected to be the first province to implement use of the app, targeting July 1st, while other provincial and territorial jurisdictions will follow when they are ready.
- Note that this is an exposure notification app, not a contact tracing app. It is another useful tool for Canadians to use to keep themselves, their loved ones, and their communities safer. This app does not replace contact tracing—a critical public health function. Contact tracing will continue to be performed manually when outbreaks are registered with local health authorities.

- The protection of Canadians' privacy is a priority for the Government of Canada. The app will undergo a thorough privacy assessment, and all data provided to the app will be securely stored and protected. The Government is engaging with the Office of the Privacy Commissioner to ensure that the app is in line with federal privacy requirements.
- The exposure notification approach used by Apple and Google is a decentralized, anonymous system—it is designed to work without storing or using any personally identifying information on any of the systems involved. This approach safeguards the privacy of Canadians by keeping all personal information on their own phones.

If asked about other GoC apps for COVID-19:

- The Canada COVID-19 app provides general information and resources about COVID-19 to all Canadians.
- The ArriveCAN mobile app is designed to collect mandatory information that will support compliance and enforcement of the mandatory 14-day quarantine or isolation requirements. This is pursuant to Emergency Orders under the *Quarantine Act*, every incoming traveller must provide information to the Government of Canada about their quarantine or isolation plans.
- ArriveCAN is not a contact tracing app, and does not overlap with any existing mobile or digital solution. ArriveCAN is strictly for incoming travellers to submit their mandatory information in support of the Public Health Agency of Canada's compliance and enforcement mandates under the Emergency order of the *Quarantine Act*.

Vaccine Research (IDPC)

5. Why has the government signed a vaccine research and development agreement (CanSino) with the Chinese communist regime?

- The National Research Council of Canada (NRC) has signed a collaboration agreement with CanSino Biologics (CanSinoBIO), a privately-held company listed on the Hong Kong stock exchange. The NRC and CanSinoBIO have been working together since 2013, and previously collaborated on the development of vaccines against tuberculosis and Ebola.
- CanSinoBIO has developed a candidate vaccine that is one of the most advanced potential vaccines against COVID-19 in the world.
- The NRC collaboration will allow the candidate vaccine to be manufactured on-site at the NRC's facilities in Montreal, for the purposes of Canadian clinical trials (i.e. testing in humans for safety and efficacy, under the full oversight and authority of Health Canada).
- On May 15, 2020, Health Canada authorized CanSino Biologics Inc. (CanSinoBio) vaccine candidate for a Phase 1/2 clinical trial in healthy adults Canada.

- If it is proven safe and effective, and approved by Health Canada, this collaboration will also allow the NRC to produce doses of the vaccine for emergency pandemic use in Canada, potentially making Canadians among the first in the world to have access to a safe and effective vaccine against COVID-19.

The NESS

6. Was the NESS adequately funded or maintained enough to respond to a global pandemic such as COVID-19? The NESS provides surge capacity to provinces and territories when their own resources have been exhausted, and fills a niche role in stockpiling certain rare and high-value assets, such as smallpox vaccine.

- The National Emergency Strategic Stockpile (NESS) was built on the assumption that provincial, territorial, and local governments would be prepared for the most common emergencies. Jurisdictions have traditionally sourced PPE directly from known suppliers, and the NESS has historically only carried relatively small amounts.
- Since 2012-13, the annual base funding for the NESS has remained stable and has been approximately \$3 million a year. This funding is included in the overall funding identified for the Health Security Infrastructure program area reported in Public Accounts.
- Additional funding has historically been provided to the NESS through internal reallocation decisions and incremental funding decisions where the Public Health Agency of Canada has received funding linked to specific purchases, such as for a four-year investment in medical countermeasures against smallpox and anthrax that began in 2015-16.
- The Government of Canada will continue to work closely with the provinces and territories to procure the health supplies necessary to continue responding to the pandemic.

Modelling (IDPC)

7. What is PHAC's response to **Personal Info** criticisms of the Canadian COVID-19 modelling? **Personal Info** also accused PHAC of censoring data provided to scientists. If true, why does PHAC censor data before disclosing it?

- The Public Health Agency of Canada's use of modelling aligns with Canadian and international approaches. It is based on methods that are used routinely among infectious disease modellers. The Agency has published the methods, which were developed in collaboration with 4 university-based modellers, used to develop COVID-19 models in the *CCDR*, a peer reviewed journal, providing full details on how models are generated (including how the case estimates were obtained and the scenarios under which different case numbers would be expected). More information on the Agency's modelling methods will be published shortly.
- Contrary to **Personal** view that a single model should be applied in our analysis, Public Health Agency of Canada modelling experts use a synopsis of modelling studies to obtain

estimates because this approach provides greater certainty compared to outputs from a single model that could have unseen flaws.

- The Agency is committed to making data publicly available, under the appropriate conditions that protect privacy and that are in keeping with data-sharing agreements with third parties.

Data Collection (HPOC)

8. Will PHAC mandate the collection of race based/desegregated data in relation to COVID-19? Why hasn't the government used its powers to make better data collection mandatory?

- The health consequences of the pandemic are likely to differ across sub-populations. Those Canadians who before the pandemic were at greater risk of poor health are likely to be at greater risk of suffering its direct and indirect (or secondary) consequences. Given this, the Public Health Agency of Canada and its partners are undertaking a number of activities to improve Canada's knowledge of the impact of COVID-19 on racialized communities.
- First, the Agency has completed a review of published literature on race and COVID-19. While there is limited evidence available overall and in Canada, studies to date do show that people reporting Black, Asian or Hispanic race appear to have a higher chance of COVID-19 infection than those who are White. Data is conflicting regarding the role race/ethnicity may play in severity of infection (ie. hospitalization, ICU admission and death).
- Second, through the Special Advisory Committee (SAC) on COVID-19 governance, Federal/Provincial/Territorial governments are exploring the inclusion of race/ethnicity as a key variable within the national data set for COVID-19. This means that race/ethnicity would be expected to be collected and reported to the Public Health Agency of Canada for COVID-19 cases.
- Third, the Agency is engaging with various partners to undertake specialized surveys and enhanced surveillance activities among key populations of interest. Studies to explore COVID-19 impact and unintended consequences of COVID-19 related public health measures on racialized communities are a key component of this work. In addition, the Agency and the Canadian Institutes of Health Research will coordinate efforts to facilitate research activities related to burden and impact of COVID-19 among racialized and marginalized communities, to further enhance and expand the knowledge base.
- Finally, the Public Health Agency of Canada is working with other partners to expand the knowledge base on racialized communities and COVID-19. Statistics Canada, for example, plans to release new ethno-cultural data from new data collection initiatives, with new data points expected starting in summer of 2020.

Border Measures

9. By late January countries such as Australia has closed their borders to all travel from China, whereas Canada kept its borders open until March. Why was the government so slow to react with its border closures?

- Each country makes decisions based on their own risk assessment and unique factors such as geographic proximity to major outbreaks, travel patterns, etc.
- In January, Canada began to monitor COVID19 closely, and issued a targeted travel health notice for Wuhan, China on January 7, 2020. We subsequently issued a progressive number of travel health notices, first for mainland China, and then other countries that experienced outbreaks of COVID-19, including Iran, Italy, and South Korea.
- On March 13th, Canada recommended against all non-essential international travel, and published a travel health notice to this effect on March 14, 2020. On March 16th, Canada banned the entry of all foreign nationals, except U.S. citizens, entering Canada. This was expanded to include U.S. citizens, in agreement with the United States, on March 18, 2020. These extraordinary measures have helped to reduce the introduction and further spread of COVID-19 in Canada.

10. Earlier in the pandemic, Dr. Tam stated that taking a person's temperature was an ineffective method of screening for COVID-19. Now, the government has mandated mandatory temperature checks of travellers boarding flights into Canada and temperature checks when they arrive in Canada as well. Why has the government changed its policy stance so late in the pandemic?

- Airport temperature screening has been endorsed by the International Air Transport Association and the International Civil Aviation Organization. Canadian implementation of this measure will support international alignment and further build confidence and trust in the global aviation system.
- Temperature screening is just one of the measures being taken by the Government of Canada at Canadian ports of entry in response to COVID-19. Other measures include:
 - Enhanced screening, including health assessments;
 - Assessments of public in transit at ports of entry; and
 - Confirming the requirement for travellers to have a suitable place to quarantine for 14 days as per the Government of Canada's Emergency Order under the *Quarantine Act*.
- Temperature screening is one way to identify individuals who may be sick, and it may also act as a deterrent for mildly ill air travellers. That said, temperature checks will not necessarily detect cases of COVID-19, as fever is not usually the first symptom of COVID-19, and in some cases, fever never develops. For example, during the SARS outbreak, 2.3 million travellers were screened using thermal scanners, and no cases of SARS were detected using this method.

- That said, as we reopen society and travelling increases, it is prudent to err on the side of caution and further enhance screening measures when possible. Public health advice will evolve in keeping with the evolution of the pandemic.

11. How long does the government intend to keep the US-Canada border closed for? When does the government expect to open up all international travel?

- Current border restrictions remain in place. The Government of Canada will take a cautious approach to reducing measures related to international travel, including travel across the Canada-United States border.
- The decision to ease the current border measures will be made in consultation with provincial, territorial and international governments, and will be based on science and an assessment of domestic and international public health measures.

LTC Facilities (IDPC)

12. A witness at a recent SOCI meeting stated that she believes delays in receiving direction and guidelines from PHAC/PT health authorities caused direct harm in LTC facilities. Why did PHAC take so long to give out the necessary guidelines?

- Protecting long-term care residents and staff is a priority and the Public Health Agency of Canada is working with provinces and territories on all aspects of their response to COVID-19 for this population.
- Developing the Infection Prevention and Control for COVID-19: Interim Guidance for Long Term Care Homes required consultation with jurisdictions and additional experts from across Canada to develop the information needed to protect residents and staff. The science on transmission of COVID-19 continues to evolve rapidly, and this guidance reflects the considered synthesis of the most recent findings on COVID-19 transmission.
- This document reflects the carefully considered and evidence-based development needed to provide the greatest protection to residents and staff of long-term care facilities in Canada.

Non-Medical Mask Use (IDPC)

13. Why has PHAC been giving inconsistent advice around the usefulness of non-medical masks? Will it admit that it may have caused harm early on in the pandemic by not issuing the right guidelines?

- The emergence of evidence that the virus can be unknowingly transmitted by infected people before they develop symptoms (pre-symptomatic transmission) or who may never

develop symptoms (asymptomatic transmission), led the Council of Chief Medical Officers of Health to advise that people could wear non-medical masks and face coverings as an additional layer of protection in settings where physical distancing might not be possible.

International Issues

14. Given the inconsistent and often faulty advice given by the WHO, does the government continue to trust, without verifying, information from the WHO?

- The ever-evolving COVID-19 pandemic has created an unprecedented situation where global cooperation on health has never been more important. Working together with our multilateral organizations - such as the World Health Organization (WHO) - are helping us accomplish together what cannot be done alone.
- Canada continues to appreciate the WHO's critical leadership and coordination in the COVID-19 response, particularly in the areas where the WHO has a clear value-added role – overseeing the International Health Regulations, driving global research collaboration, supporting most vulnerable countries, and leading the UN system's global health response.
- The WHO has also been providing technical guidance and advice to countries based on the best-available evidence in a context which has been rapidly evolving, as all have learned more about COVID-19, as new evidence has emerged, and as our experience with the response has grown.
- We have and continue to engage and collaborate with many types of international partners through various means and at multiple levels. For instance, Canada has engaged bilaterally with the United States and the United Kingdom to discuss our respective COVID-19 responses. These discussions are valuable opportunities to learn from each other and strengthen our domestic responses.
- The entire global community will have lessons to learn following this pandemic. The WHO may not be perfect, but Canada is fully committed to supporting a WHO that is a strong, effective, and accountable institution. Canada has consistently supported the need for an independent, comprehensive post-crisis review of the global response to COVID-19, including the actions of the WHO. We expect this review will include the technical guidance provided by WHO, and consider options to enhance WHO's critical normative role as a science based organization to strengthen the development, issuance, and uptake of WHO technical guidance.

Others

15. On January 25, the WHO assessed the risk of a COVID-19 event to be moderate at the global level, while PHAC assessed the risk for Canada as low. On February 2, the WHO changed that threat level to high. Yet after that date, you continued to insist the risk to Canada was low.

Why did PHAC insist on recommending the risk to Canadians was low, when clearly it was not? (HPOC)

- In March 2020, the public health risk assessments evolved based on the risk of COVID-19 to Canadians in Canada at that time. The risk to the public within Canada evolved from being assessed as low (as there was no evidence that COVID-19 was circulating within the Canadian population), to low for the general population and moderate for the elderly and those with underlying medical conditions, followed by high for the full population because of the appearance of community spread of COVID-19 within the Canadian population.
- The Public Health Agency of Canada used a risk assessment framework to guide decision-making for public health measures and decisions related to COVID-19. The level of risk identified by the Agency took into account both the likelihood and the impact of a COVID-19 outbreak occurring in Canada. The reports considered the most recent scientific literature, as well as the current epidemiology within Canada (such as the number of cases in Canada, the presence of community spread, the number of hospitalizations and deaths due to the virus).

16. Can you explain why the National Microbiology Lab (NML) transferred samples of Ebola and Henipah viruses to the Wuhan Institute of Virology (WIV) only months after the RCMP started an investigation into Chinese researchers at the NML, including one researcher that was involved in sending the samples?

- The administrative investigation into two researchers at the NML is not related to the shipment of virus samples to China. The NML routinely shares samples with other laboratories, to help advance the international community's knowledge of certain illnesses.

17. How are the decisions to award sole-source contracts made? Why were other companies, one of which had received a letter of intent, left out of the running?

- Normally, Government Contracts Regulations require the solicitation of bids; however, for procurements not subject to trade agreements, the regulations allow for exceptions where the need is a pressing emergency where delay would be injurious to the public interest.
- Given the current pandemic, there was an urgency to ensure sufficient domestic manufacturing capacity of critical inputs required for diagnostic testing **3rd Party Info**
3rd Party Info
3rd Party Info
 A contract was subsequently awarded on June 12, 2020.
- The key considerations in awarding this sole source contract included:
 - suitability of product ('fit for purpose')
 - availability of required product volume

- delivery timeframes

- 3rd Party Info
[REDACTED]
- third party
[REDACTED]
- The National Microbiology Laboratory (NML) continues to seek products to bolster domestic supply of the raw materials needed for laboratory testing, and welcomes further discussion with 3rd [REDACTED] as they continue product development and augmentation of production capabilities.
- The NML actively seeks to diversify its supply chain to obtain materials from various vendors to support domestic capacity and would certainly consider procuring products from alternate sources, including 3rd [REDACTED]



INQUIRY OF MINISTRY DEMANDE DE RENSEIGNEMENT AU GOUVERNEMENT

PREPARE IN ENGLISH AND FRENCH MARKING "ORIGINAL TEXT" OR "TRANSLATION"
PRÉPARER EN ANGLAIS ET EN FRANÇAIS EN INDIQUANT "TEXTE ORIGINAL" OU "TRADUCTION"

QUESTION NO./N° DE LA QUESTION Q-25	BY / DE Mrs. Jansen (Cloverdale—Langley City)	DATE September 23, 2020
--	--	----------------------------

Reply by the Minister of Health
Réponse de la ministre de la Santé

Signed by Mr. Darren Fisher

PRINT NAME OF SIGNATORY
INSCRIRE LE NOM DU SIGNATAIRE


 SIGNATURE
 MINISTER OR PARLIAMENTARY SECRETARY
 MINISTRE OU SECRÉTAIRE PARLEMENTAIRE

QUESTION

With regard to the transfer of Ebola and Henipah viruses from the National Microbiology Laboratory (NML) to persons, laboratories, and institutions in China: (a) who in China requested the transfer; (b) other than the Wuhan Institute of Virology (WIV), which laboratories in China requested the transfer; (c) for the answers in (a) and (b) which are affiliated with the military of China; (d) on what date was the WIV's request for the transfer received by the NML; (e) what scientific research was proposed, or what other scientific rationale was put forth, by the WIV or the NML scientists to justify the transfer of Ebola and Henipah viruses; — **See full text of the question attached.**

REPLY / RÉPONSE

ORIGINAL TEXT
TEXTE ORIGINAL

TRANSLATION
TRADUCTION

Public Health Agency of Canada

- (a) The Director of National Biosafety Laboratory, Wuhan Institute of Virology.
- (b) Only the WIV requested the transfer.
- (c) N/A.
- (d) June 28, 2018.
- (e) Research on infectious immunological mechanisms, antivirals and virus-cell interactions of the Ebola virus (EBOV) and the Nipah virus (NiV).
- (f) 12 strains of EBOV and 3 strains of NiV were authorized for transfer.
- (g) For shipping purposes, a nominal monetary value of \$75.00 was assigned to the samples. It was never intended to be an invoice for payment and no payment was received.
- (h) No compensation was received.
- (i) No. The National Microbiology Laboratory (NML) complies with all applicable requirements of the *Human Pathogens and Toxins Act* (HPTA), the *Transportation of Dangerous Goods Act* (TDGA), and the Canadian Biosafety Standard when sharing samples of pathogens and toxins with partner laboratories in Canada and in other countries.
- (j) There were no conditions on the transfer of the material to WIV. The NML ensured all applicable requirements of the HPTA, the TDGA and the Canadian Biosafety Standard were followed.
- (k) The NML received a letter from the Director of the National Biosafety Laboratory (WIV), outlining the intent to study these viruses under their National Key Research and Development Plan. The intended areas of study were infectious immunological mechanisms, antivirals and virus-cell interactions of EBOV and NiV. The Director also guaranteed in his signed attestation letter that the viruses will only be used for research purposes. The virus samples were not transferred to any other institutions as outlined in part (b).

- 2 -

The NML is required, as per the *Human Pathogens and Toxins Regulations* (HPTR), to receive, from any laboratory requesting pathogens, proof that they have the containment level of laboratory required for handling that pathogen. In this case, the Biosafety Officer at the WIV provided an official written statement (as specified in the HPTR) outlining the WIV facility had the appropriate containment for the pathogens being shipped.

- (l) The Government of Canada does not have jurisdiction to audit and inspect laboratories in other countries. The NML is required, as per the HPTR, to receive, from any laboratory requesting pathogens, proof that they have the containment level of laboratory required for handling that pathogen. This is in the form of a certification or license from a regulatory body in that country or, in countries who do not have such schemes, an attestation from a Biosafety Officer in the facility stating that the laboratory meets the necessary containment level. In this case, the Biosafety Officer at the WIV provided an official written statement (as specified in the HPTR) outlining the WIV facility had the appropriate containment for the pathogens being shipped.
- (m) See the previous response to part (l).
- (n) No follow up was required, as per question (b) there were no other institutions.
- (o) Intellectual property protections are not required for the sharing of samples.
- (p) The NML has a variety of EBOV strains stored in the Containment Level 4 (CL4) of the NML. This shipment contained samples representative of approximately 60% of the EBOV strains housed in the CL4. Two vials per strain were shipped which represents less than 1% of the total EBOV housed in the CL4.
- (q) There are six papers (including the one referenced in this part) listed with at least one author with Special Pathogens affiliation and one author with an affiliation to the military of China. They are:
- A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses;
 - Identification of a clinical compound losmapimod that blocks Lassa virus entry;
 - Tangeretin, an extract from Citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever;
 - Equine immunoglobulin F(ab')₂ fragments protect mice from Rift Valley fever virus infection;
 - Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection; and
 - Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.

There are no unpublished studies that we are aware of that were performed with scientists affiliated with the military of China.

- (r) There are no current collaborations at the NML with the WIV, China's Academy of Military Medical Sciences, or other parts of China's military establishment.
- (s) There was a typo that occurred in an email on February 5, 2019, between Special Pathogens and World Courier Toronto. This email correspondence occurred five weeks before the shipment date (March 29, 2019). Material was shipped using the correct packaging.
- (t) No error was made – see the previous response to part (s).
- (u) These comments relate to the administrative process associated with transit through Toronto. The process for shipment through Vancouver is simpler.
- (v) On March 29, 2019, the risk group 4 (RG4) shipment was scheduled to depart from the NML in Winnipeg between 13:30-14:00 EDT. No flight number was provided.

On March 31, 2019, the RG4 shipment had departed Toronto for Beijing on flight AC031.

On April 1, 2019, PHAC was notified that the package had arrived safely in Wuhan.

- 3 -

- (w) It is the responsibility of the courier, as the NML does not control what airlines and airports are used to ship the samples.
- (x) The other names listed are different strains of EBOV and NiV. No other viruses were shipped.
- (y) No other viruses have been sought by or transferred to the WIV.
- (z) All transfers of RG4 samples follow strict transportation requirements and are authorized by senior NML officials. The NML tracks and keeps electronic records of all shipments of samples in accordance with the HPTA and the HPTR.

On the specific shipment to China, PHAC confirmed that all protocols were followed as directed by legislation and Standards.

- (aa) Documents provided through the *Access to Information Act* (ATIA) were processed in accordance with the ATIA.
- (bb) In Canada, PHAC administers the HPTA and the HPTR.

Global Affairs Canada (GAC) has oversight on export of any controlled materials, including risk group 3 and RG4 pathogens, under the *Export and Import Permits Act* (EIPA). Under the EIPA, anyone (unless otherwise excluded, such as Crown organizations) wishing to export any materials included on the Export Control List or to a country included in the Area Control List must first receive a Permit to Export from GAC.

As per standard practice in consultation with GAC, the NML is not required to obtain an export permit.

References:

HPTA and HPTR

<https://laws.justice.gc.ca/eng/acts/H-5.67/>

<https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/licensing-program.html>

EIPA

<https://laws-lois.justice.gc.ca/eng/acts/e-19/>

<https://www.international.gc.ca/controls-controles/index.aspx?lang=eng>

- (cc) Canada does have a legal framework for this. See the response for (bb) above.
- (dd) With respect to the transfer to the WIV, the NML complied with all applicable requirements of the HPTA, the TDGA, and the Canadian Biosafety Standard.

The NML is authorized and licensed under the HPTA and the TDGA to ship RG4 pathogens. When shipping RG4 pathogens, the NML is required to submit an Emergency Response Assistance Plan to Transport Canada. For the shipment to WIV, all TDGA documentation was submitted correctly. See also (l) above.

- (ee) See the response to part (bb) above.
- (ff) See the previous response to part (l).
- (gg) There have been no requests from the NML for material from the WIV.

- 4 -

Q-25² — September 23, 2020 — Mrs. Jansen (Cloverdale—Langley City) — With regard to the transfer of Ebola and Henipah viruses from the National Microbiology Laboratory (NML) to persons, laboratories, and institutions in China: (a) who in China requested the transfer; (b) other than the Wuhan Institute of Virology (WIV), which laboratories in China requested the transfer; (c) for the answers in (a) and (b) which are affiliated with the military of China; (d) on what date was the WIV's request for the transfer received by the NML; (e) what scientific research was proposed, or what other scientific rationale was put forth, by the WIV or the NML scientists to justify the transfer of Ebola and Henipah viruses; (f) what materials were authorized for transfer pursuant to Transfer Authorization NML-TA-18-0480, dated October 29, 2018; (g) did the NML receive payment of \$75, per its commercial invoice of March 27, 2019, for the transfer, and on what date was payment received; (h) what consideration or compensation was received from China in exchange for providing this material, broken down by amount or details of the consideration or compensation received by each recipient organization; (i) has the government requested China to destroy or return the viruses and, if not, why; (j) did Canada include, as a term of the transfer, a prohibition on the WIV further transferring the viruses with others inside or outside China, except with Canada's consent; (k) what due diligence did the NML perform to ensure that the WIV and other institutions referred to in (b) would not make use of the transferred viruses for military research or uses; (l) what inspections or audits did the NML perform of the WIV and other institutions referred to in (b) to ensure that they were able to handle the transferred viruses safely and without diversion to military research or uses; (m) what were the findings of the inspections or audits referred to in (l), in summary; (n) after the transfer, what follow-up has Canada conducted with the institutions referred to in (b) to ensure that the only research being performed with the transferred viruses is that which was disclosed at the time of the request for the transfer; (o) what intellectual property protections did Canada set in place before sending the transferred viruses to the persons and institutions referred to in (a) and (b); (p) of the Ebola virus strains sent to the WIV, what percentages of the NML's total Ebola collection and Ebola collection authorized for sharing is represented by the material transferred; (q) other than the study entitled "Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease", which other published or unpublished studies did the NML scientists perform with scientists affiliated with the military of China; (r) which other studies are the NML scientists currently performing with scientists affiliated with the WIV, China's Academy of Military Medical Sciences, or other parts of China's military establishment; (s) what is the reason that Anders Leung of the NML attempted to send the transferred viruses in incorrect packaging (type PI650), and only changed its packaging to the correct standard (type PI620) after being questioned by the Chinese on February 20, 2019; (t) has the NML conducted an audit of the error of using unsafe packaging to transfer the viruses, and what in summary were its conclusions; (u) what is the reason that Allan Lau and Heidi Wood of the NML wrote on March 28, 2019, that they were "really hoping that this [the transferred viruses] goes through Vancouver" instead of Toronto on Air Canada, and "Fingers crossed!" for this specific routing; (v) what is the complete flight itinerary, including airlines and connecting airports, for the transfer; (w) were all airlines and airports on the flight itinerary informed by the NML that Ebola and Henipah viruses would be in their custody; (x) with reference to the email of Marie Gharib of the NML on March 27, 2019, other than Ebola and Henipah viruses, which other pathogens were requested by the WIV; (y) since the date of the request for transfer, other than Ebola and Henipah viruses, which other pathogens has the NML transferred or sought to transfer to the WIV; (z) did the NML inform Canada's security establishment, including the RCMP, the Canadian Security Intelligence Service, the Communications Security Establishment, or other such entity, of the transfer before it occurred, and, if not, why not; (aa) what is the reason that the Public Health Agency of Canada (PHAC) redacted the name of the transfer recipient from documents disclosed to the Canadian Broadcasting Corporation (CBC) under the Access to Information Act, when the PHAC later willingly disclosed that information to the CBC; (bb) does Canada have any policy prohibiting the export of risk group 3 and 4 pathogens to countries, such as China, that conduct gain-of-function experiments, and in summary what is that policy; (cc) if Canada does not have any policy referred to in (bb), why not; (dd) what is the reason that did the NML or individual employees sought and obtained no permits or authorizations under the Human Pathogens and Toxins Act, the Transportation of Dangerous Goods Act, the Export Control Act, or related legislation prior to the transfer; (ee) what legal controls prevent the NML or other government laboratories sending group 3 or 4 pathogens to laboratories associated with foreign militaries or laboratories that conduct gain-of-function experiments; (ff) with respect to the September 14, 2018, email of Matthew Gilmour, in which he writes that "no certifications [were] provided [by the WIV], they simply cite they have them", why did the NML proceed to transfer Ebola and Henipah viruses without proof of certification to handle them safely; and (gg) with respect to the September 14, 2018, email of Matthew Gilmour, in which he asked "Are there materials that [WIV] have that we would benefit from receiving? Other VHF? High path flu?", did the NML request these or any other materials in exchange for the transfer, and did the NML receive them?



INQUIRY OF MINISTRY DEMANDE DE RENSEIGNEMENT AU GOUVERNEMENT

PREPARE IN ENGLISH AND FRENCH MARKING "ORIGINAL TEXT" OR "TRANSLATION"
PRÉPARER EN ANGLAIS ET EN FRANÇAIS EN INDIQUANT "TEXTE ORIGINAL" OU "TRADUCTION"

QUESTION NO./N° DE LA QUESTION Q-25	BY / DE Mme Jansen (Cloverdale—Langley City)	DATE Le 23 septembre 2020
--	---	------------------------------

Reply by the Minister of Health
Réponse de la ministre de la Santé

Signé par M. Darren Fisher

PRINT NAME OF SIGNATORY
INSCRIRE LE NOM DU SIGNATAIRE



SIGNATURE
MINISTER OR PARLIAMENTARY SECRETARY
MINISTRE OU SECRÉTAIRE PARLEMENTAIRE

QUESTION

En ce qui concerne le transfert des virus Ebola et Henipah du Laboratoire national de microbiologie (LNM) à des personnes, laboratoires et institutions en Chine : a) quelles sont les personnes en Chine qui ont demandé le transfert; b) à part l'Institut de virologie de Wuhan (IVW), quels laboratoires en Chine ont demandé le transfert; c) pour les réponses en a) et b), lesquelles de ces personnes ou institutions sont affiliées avec l'appareil militaire chinois; d) à quelle date le LNM a-t-il reçu la demande de transfert de l'IVW; e) quels projets de recherche scientifique, ou quelles autres raisons scientifiques, les chercheurs de l'IVW ou du LNM ont-ils invoqués pour justifier le transfert des virus Ebola et Henipah; – **Voir ci-joint pour le texte complet de la question**

REPLY / RÉPONSE

ORIGINAL TEXT
TEXTE ORIGINAL

TRANSLATION
TRADUCTION

Agence de la santé publique du Canada

- a) Le directeur du laboratoire national de biosécurité, Institut de virologie de Wuhan.
- b) Seul l'IVW a demandé le transfert.
- c) S.O.
- d) Le 28 juin 2018.
- e) Recherche sur les mécanismes immunologiques infectieux, les antiviraux et les interactions virus-cellules des virus Ebola (EBOV) et Nipah (NiV).
- f) Le transfert de 12 souches d'EBOV et de 3 souches de NiV a été autorisé.
- g) Pour l'expédition, une valeur monétaire non indexée de 75 \$ a été attribuée aux échantillons. Cela n'était pas censé être une facture et aucun paiement n'a été reçu.
- h) Aucune rémunération n'a été reçue.
- i) Non. Le Laboratoire national de microbiologie (LNM) se conforme à toutes les exigences applicables de la *Loi sur les agents pathogènes humains et les toxines* (LAPHT), de la *Loi sur le transport des marchandises dangereuses* (LTMD) et de la Norme canadienne de biosécurité lorsqu'il échange des échantillons d'agents pathogènes et de toxines avec des laboratoires partenaires au Canada et à l'étranger.
- j) Aucune condition n'a été imposée au transfert du matériel à l'Institut de virologie de Wuhan. Le LNM a veillé à ce que toutes les exigences applicables de la LATHP, de la LTMD et de la Norme canadienne sur la biosécurité soient respectées.
- k) Le LNM a reçu une lettre du directeur du Laboratoire national de biosécurité (WIV), décrivant l'intention d'étudier ces virus dans le cadre de son plan national de recherche et de développement clé. Les domaines d'étude visés étaient les mécanismes immunologiques infectieux, les antiviraux et les interactions virus-cellules de l'EBOV et du NiV. Le directeur a également garanti dans sa lettre d'attestation signée que les virus ne seront utilisés qu'à des fins de recherche. Les échantillons de virus n'ont été transférés à aucun autre établissement comme indiqué en partie b.

- 2 -

Le LNM, en vertu du *Règlement sur les agents pathogènes humains et les toxines (RAPHT)*, est tenu de recevoir, de tous les laboratoires demandant des agents pathogènes, la preuve qu'ils ont le niveau de confinement de laboratoire requis pour la manipulation de cet agent pathogène. Dans ce cas, le responsable de la biosécurité à l'IVW a fourni une déclaration écrite officielle (tel que stipulé dans le RAPHT) indiquant que le laboratoire de l'IVW disposait du confinement approprié pour les agents pathogènes expédiés.

- l) Le gouvernement du Canada n'a pas compétence pour vérifier et inspecter les laboratoires d'autres pays. Le LNM, en vertu du RAPHT, est tenu de recevoir, de tous les laboratoires demandant des agents pathogènes, la preuve qu'ils ont le niveau de confinement de laboratoire requis pour la manipulation de cet agent pathogène. Il s'agit d'une certification ou d'une licence délivrée par un organisme de réglementation de ce pays ou, dans les pays qui n'ont pas de tels systèmes, d'une attestation d'un responsable de la biosécurité de l'installation concernée indiquant que le laboratoire satisfait au niveau de confinement nécessaire. Dans ce cas, le responsable de la biosécurité à l'IVW a fourni une déclaration écrite officielle (tel que stipulé dans les règlements de la RAPH) indiquant que le laboratoire de l'IVW disposait du confinement approprié pour les agents pathogènes expédiés.
- m) Voir la réponse précédente au point l).
- n) Aucun suivi n'a été requis, comme indiqué à la question (b), il n'y avait pas d'autres institutions.
- o) La protection de la propriété intellectuelle n'est pas nécessaire pour l'échange de échantillons.
- p) Le LNM possède une variété de souches d'EBOV stockées dans le niveau de confinement (CL4) du LNM. Cette cargaison contenait des échantillons représentatifs d'environ 60 % de toutes les souches d'EBOV logées dans CL4 du LNM. Deux flacons par souche ont été expédiés, ce qui représente moins de 1 % du total d'EBOV logés dans la CL4.
- q) Il y a six articles (y compris celui mentionné dans cette section) dans la liste, avec au moins un auteur ayant une affiliation avec la division des pathogènes spéciaux et un auteur ayant une affiliation avec l'armée chinoise. Voici les articles :
- *A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses (Un candidat vaccin à particules de type virus chimérique soudanais produit par un système de baculovirus recombinant induit des réponses immunitaires spécifiques chez les souris et les chevaux)*
 - *Identification of a clinical compound losmapimod that blocks Lassa virus entry (Identification d'un composé clinique, le losmapimod, qui bloque l'entrée du virus Lassa)*
 - *Tangeretin, an extract from Citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever (La tangérétine, un extrait des écorces d'agrumes, bloque l'entrée cellulaire des arénavirus qui provoquent la fièvre hémorragique virale)*
 - *Equine immunoglobulin F(ab')₂ fragments protect mice from Rift Valley fever virus infection (Des fragments d'immunoglobuline équine F(ab')₂ protègent les souris contre l'infection par le virus de la fièvre de la vallée du Rift)*
 - *Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection (Le traitement par immunoglobuline équine hyperimmune ou par fragments d'immunoglobuline protège complètement les rongeurs contre l'infection par le virus Ebola)*
 - *Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease (Des fragments d'immunoglobulines d'origine équine protègent les primates non humains contre la maladie du virus Ebola)*

À notre connaissance, aucune étude non publiée n'a été réalisée avec des scientifiques affiliés à l'armée chinoise.

- r) Le LNM ne collabore pas actuellement avec l'Institut de virologie de Wuhan, l'Académie chinoise des sciences médicales militaires ou d'autres parties du système militaire chinois.

- 3 -

- s) Une faute de frappe s'est glissée dans un courriel du 5 février 2019, entre la division des pathogènes spéciaux et World Courier Toronto (YYZ-Ops). Cette correspondance électronique a eu lieu cinq semaines avant la date d'expédition (le 29 mars 2019). Le matériel a été expédié dans un emballage approprié.
- t) Aucune erreur n'a été commise – voir la réponse précédente au point (s).
- u) Ces commentaires portent sur le processus administratif associé au transit par Toronto. Le processus d'expédition par Vancouver est plus simple.
- v) Le 29 mars 2019, l'expédition du groupe de risque 4 devait partir du LNM de Winnipeg entre 13 h 30 et 14 h, HAE. Aucun numéro de vol n'a été fourni.

Le 31 mars 2019, l'expédition du groupe de risque 4 avait quitté Toronto pour Beijing sur le vol AC 031.

Le 1 avril 2019, l'ASPC a été informée que le colis était arrivé en toute sécurité à Wuhan.

- w) Cette responsabilité incombe au transporteur, car le LNM ne contrôle pas les compagnies aériennes et les aéroports utilisés pour expédier les échantillons.
- x) Les autres noms cités sont des souches différentes des virus EBOV et NIV. Aucun autre virus n'a été expédié.
- y) Aucun autre virus n'a été recherché par le l'IVW ou transféré à ce dernier.
- z) Tous les transferts d'échantillons du groupe de risque 4 sont assujettis à des exigences strictes en matière de transport et sont autorisés par les hauts responsables du LNM. Le LNM suit et conserve des enregistrements électroniques de toutes les expéditions d'échantillons conformément à la LAPHT et au RAPHT.

En ce qui concerne cet envoi précis vers la Chine, l'ASPC a confirmé que tous les protocoles étaient suivis conformément à la législation et aux normes.

aa) Les documents fournis en vertu de la *Loi sur l'accès à l'information* (LAI) ont été traités conformément à cette loi.

bb) Au Canada, l'ASPC administre la LAPHT et le RAPHT.

Affaires mondiales Canada (AMC) surveille l'exportation de tout matériel contrôlé, y compris les agents pathogènes des groupes de risque 3 et 4, en vertu de la *Loi sur les licences d'exportation et d'importation* (LLEI). En vertu de la LLEI, toute personne (sauf exclusion contraire, comme les organisations de la Couronne) souhaitant exporter des matières figurant sur la liste de contrôle des exportations ou vers un pays inclus dans la liste de contrôle régional doit d'abord recevoir un permis d'exportation de AMC.

Conformément à la pratique normalisée en consultation avec AMC, le LNM n'est pas exigé d'obtenir un permis d'exportation.

Références :

LAPHT et RAPHT

<https://laws.justice.gc.ca/fra/lois/H-5.67/>

<https://www.canada.ca/fr/sante-publique/services/biosecurite-biosurete-laboratoire/programme-delivrance-permis.html>

Loi sur les licences d'exportation et d'importation (LLEI)

<https://laws-lois.justice.gc.ca/fra/lois/e-19/>

<https://www.international.gc.ca/controls-controles/index.aspx?lang=fra>

cc) Le Canada bien dispose d'un cadre juridique à cet effet. Voir la réponse au point (bb) ci-dessus.

dd) En ce qui concerne le transfert à l'IVW, le LNM a respecté toutes les exigences applicables de la LAPHT, de la LTMD et de la Norme canadienne sur la biosécurité.

- 4 -

Le LNM est autorisé et agréé en vertu de la LAPHT et de la LTMD pour expédier les agents pathogènes RG 4. Lorsqu'il expédie des agents pathogènes RG4, le LNM est tenu de soumettre un plan d'intervention d'urgence à Transports Canada. Pour l'envoi à l'IVW, tous les documents exigés par la *Loi sur le transport des marchandises dangereuses* ont été correctement soumis. Voir également le point l) ci-dessus.

ee) Voir la réponse au point (bb) ci-dessus.

ff) Voir la réponse pour (l).

gg) Le LNM n'a adressé aucune demande de matériel à l'Institut de virologie de Wuhan.

Q-25² — 23 septembre 2020 — Mme Jansen (Cloverdale—Langley City) — En ce qui concerne le transfert des virus Ebola et Henipah du Laboratoire national de microbiologie (LNM) à des personnes, laboratoires et institutions en Chine : a) quelles sont les personnes en Chine qui ont demandé le transfert; b) à part l'Institut de virologie de Wuhan (IVW), quels laboratoires en Chine ont demandé le transfert; c) pour les réponses en a) et b), lesquelles de ces personnes ou institutions sont affiliées avec l'appareil militaire chinois; d) à quelle date le LNM a-t-il reçu la demande de transfert de l'IVW; e) quels projets de recherche scientifique, ou quelles autres raisons scientifiques, les chercheurs de l'IVW ou du LNM ont-ils invoqués pour justifier le transfert des virus Ebola et Henipah; f) de quels matériaux le transfert a-t-il été autorisé au moyen de l'autorisation de transfert NML-TA-18-0480, daté du 29 octobre 2018; g) le LNM a-t-il reçu le paiement de 75 \$ pour le transfert, conformément à sa facture commerciale du 27 mars 2019, et à quelle date l'a-t-il reçu; h) quelle contrepartie a été reçue de la Chine en échange de ces matériaux, ventilée par montant ou détails de la contrepartie reçue par chacun des organismes; i) le gouvernement a-t-il demandé à la Chine de détruire ou de retourner les virus et dans la négative, pourquoi pas; j) le Canada a-t-il assujéti le transfert à l'interdiction, pour l'IVW, de transférer les virus à d'autres entités ou personnes à l'intérieur ou à l'extérieur de la Chine, sans le consentement du Canada; k) quelle diligence raisonnable le LNM a-t-il exercée pour s'assurer que l'IVW et les autres institutions mentionnées en b) n'utiliseraient pas les virus transférés à des fins de recherche militaire ou à d'autres fins militaires; l) à quelles inspections ou vérifications le LNM a-t-il soumis l'IVW et les autres institutions mentionnées en b) pour s'assurer qu'ils pouvaient manipuler les virus transférés de manière sécuritaire et sans qu'ils soient détournés à des fins de recherche militaire ou à d'autres fins; m) quels ont été les résultats sommaires des inspections ou vérifications mentionnées en l); n) après le transfert, quels suivis le Canada a-t-il effectués auprès des institutions mentionnées en b) pour s'assurer que les seules recherches effectuées sur les virus transférés sont celles mentionnées au moment de la demande de transfert; o) quelles mesures de protection de la propriété intellectuelle le Canada a-t-il mises en place avant d'envoyer les virus transférés aux personnes et aux institutions mentionnées en a) et b); p) quels pourcentages les souches du virus Ebola envoyées à l'IVW représentent-elles de la collection totale d'Ebola du LNM et de la collection d'Ebola dont le partage est autorisé; q) à part l'étude intitulée « Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease », quelles autres études publiées ou inédites les chercheurs du LNM ont-ils réalisées en collaboration avec des chercheurs scientifiques affiliés à l'appareil militaire chinois; r) quelles autres études les chercheurs du LNM mènent-ils à l'heure actuelle avec des chercheurs scientifiques affiliés à l'IVW, à l'Académie des sciences médicales militaires de Chine ou à d'autres entités de l'appareil militaire chinois; s) pour quelle raison Anders Leung, du LNM, a-t-il tenté d'expédier les virus transférés dans un emballage incorrect (de type PI650) et n'a-t-il utilisé plutôt l'emballage prescrit (de type PI620) qu'après avoir été questionné par les Chinois le 20 février 2019; t) le LNM a-t-il effectué une vérification à la suite de l'erreur consistant à transférer les virus dans un emballage non sécuritaire, et quelles en ont été les conclusions sommaires; u) pour quelle raison Allan Lau et Heidi Wood du LNM ont-ils écrit, le 28 mars 2019, qu'ils espéraient vraiment que les virus transférés passent par Vancouver et non Toronto à bord d'Air Canada, et « Fingers crossed! » (Croisons-nous les doigts!) pour cet itinéraire particulier; v) quel est l'itinéraire aérien complet du transfert, y compris les compagnies aériennes et aéroports de transit; w) est-ce que toutes les compagnies aériennes et tous les aéroports de transit de l'itinéraire aérien ont été avisés par le LNM qu'ils auraient sous leur garde des souches des virus Ebola et Henipah; x) en ce qui a trait au courriel de Marie Gharib du LNM daté du 27 mars 2019, à part les virus Ebola et Henipah, quels autres pathogènes l'IVW a-t-il demandés; y) depuis la demande de transfert, à part les virus Ebola et Henipah, quels autres pathogènes le LNM a-t-il transférés ou voulu transférer à l'IVW; z) le LNM a-t-il informé, avant le transfert, les services de sécurité du Canada, que ce soit la GRC, le Service canadien du renseignement de sécurité, le Centre de la sécurité des télécommunications ou quelque autre entité du même type, et dans la négative, pourquoi pas; aa) pour quelle raison l'Agence de la santé publique du Canada a-t-elle caviardé le nom du destinataire du transfert dans les documents communiqués à la CBC aux termes de la Loi sur l'accès à l'information, alors qu'elle a bien voulu communiquer ce renseignement à la CBC par la suite; bb) le Canada a-t-il une politique interdisant l'exportation de pathogènes des groupes de risque 3 et 4 vers des pays, comme la Chine, qui mènent des expériences de gain de fonction, et quelle est, en résumé, cette politique; cc) si le Canada n'a pas de politique comme celle mentionnée au point bb), pourquoi pas; dd) pour quelle raison le LNM ou des employés individuels ont-ils demandé et obtenu des permis ou autorisations en vertu de la Loi sur les agents pathogènes humains et les toxines, de la Loi sur le transport des marchandises dangereuses, de la Loi sur les licences d'exportation et d'importation ou de lois connexes avant le transfert; (ee) quels contrôles juridiques empêchent le LNM ou d'autres laboratoires gouvernementaux d'envoyer des pathogènes des groupes 3 ou 4 à des laboratoires associés à des appareils militaires ou laboratoires étrangers qui mènent des expériences de gain de fonction; ff) en ce qui a trait au courriel du 14 septembre 2018 de Matthew Gilmour, dans lequel il écrit que l'IVW n'a fourni aucune certification, mais a simplement indiqué qu'il détenait les certifications nécessaires, pourquoi le LNM a-t-il procédé au transfert des virus Ebola Henipah sans avoir obtenu les preuves de certification des capacités de manipulation sécuritaire; gg) en ce qui a trait au courriel du 14 septembre 2018 de Matthew Gilmour, dans lequel il demande si l'IVW possède des matériaux qui nous seraient utiles, tels que des souches de fièvre hémorragique virale ou d'influenza hautement pathogène, le LNM a-t-il demandé ces matériaux, ou d'autres, en échange du transfert, et les a-t-il reçus?



INQUIRY OF MINISTRY DEMANDE DE RENSEIGNEMENT AU GOUVERNEMENT

PREPARE IN ENGLISH AND FRENCH MARKING "ORIGINAL TEXT" OR "TRANSLATION"
PRÉPARER EN ANGLAIS ET EN FRANÇAIS EN INDIQUANT "TEXTE ORIGINAL" OU "TRADUCTION"

QUESTION NO./N° DE LA QUESTION Q-26	BY / DE Mrs. Jansen (Cloverdale—Langley City)	DATE September 23, 2020
--	--	----------------------------

Reply by the Minister of Health
Réponse de la ministre de la Santé

Signed by Mr. Darren Fisher

PRINT NAME OF SIGNATORY
INSCRIRE LE NOM DU SIGNATAIRE


 SIGNATURE
 MINISTER OR PARLIAMENTARY SECRETARY
 MINISTRE OU SECRÉTAIRE PARLEMENTAIRE

QUESTION

With regard to both the administrative and RCMP investigations of the National Microbiology Lab (NML), Xiangguo Qiu, and Keding Cheng: (a) with respect to the decision of the NML and the RCMP to remove Dr. Qiu and Dr. Cheng from the NML facilities on July 5, 2019, what is the cause of delay that has prevented that the NML and the RCMP investigations concluding; (b) in light of a statement by the Public Health Agency of Canada to the Canadian Broadcasting Corporation which was reported on June 14, 2020, and which stated, "the administrative investigation of [Dr. Qiu or Dr. Cheng] is not related to the shipment of virus samples to China", what are these two scientists being investigated for; (c) did Canada receive information from foreign law enforcement or intelligence agencies which led to the investigations against Dr. Qiu or Dr. Cheng, and, in summary, what was alleged; (d) which other individuals apart from Dr. Qiu or Dr. Cheng are implicated in the investigations; (e) are Dr. Qiu or Dr. Cheng still in Canada; (f) are Dr. Qiu or Dr. Cheng cooperating with law enforcement in the investigations; (g) are Dr. Qiu or Dr. Cheng on paid leave, unpaid leave, or terminated from the NML; (h) what connection is there between the investigations of Dr. Qiu or Dr. Cheng and the investigation by the United States National Institutes of Health which has resulted in 54 scientists losing their jobs mainly due to receiving foreign funding from China, as reported by the journal Science on June 12, 2020; (i) does the government possess information that Dr. Qiu or Dr. Cheng solicited or received funding from a Chinese institution, and, in summary what is that information; and (j) when are the investigations expected to conclude, and will their findings be made public?

REPLY / RÉPONSE

ORIGINAL TEXT
TEXTE ORIGINAL



TRANSLATION
TRADUCTION



Public Health Agency of Canada

- (a) Due process is being followed in the execution of this administrative investigation.
- (b) An administrative investigation pertaining to possible policy breaches is underway.
- (c) The Public Health Agency of Canada (PHAC) has no knowledge pertaining to this.
- (d) The information requested is considered personal information and is subject to the *Privacy Act*. Therefore PHAC will not comment on details pertaining to individual employees.
- (e) The information requested is considered personal information and is subject to the *Privacy Act*. Therefore PHAC will not comment on details pertaining to individual employees.
- (f) The information requested is considered personal information and is subject to the *Privacy Act*. Therefore PHAC will not comment on details pertaining to individual employees.
- (g) The information requested is considered personal information and is subject to the *Privacy Act*. Therefore PHAC will not comment on details pertaining to individual employees.
- (h) There is no connection.
- (i) Funding has not been solicited or received by the National Microbiology Laboratory from any Chinese institution.
- (j) Conclusion of the investigations depend on the completion of due process.



INQUIRY OF MINISTRY DEMANDE DE RENSEIGNEMENT AU GOUVERNEMENT

PREPARE IN ENGLISH AND FRENCH MARKING "ORIGINAL TEXT" OR "TRANSLATION"
PRÉPARER EN ANGLAIS ET EN FRANÇAIS EN INDIQUANT "TEXTE ORIGINAL" OU "TRADUCTION"

QUESTION NO./N° DE LA QUESTION Q-26	BY / DE Mme Jansen (Cloverdale—Langley City)	DATE Le 23 septembre 2020
--	---	------------------------------

Reply by the Minister of Health
Réponse de la ministre de la Santé

Signé par M. Darren Fisher

PRINT NAME OF SIGNATORY
INSCRIRE LE NOM DU SIGNATAIRE



SIGNATURE
MINISTER OR PARLIAMENTARY SECRETARY
MINISTRE OU SECRÉTAIRE PARLEMENTAIRE

QUESTION

En ce qui concerne l'enquête administrative et l'enquête de la GRC portant sur le Laboratoire national de microbiologie (LNM), Xiangguo Qiu et Keding Cheng : a) pour ce qui est de la décision qu'ont prise le LNM et la GRC de retirer Mme Qiu et M. Cheng des installations du LNM le 5 juillet 2019, quelle est la cause du retard ayant empêché les enquêtes du LNM et de la GRC de se conclure; b) selon la déclaration de l'Agence de la santé publique du Canada dont la CBC a parlé le 14 juin 2020, « l'enquête administrative sur Mme Qiu et M. Cheng ne se rapporte pas à l'envoi d'échantillons de virus en Chine », pour quel motif ces deux chercheurs font-ils alors l'objet d'enquêtes; c) les enquêtes sur Mme Qiu et M. Cheng découlent-elles de renseignements fournis au Canada par les forces de l'ordre ou les services de renseignements d'autres pays et, si oui, que disaient ces renseignements, en gros; d) en plus de Mme Qiu et de M. Cheng, sur quelles autres personnes portent les enquêtes; e) Mme Qiu et M. Cheng sont-ils toujours au Canada; f) Mme Qiu et M. Cheng coopèrent-ils avec les forces de l'ordre pendant les enquêtes; g) Mme Qiu et M. Cheng sont-ils en congé payé, en congé non payé ou ont-ils été licenciés du LNM; h) quels sont les liens entre les enquêtes dont font l'objet Mme Qiu et M. Cheng et l'enquête des National Institutes of Health des États-Unis à l'issue de laquelle 54 chercheurs ont perdu leur emploi, principalement pour avoir reçu du financement étranger de la Chine (revue Science, 12 juin 2020); i) le gouvernement détient-il des renseignements selon lesquels Mme Qiu et M. Cheng auraient sollicité ou obtenu des fonds d'une institution chinoise, et que disent ces renseignements, en gros; j) quand les enquêtes devraient-elles se terminer et les conclusions de ces enquêtes seront-elles rendues publiques?

REPLY / RÉPONSE

ORIGINAL TEXT
TEXTE ORIGINAL

TRANSLATION
TRADUCTION

Agence de la santé publique du Canada

- a) Nous suivons une procédure régulière dans l'exécution de cette enquête administrative.
- b) Une enquête administrative concernant d'éventuelles violations de la politique est en cours.
- c) L'Agence de la santé publique du Canada (ASPC) n'a aucune connaissance à ce sujet.
- d) Les informations demandées sont considérées comme des informations personnelles et sont soumises à la *Loi sur la protection des renseignements personnels*. Par conséquent, nous ne commenterons pas ces détails des employés individuels.
- e) Les informations demandées sont considérées comme des informations personnelles et sont soumises à la *Loi sur la protection des renseignements personnels*. Par conséquent, nous ne commenterons pas ces détails des employés individuels.
- f) Les informations demandées sont considérées comme des informations personnelles et sont soumises à la *Loi sur la protection des renseignements personnels*. Par conséquent, nous ne commenterons pas ces détails des employés individuels.
- g) Les informations demandées sont considérées comme des informations personnelles et sont soumises à la *Loi sur la protection des renseignements personnels*. Par conséquent, nous ne commenterons pas ces détails des employés individuels.
- h) Elles ne sont pas liées.
- i) Aucun financement n'a été sollicité ni reçu par le Laboratoire national de microbiologie d'aucune institution chinoise.

- 2 -

j) La conclusion des enquêtes dépend de l'achèvement de la procédure régulière.

Guerra, Paula (PHAC/ASPC)

From: Beaudoin, John (PHAC/ASPC)
Sent: 2020-11-10 1:57 PM
To: **Personal** (HC/SC); Prokipcak, Joseph (HC/SC); Mead, Jobina (PHAC/ASPC)
Cc: Eng, Connie (HC/SC); **Personal info** (HC/SC); Beaudoin, John (PHAC/ASPC)
Subject: RE: Q-25


Hi **Perso** - I note that this WQ is similar to Q-533 prior to prorogation.

NML provided answers below to your questions and validated the tables provided in August (they are still up to date). Let me know if you would like further information or have follow-up questions.


1. How many foreign laboratories has the NML received requests to ship samples to over the past 10 years (and how many of these were fulfilled)?
 - a. The NML does not track the exact number of requests to ship samples to other labs due to the high volume of these requests, but it will only send samples to reputable labs who meet the appropriate federal lab requirements. All of the fulfilled requests to ship samples from the last 10 years are in the second table below (with 14 fulfilled requests).
2. How many of these were Ebola strains?
 - a. As described in the second table below, 10 of these shipments contained Ebola strains.
3. How many of these requests were from laboratories located in China?
 - a. As described in the second table below, 1 of these shipments was sent to a lab in China (to the WIV, the lab which is referred to in Q-25 itself).
4. Has the NML requested (and received) samples from laboratories located in China over the past 10 years? If so how many and what substances.
 - a. No it has not.
5. Has the NML requested (and received) samples from foreign laboratories over the past 10 years? If so how many and what substances?
 - a. See the first table below.

Table 1. (Risk Group 4 imports from the last 10 years)

3rd Party Info



3rd Party Info



John

personal

From: personal information @canada.ca>

Sent: 2020-11-10 11:36 AM

To: Prokipcak, Joseph (HC/SC) <joseph.prokipcak@canada.ca>; Mead, Jobina (PHAC/ASPC) <jobina.mead@canada.ca>

Cc: Eng, Connie (HC/SC) <connie.eng@canada.ca>; personal information @canada.ca>; Beaudoin, John (PHAC/ASPC) <john.beaudoin@canada.ca>

Subject: Q-25

Hi Joe,

Couple questions regarding Q-25:

How many foreign laboratories has the NML received requests to ship samples to over the past 10 years (and how many of these were fulfilled)?

How many of these were Ebola strains?

How many of these requests were from laboratories located in China?

Has the NML requested (and received) samples from laboratories located in China over the past 10 years? If so how many and what substances.

Has the NML requested (and received) samples from foreign laboratories over the past 10 years? If so how many and what substances? If this list is too long or onerous to compile a brief summary will suffice.

personal information



Key Messages and Q's and A's – CACN - March 22, 2021

1. Research Collaboration and Transfers of Products	3
What is NML currently doing with China? Is the NML currently collaborating with China on any scientific research?	
Will Canada continue to collaborate and share scientific information with China? [from approved MLs]	3
Why does PHAC engage in academic collaborations with other countries? Why is it beneficial for the Public Health Agency of Canada to enter in to such collaborative research projects internationally? Are there not risks? What are the benefits?	3
Agreements with Working Officials	4
The transfer of Ebola and Henipah viruses from the NML to persons, laboratories, and institutions in China (On Oct 29, 2019, 12 strains of EBOV and 3 strains of NiV were authorized for transfer)	4
Publications with scientists affiliated with the military of China	5
Material Transfer Agreements (MTAs)	5
Why was an MTA not used for the WIV transfer in 2018?	5
IP protection	5
2. NML Security (Physical)	6
Physical Security in the NML	6
Security protocols for foreign academics	6
3. PPE Procurement / Quality Assurance / Export Requirements /Contract Disputes	7
Canada's donation of PPE to China	7
Testing of products and quality assurance	7
What is role of NML in testing of PPE?	7
If asked how many N95 or KN95 masks have been rejected for failing to meet federal standards	7
If asked about products that fail to meet technical specifications, contract disputes or incorrect items received	7
If asked about evolving export requirements	8
PPE and forced labour	8
PPE procurements linked to Xinjiang, China	8
4. WHO/Bilateral/Multilateral Health Collaboration	9
Bilateral and Multilateral Relations in Health	9
General line	9
What is the current status of the Canada-China relationship in health?	9
How do Canada and China engage at multilateral fora?	9
What are your plans for future collaboration in health with China?	9
Undue Chinese Influence on WHO. What are Canada's views on allegations of undue Chinese influence on the WHO?	10

Origins Mission - What is the current status of the international expert mission to trace the origins of SARS-CoV-2?	10
What has been Canada's role in mission?	10
What is Canada's position on the mission and its findings?	10
Is Canada satisfied with the WHO's role in this investigation?	11
What are Canada's views on the theory promoted by Chinese authorities that the virus could have entered the Wuhan market via imported frozen food packaging?	11
5. Early Stages of the Pandemic and GPHIN / GPHIN Report	11
GPHIN	11

#	Subject
	<p data-bbox="99 155 1549 197">1. Research Collaboration and Transfers of Products</p> <p data-bbox="99 260 1549 386">What is NML currently doing with China? Is the NML currently collaborating with China on any scientific research? Will Canada continue to collaborate and share scientific information with China? [from approved MLs]</p> <ul data-bbox="99 399 1549 693" style="list-style-type: none"> <li data-bbox="99 399 1549 430">• No current collaborations between the NML and labs/institutions in China. <li data-bbox="99 451 1549 535">• Canada's NML is known around the world for scientific excellence/ contributions to global health. <li data-bbox="99 556 1549 693">• PHAC engages in important scientific research relationships to advance PH research and science aimed at improving PH. Collaborations with labs outside of Canada critical to advance PH research into infectious diseases. <p data-bbox="99 756 1549 882">Why does PHAC engage in academic collaborations with other countries? Why is it beneficial for the Public Health Agency of Canada to enter in to such collaborative research projects internationally? Are there not risks? What are the benefits?</p> <ul data-bbox="99 894 1549 1869" style="list-style-type: none"> <li data-bbox="99 894 1549 1081">• PHAC's researchers/scientists part of global community of scientific and scholarly expertise - their contribution critical to maintaining/enhancing credibility and reputation of PHAC and our experts, and PHAC contribution to Canada's social and economical development. <li data-bbox="99 1102 1549 1344">• we encourage and facilitate domestic and international scientific research, collaborations and partnerships with the external research and development communities in universities and colleges, and in PT or Indigenous governments - linkages provide opportunities to leverage global expertise, knowledge and infrastructure in developing research and scientific knowledge to address a wide scope of PH issues for the benefit of Canadians. <li data-bbox="99 1365 1549 1606">• PHAC recognizes the various challenges presented by current threats to research security, nationally and internationally, and is engaged with federal departments and international counterparts in raising awareness and enhancing dialogue among the research community, and engaging with partners on threat definition and solution implementation. <li data-bbox="99 1627 1549 1869">• PHAC adopted a new Scientific Integrity Policy in 2019. Scientific integrity involves the application of concepts of transparency, openness, high quality work, avoidance of conflict of interest and ensuring high standards of impartiality and research ethics. Employees involved in science or research must uphold and conform to the standards of responsible research and science excellence.

Agreements with Working Officials

- NML Science Excellence Program launched in September 2019 - strengthening policies and processes that allow for appropriate scientific collaboration while adhering to established security controls.
- Steering Committee oversight to strengthen the scientific administration of the organization.
- NML finalizing the **Engagement of Working Official Policy**, which includes a **Working Official Agreement** - formalizes the relationship between PHAC and Working Officials, including IP rights and use of PHAC facilities.
- The Science and Security Working Group reviews all proposed Working Official Agreements, **Collaboration Agreement** must also be signed for all collaborations.
- All Working Officials require an appropriate **security clearance** prior to entering the NML, and a **Material Transfer Agreement** must be in place before any movement of research materials.
- For all current COVID-19 projects, NML has **Research Plan** in place that covers associated risks. All projects (and associated risks) recorded and monitored in the NML's Science Planning Information System.

The transfer of Ebola and Henipah viruses from the NML to persons, laboratories, and institutions in China (On Oct 29, 2019, 12 strains of EBOV and 3 strains of NiV were authorized for transfer) [based on written Q-25]

- NML complies with all applicable requirements of the *Human Pathogens and Toxins Act* (HPTA), the *Transportation of Dangerous Goods Act* (TDGA), and the Canadian Biosafety Standard when sharing samples of pathogens and toxins with partner laboratories in Canada and in other countries.
- June 28, 2018, NML received a letter from the Director of the National Biosafety Laboratory at the Wuhan Institute of Virology (WIV) outlining intent to study Ebola virus (EBOV) and the Nipah virus (NiV) under their National Key Research and Development Plan.
- Areas of study were infectious immunological mechanisms, antivirals and virus-cell interactions of EBOV and NiV. WIV Director also guaranteed in his signed attestation letter that the viruses will only be used for research purposes. The virus samples were not transferred to any other institutions.
- NML is required, as per HPTRs, to receive, from any laboratory requesting pathogens, proof that they have the containment level of laboratory required for handling that pathogen. In this case, the Biosafety Officer at the WIV complied.

- IP protections were not required for the sharing of these samples - purpose was to facilitate research to benefit human health and advance scientific enquiry on preventing and treating infectious diseases.

Publications with scientists affiliated with the military of China

There are six papers listed with at least one author with Special Pathogens affiliation and one author with an affiliation to the military of China

- [remit]

Material Transfer Agreements (MTAs)

- NML's Science Excellence Program strengthening policies and processes that allow for appropriate scientific collaboration while adhering to established security controls.
- (as of early 2020) for clarity to employees and safeguards for our science, MTAs are required for all sharing or receiving of biological materials with other research organizations.

Why was an MTA not used for the WIV transfer in 2018?

- Complex decisions on what constituted an appropriate use of a MTA.
 - global partnerships, open science and collaboration as core aspects of our work
 - need to balance this against agreements in place that dictate the terms of collaboration.
- In this case, relationship building with WIV, sharing done to foster robust global health agenda by enabling scientific advancements on pathogens with potentially significant societal consequences.

IP protection

- NML manages IP in compliant manner (*Public Servants Invention Act*, the Canadian Federal IP Guidelines (2012), IP Policy Framework for the Science Based Departments and Agencies of the Government of Canada (2016) and the PHAC IP Policy (2017).
- As IP has evolved, so did PHAC approach to IP as it pertains to public health - current approach aimed at balancing the protection of commercial interests and helping promote development of accessible IP to bring PH solutions to those in need (particularly important during a pandemic).
- PHAC participated in GoC National Research Security Coordination committee that identifies emerging research security issues and act as a secure Government of Canada forum for info-sharing on research security issues.

2. NML Security (Physical)

Physical Security in the NML

- Entrance to the NML requires two-step verification process - includes photo ID and access card prepared by the Security Management Division at the facility.
- All persons are subject to extra random screening, entering or leaving the facility, with x-ray scans of effects at front entrance.
- All entry and movement of staff and visitors restricted to approved areas of the Canadian Science Centre for Human and Animal Health. Access card entry only into each zone, and all high security laboratories.
- PHAC National Security Management Division provides security awareness briefings and training, security investigations, internal physical security risk assessments and background verification for all staff and visitors.
- Threat and Risk Assessment's are regularly conducted by external agents for the physical security infrastructure as well as all the IT networks.

Security protocols for foreign academics

- Restrictions may be imposed on Visiting Scientists, or Working Officials, all of whom must have Secret security clearance, that can include escort in and out of the facility and constant supervision and other restrictions as necessary.

3. PPE Procurement / Quality Assurance / Export Requirements /Contract Disputes

Canada's donation of PPE to China

- GoC donated PPE to China in January 2020 to support ongoing efforts to prevent COVID-19 spread.
- Donation did not compromise Canada's domestic preparedness.
- Donation included 27,870 coveralls, 50,000 face shields and 200,000 nitrile gloves, which were close to expiry or considered surplus to Canada's needs.
- Chinese Ministry of Foreign Affairs returned the favour in spring 2020 with a generous donation of PPE and test kits.

Testing of products and quality assurance: [from QP note]

- Products undergo quality verification before distribution to PTs – process supported by testing capacity within the PHAC, NRC and independent laboratories.
- Products that fail to meet technical specifications for the healthcare sector are not distributed to PTs for frontline healthcare response.
- HC continues to monitor authorized medical devices for safety and effectiveness after authorization for use in Canada.
- HC takes appropriate action to protect the health and safety of Canadians, if concerns arise.

What is role of NML in testing of PPE?

[nil – limited to testing of reagents and supplies used by NML]

If asked how many N95 or KN95 masks have been rejected for failing to meet federal standards: [from response to approved senate question S-125]

- Approximately 200,000 N95 and 10 million KN95 masks have failed to meet the technical specifications for healthcare settings for COVID-19 response.

If asked about products that fail to meet technical specifications, contract disputes or incorrect items received: [from response to approved senate question S-125]

- NESS works with PSPC to determine the appropriate recourse as outlined in the contract.
- could include returning product to supplier for full refund/replacement.

If asked about evolving export requirements: [From a previously approved QP note, has been publicly disclosed]

- In May 2020, the Government of China imposed more stringent certification and customs regulations for masks and other PPE aimed at addressing quality control of exported products.
- As an importer, PHAC required to sign joint declaration with exporter attesting that products meet standards/certification requirements of the destination country.
- For products not certified as medical devices in China, the joint declaration stipulates that the item is “not for medical use” even if it meets Canada’s technical specifications for healthcare settings.
- All PPE supplies distributed by PHAC to PTs are labelled confirming they meet the GoC’s technical specifications for healthcare settings.

PPE and forced labour: [from previously approved HESA supplementary messages]

- GoC committed to addressing risk of forced labour and human trafficking in federal procurement supply chains through the National Strategy to Combat Human Trafficking.
- PSPC able to speak to work it is undertaking to ensure we do business with ethical suppliers.

PPE procurements linked to Xinjiang, China: [from previously approved HESA supplementary messages]

- GoC aware of the risks of forced labour associated with international and Chinese supply chains.
- GoC favoured a made-in-Canada solution to ramp up domestic production of PPE to reduce exposure to global supply chains that could be vulnerable to forced labour.

4. WHO/Bilateral/Multilateral Health Collaboration

Bilateral and Multilateral Relations in Health

***Any questions relating to foreign policy issues and the broader bilateral relationship (i.e. Meng Wanzhou and related consular cases, human rights in China, Hong Kong, etc.)**

- refer to Global Affairs Canada.

General line

- As the COVID-19 situation continues to evolve around the world, Canada will continue to work closely with its international partners, including the WHO and China, to reduce risks to Canadians and the global community.

What is the current status of the Canada-China relationship in health?

- Canada and China share longstanding relationship in health that dates back to MOU signed in 1995 calling for regular dialogue on health-related issues.
- Under MOU, Canada-China Policy Dialogue on Health (CCPD) is main vehicle for formal bilateral engagement, including at the ministerial level.
 - four dialogues in 2009, 2010, 2011, and 2014.
- since 2014, **engagement primarily in health-related multilateral fora** (WHO, the Global Health Security Agenda, Asia-Pacific Economic Cooperation (APEC) Health Working Group)
- also more technical level fora related to food and consumer product safety (HC mandate)

How do Canada and China engage at multilateral fora?

- primarily limited to participation in same meetings, such as annual World Health Assembly.
- very limited bilateral engagement on the margins of these events.
- last bilat at ministerial level took place on margins of WHA in May 2018 - introductory meeting where respective health priorities discussed.

What are your plans for future collaboration in health with China?

- We have no specific plans for future collaboration that departs from the nature of our current engagement.
- PHAC's primary objective is protecting the health and safety of Canadians. We will continue to engage with China on health issues, where it advances this objective.
- This has been, and will continue to be, our guiding principle as we move forward in the relationship.

WHO

Undue Chinese Influence on WHO. What are Canada's views on allegations of undue Chinese influence on the WHO?

- We value WHO's global leadership and coordination during pandemic, and have confidence WHO is working with and for all Member States
- Continued commitment to the WHO towards making it a strong, accountable, inclusive and well-governed institution, whose actions and recommendations are guided by Member States, and best available science/evidence.
- We will continue to actively participate in oversight and accountability review processes for the WHO, including any comprehensive review of the global COVID-19 response
- This includes the work of the Independent Panel on Pandemic Preparedness and Response, which is leading an impartial and independent evaluation of the global response to the COVID-19 pandemic.

Origins Mission - What is the current status of the international expert mission to trace the origins of SARS-CoV-2?

- In January, an international team of experts (no Canadians) convened by WHO undertook a joint mission with Chinese counterparts to trace the zoonotic origins of Sars-CoV-2 and its route of introduction into the human population
- Preliminary findings shared earlier this month. Experts unable to determine origins, but concluded that most likely scenario was from an animal host (likely a bat) via an intermediary host species.
- The mission will produce two reports: a summary version expected shortly, and a full report.
- This is one step in a longer-term effort to identify the origins of the virus. A key outcome will be the identification of further studies to advance this work.

What has been Canada's role in mission?

- Canada has been a strong supporter of this mission and its findings.
- Canada co-sponsored a WHA resolution in May 2020 that called for this work, and raised its importance in bilateral discussions with WHO and during Jan 2021 WHO Executive Board Meeting.
- No Canadians participated - mission team was comprised of 17 Chinese and 17 international experts from 10 countries.

What is Canada's position on the mission and its findings?

- Canada has repeatedly emphasized the need for China to be open and transparent as part of this important process and has shared our expectations for timely, complete, and unfettered access, including directly with Chinese counterparts.

- Mission is an important example of international scientific collaboration to advance global health security.
- Canada will continue to work closely with other countries and WHO, including with respect to addressing concerns about the level of access that the mission team received in Wuhan.

Is Canada satisfied with the WHO's role in this investigation?

- As a Member State organization, WHO does not have powers over China (or other Member States), so it must work with China to gain access for the international expert team.
- Member States must meet their obligations under the IHRs (i.e. the sharing of timely, accurate and sufficiently detailed PH information).
- We are aware of reports that the WHO team did not receive complete and unfettered access.
- WHO has made clear that it reserves the right to disagree on the joint report findings.

What are Canada's views on the theory promoted by Chinese authorities that the virus could have entered the Wuhan market via imported frozen food packaging?

- These scientific studies must follow the facts – to review the full report and receive more details before commenting on preliminary theories

5. Early Stages of the Pandemic and GPHIN / GPHIN Report

GPHIN

- Established in 1997, the Global Public Health Intelligence Network (GPHIN) is PHAC's open-source event-based global surveillance system.
- GPHIN provides early-warning and situational awareness for potential CBRN public health threats worldwide - includes monitoring of infectious disease outbreaks.
- The first report of a mysterious pneumonia outbreak in China, which would later be known as COVID-19, was detected by GPHIN on the evening of December 30, 2019.
- This information was distributed to Canadian PH practitioners at FPT levels on December 31, 2019 via the GPHIN Daily Report.
- Enhanced reporting and surveillance began immediately and enabled a rapid response. By the evening of December 31, 2019, the significance of this event was clear in the PH surveillance community.

Interim report released March 20 [from MLQAs]

Key messages

- Established in 1997, GPHIN is an open source event-based surveillance system intended to provide early-warning and situational awareness for potential CBRN PH threats worldwide, including monitoring of infectious disease outbreaks.

- **In November 2020, Minister of Health announced independent panel review**
- **This independent review will provide opportunity to identify:**
 - capabilities of the existing system;
 - its role in detecting and informing the Agency's response to COVID-19;
 - opportunities for system enhancements; and
 - opportunities to improve how the Agency synthesizes, shares and leverages key information sources for early detection.
- **GoC looks forward to receiving the final report and recommendations from the External Review Panel in late spring. The Panel's recommendations will be used to support PHAC in determining how this global public health surveillance system can best serve Canadians and the international community.**

What is the Government of Canada's response to this interim report from the Panel?

- **GoC welcomes the interim update from the External Review Panel on the progress of this important review.**
- **PHAC will be considering both the interim and final reports in determining how GPHIN can best serve Canadians and the international community.**
- **interim report: (1) highlights the Panel's approach and work to date on this review, which includes a look at the past and present state of GPHIN, from its creation in the 1990s to its current operations; (2) provides overview of GPHIN's structure and functions; and (3) GPHIN's initial detection of what would become the COVID-19 pandemic.**
- **report also points to where Panel plans to focus attention as it begins to develop recommendations, such as:**
 - the operational context, role and mandate of GPHIN;
 - governance structures that support GPHIN;
 - partnerships and flows of information between GPHIN and stakeholders, domestically and globally;
 - lessons learned from COVID-19 and opportunities to improve the system; and
 - advice on the next generation of public health intelligence systems and the future of surveillance tools.

Why was the review requested?

- **The review was requested to support and enhance PHAC's ability to detect, monitor and respond to public health issues of concern.**

- Since GPHIN was established in 1997, a significant number of non-governmental entities now conduct open source surveillance and alerting alongside governmental systems. These global shifts have impacted the role that GPHIN plays in Canada and on the world stage.

What did PHAC learn in its review that prompted the Minister to request an independent review of GPHIN?

- Minister received briefings about GPHIN, including an overview of the system since its inception, the role of GPHIN during COVID-19, and how processes had evolved over time.
- Decision for independent review was to assess how GPHIN can continue to meet today's public health needs. Panelists selected based on experience and expertise.

Were the Panel members Ministerial appointments or Governor in Council appointments?

- Minister appointed Panel members.

How much will this review cost?

- estimated \$150,000 over 2020-21 and 2021-22 FYs.

When will the final report be completed and will it be made public?

- review anticipated to take 5-6 months, with Minister receiving final report in late spring 2021. The report will be made publicly available.

Will this review overlap with the Auditor General of Canada's audit of PHAC's surveillance and data programs?

- may be common elements between the OAG performance audit about Pandemic Preparedness and Response being conducted and this independent review.

About GPHIN

What is the difference between a GPHIN Alert and other GPHIN information products and their distribution?

- GPHIN develops and distributes a variety of PH surveillance information products free of charge to subscribers, including:
 - GPHIN Daily Report: a summary of relevant public health articles from around the world on key topics distributed to Canadian public health officials. It highlights the main domestic and international issues or reports in order to facilitate early warning and ongoing situational awareness of emerging or evolving public health risks or threats in Canada and worldwide.
 - GPHIN Alert: an email with a highlighted article about a health event of potential interest to international and domestic subscribers.
 - GPHIN Platform: a searchable public health surveillance database available to all subscribers (public health professionals).

- GPHIN also produces other reports on an as-requested basis.
- A GPHIN Alert does not include a risk assessment or recommendations for specific action or response.

About GPHIN and COVID-19

What was GPHIN's early response to COVID-19?

- The first report of a mysterious pneumonia outbreak in China, which would later be known as COVID-19, was described in Agence France-Presse on the **evening of December 30, 2019**.
- This information was disseminated quickly to public health authorities through multiple mechanisms, including:
 - The **December 31, 2019**, GPHIN Daily Report distributed to Canadian public health practitioners at the federal, provincial and territorial levels;
 - A posting on the widely subscribed Program for Monitoring Emerging Diseases (ProMED); and
 - An official reporting from the Wuhan Municipal Health Commission.
- The WHO stood up its Incident Management Support Team on **January 1, 2020**.
- Enhanced reporting and surveillance began immediately and enabled a rapid response. By the evening of **December 31, 2019**, the significance of this event was clear in PH surveillance community.

Was the program shut down?

- never been shut down. While number of alerts has decreased over the past years, GPHIN has continued to operate without reductions in its team size or budget.
- Canadian users including FPT government officials, have maintained access to the GPHIN Daily Report and receive timely information about PH issues. GPHIN program's health expertise continues to contribute to global PH surveillance knowledge for the WHO and countries, regions and Canada.

If the program wasn't shut down, why did the number of alerts decrease over the past number of years?

- GPHIN activity over this period, including the GPHIN Daily Report, GPHIN Alerts, and updates to the GPHIN Platform, are part of the subject matter being examined by the External Review Panel for this review requested by the Minister of Health.

If needed:

- PHAC implemented a standard operating procedure on the issuance of GPHIN alerts in September 2020 to clarify the process.
- The decision to issue a GPHIN Alert begins with the GPHIN analysts and the senior epidemiologist considering whether a signal meets the criteria set out in the International Health Regulations (2005) for a Public Health Emergency of International Concern. Other considerations include whether the event could or represent a CBRN incident posing an immediate threat to human health or the environment. The Director of PHAC's Office of Situational Awareness then reviews the case.

Q12. Why wasn't a GPHIN alert sent for COVID-19?

- Canada's response to the initial report of the "mysterious pneumonia" in China was swift. Enhanced surveillance and reporting began immediately. A GPHIN alert would not have made Canada's response to COVID-19 faster or more effective as information had already been disseminated widely through a number of other mechanisms.
- GoC looks forward to receiving the final report and recommendations from the Panel in late spring. We trust that the Panel's recommendations will support PHAC in determining how we can position the global PH surveillance system to best serve Canadians and the international community

Employment status of two National Microbiology Laboratory scientists

SYNOPSIS / POTENTIAL QUESTION

- Questions arose from opposition MPs at the special committee on Canada-China relations of March 22, 2021 regarding the employment status of the 2 NML Scientists. The Committee has given the President of PHAC until Friday March 26 2021 to explain.

personal information

SOMMAIRE/ QUESTION POTENTIELLE

-

KEY MESSAGES

- **Status of employment:**
I can confirm that the two scientists are no longer employed by the Public Health Agency of Canada as of January 20, 2021.
- **Request for details:**
At this time, I cannot disclose additional information nor comment further for national security and privacy reasons. A response will be provided to the Committee before the indicated deadline.
- **Impact on Canadians:**
I can assure Canadians that their health and safety is not compromised and that the National Microbiology Laboratory continues to play a critical role in protecting the health and safety of Canadians.

MESSAGES CLÉS

IF PRESSED...

Q1. Are security partners involved?

It is normal procedure for the Agency to consult with security partners as required. It would be inappropriate to comment any further given privacy and other considerations.

Q2. Is there a link between the scientists and China and did that lead to them no longer being employed by PHAC?

We cannot disclose specific information nor comment further.

Q3. What is the risk to national security?

The Government of Canada takes any threat to Canada's national security seriously and works with federal partners to keep Canadians safe. As you can expect, we do not publicly comment, or confirm or deny the specifics of investigations, operational interests, or activities.

Q4. Is the NML currently collaborating with China on any scientific research? Will Canada continue to collaborate and share scientific information with China?

There are no current collaborations between the NML and labs/institutions in China. Canada's National Microbiology Laboratory is known around the world for its scientific excellence and contributions to global health. PHAC engages in important scientific research relationships to advance public health research and science aimed at improving public health. Collaborations with labs outside of Canada is critical to advance public health research into infectious diseases.

Q5. Is the RCMP investigation complete? Why is it taking so long? Have charges been laid?

Refer to the RCMP

BACKGROUND/CONTEXTE

Not applicable

CONTACT: Daryl Gauthier, Director General Human Resources HC/PHAC (343-542-2293)

Approved by: Debbie Beresford-Green, ADM Corporate Services HC/PHAC (613)946-3200

Chronology - A-2019-000061

Date	Details
28-Jun-2018	Request letter received for samples
14-Sep-2018	SES received the request for shipment and provided a package of what was required from the Wuhan lab Senior Management informed of request
29-Oct-2018	Transfer Authorization issued
01-Jan-2019	Qiu was provided all documents required to complete
05-Feb-2019	Typo made in an email to 3rd party regarding packaging type (PI650)
20-Feb-2019	3rd party advises that the Wuhan lab has flagged the typo (packaging should be PI620)
26-Feb-2019	NML confirms that packaging should be PI620
27-Feb-2019	3rd party requested certificate approval of packaging
18-Mar-2019	Samples stored at NCFAD until all paperwork is completed NML Senior Management informed of the pending shipment
26-Mar-2019	NML Operations Centre advised of the shipment Paperwork sent to 3rd party
27-Mar-2019	Documents sent to NML Specimen Receiving Transfer request sent to CFIA - asked for additional information Answers provided to CFIA ERAP notification issued by NML OC (HPOC acknowledged receipt) Customs invoice and shipper declaration sent to 3rd party

- 28-Mar-
2019 CEPR requested information about the shipment
Brd party received approval to send the shipment
- 29-Mar-
2019 Shipment picked up by Brd party
Shipping notification sent to ERAP group
Dangerous goods declaration is revised to include dry ice
- 31-Mar-
2019 Shipment sent to Wuhan on flight AC031 from Toronto
- 01-Apr-
2019 Shipment arrived in Wuhan

Home Logout

Logged In : mledieu

Search Packages

PO Number:

Internal Tracking Number:

Courier Tracking Number:

Client Name:

Company Name:

Incoming Outgoing Both

Start Date: format (yyyy-mm-dd)

End Date: format (yyyy-mm-dd)

Courier:

Search Results

- Shipments not assigned to an order
- Packages not assigned to a shipment
- Shipment ID: d883015e065d
- Shipment ID: 5be07f00163c
- Shipment ID: 1b72d883f4dc
- Shipment ID: 394df8dd0b98
- Shipment ID: ac6178f2c2d8
- Shipment ID: 4a373c8b4ab7
- Shipment ID: 3afe0936b591
- Shipment ID: 8fb93ded477a
- Shipment ID: 5a28d68ef28
- Shipment ID: 1fae3356badf
- Shipment ID: 7531ce65e8b5
- Shipment ID: a7b24795f44d
- Shipment ID: f32341103c5f
- Shipment ID: e0130c194364
- Shipment ID: 2d87e531c0d2
- Shipment ID: e2cd2beb4590
- Shipment ID: dd346b36891f
- Shipment ID: 1bcc5542d745
- Shipment ID: aeaf903b0d63
- Shipment ID: d83e3835627a
- Shipment ID: 101102150fb6
- Shipment ID: 65ae82eca79b
- Shipment ID: 7ffad617b9f8
- Shipment ID: 2ce019b438cb
- Shipment ID: 46e58b590582
- Shipment ID: e0779fb463f7
- Shipment ID: 4a93dfef5de6
- Shipment ID: d5dc75b7554f
- Shipment ID: 7489f4393adc
- Shipment ID: b10a87d03199
- Shipment ID: 47e52758ca09
- Package ID: 231856
- Shipment ID: 306edeb7c30f
- Shipment ID: d2e90fcd18cb
- Shipment ID: 7d53c2ac8fef
- Shipment ID: ead133a05bd5
- Shipment ID: 5049c0a6a1b1
- Shipment ID: 0fb33cb3e93d
- Package ID: 235190
- Shipment ID: f549bae08e1c
- Shipment ID: fb6da92ac480
- Shipment ID: odd13dd64af3
- Shipment ID: 93dce0400ba9
- Shipment ID: baa6a570162a
- Shipment ID: 2bf4c5b2fcd6
- PO: NO CHARGE
- Shipment ID: e20045a99ea7
- Package ID: 251123

Shipment Details

Created: 2019-03-29 1:52 PM

Created By:

Shipment ID:

Primary Package ID:

Courier Tracking No:

Contact Phone:

Incoming: Processing Complete:

From Client

Name: QIU, XIANGGUO

Company: PUBLIC HEALTH AGENCY OF CANADA

Address: 1015 Arlinglorn Street

Postal/Zip: R3E 3R2

City: Winnipeg

State/Prov: Manitoba

Country: Canada

To Client

Name:

Company: WUHAN INSTITUTE OF VIROLOGY

Address: NO 44 XIAOHONGSHAN

Postal/Zip: 430071

City: WUHAN

State/Prov: PEOPLE'S REPUBLIC

Country: CHINA

Order Information

PO Number:

Ordered By:

Courier Information

Courier:

Route: AIR FREIGHT

Conf No:

Billing Information

Bill To: DEPARTMENT

Department: NML

Account No: 50943

Special Information

Biological Material Desc.: INFECTIOUS SUBSTAN

Dangerous: TDG Document Required: For Specimen Receiving:

Existing Memos

created	memo
2019-03-29 1:52 PM	UN2814 CATEGORY A INFECTIOUS SUBSTANCE AFFECTING HUMANS (EBOLA VIRUS, HENIPAH VIRUS) - CLASS 6.2 - 30 VIALS X 0.5 ML - ATTN <input type="text" value="3rd party"/>

Home Logout

Logged In : mledieu

Search Packages

PO Number:

Internal Tracking Number:

Courier Tracking Number:

Client Name:

Company Name:

Incoming Outgoing Both

Start Date: format (yyyy-mm-dd)

End Date: format (yyyy-mm-dd)

Courier:

Search Results

- [-] Shipments not assigned to an order
- [-] Packages not assigned to a shipment
- [-] Shipment ID: d883015e065d
- [-] Shipment ID: 5be07f00163c
- [-] Shipment ID: 1b72d883f4dc
- [-] Shipment ID: 394df8dd0b98
- [-] Shipment ID: ac6178f2c2d8
- [-] Shipment ID: 4a373c8b4ab7
- [-] Shipment ID: 3afe0936b591
- [-] Shipment ID: 8fb93ded477a
- [-] Shipment ID: 5a288d68ef28
- [-] Shipment ID: 1fae3356badf
- [-] Shipment ID: 7531ce65e8b5
- [-] Shipment ID: a7b24795f44d
- [-] Shipment ID: f32341103c5f
- [-] Shipment ID: e0130c194364
- [-] Shipment ID: 2d87e531c0d2
- [-] Shipment ID: e2cd2beb4590
- [-] Shipment ID: dd346b36891f
- [-] Shipment ID: 1bcc5542d745
- [-] Shipment ID: aeaf903b0d63
- [-] Shipment ID: d83e3835627a
- [-] Shipment ID: 101102150fb6
- [-] Shipment ID: 65ae82eca79b
- [-] Shipment ID: 7ffad617b9f8
- [-] Shipment ID: 2ce019b438cb
- [-] Shipment ID: 46e58b590582
- [-] Shipment ID: e0779fb463f7
- [-] Shipment ID: 4a93dfb5de6
- [-] Shipment ID: d5dc75b7554f
- [-] Shipment ID: 7489f4393adc
- [-] Shipment ID: b10a87d03199
- [-] Shipment ID: 47e52758ca09
 - [-] Package ID: 231856
 - [-] Shipment ID: 306edeb7c30f
 - [-] Shipment ID: d2e90fdc18cb
 - [-] Shipment ID: 7d53c2ac8fef
 - [-] Shipment ID: ead133a05bd5
 - [-] Shipment ID: 5049c0a6a1b1
 - [-] Shipment ID: 0fb33cb3e93d
 - [-] Package ID: 235190
 - [-] Shipment ID: f549bae08e1c
 - [-] Shipment ID: fb6da92ac480
 - [-] Shipment ID: 0dd13dd64af3
 - [-] Shipment ID: 93dce0400ba9
 - [-] Shipment ID: baa6a570162a
 - [-] Shipment ID: 2bf4c5b2fcd6
 - [-] PO: NO CHARGE
 - [-] Shipment ID: e20045a99ea7
 - [-] Package ID: 251123

Shipment Details

Created: 2018-12-31 10:34 AM

Created By: 3rd

Shipment ID: 3rd party

Primary Package ID: 3rd party

Courier Tracking No: 3rd

Contact Phone: 3rd

Incoming: Processing Complete:

From Client

Name:

Company: WUHAN INSTITUTE OF VIROLOGY

Address: NO. 44 XIAOHONGSHAN

Postal/Zip: 430071

City: WUHAN

State/Prov: PEOPLE'S REPUBLIC

Country: CHINA

To Client

Name: ASHLEY, DON

Company: PUBLIC HEALTH AGENCY OF CANADA

Address: 1015 Arlington Street

Postal/Zip: R3E 3R2

City: Winnipeg

State/Prov: Manitoba

Country: Canada

Order Information

PO Number:

Ordered By:

Courier Information

Courier: 3rd party

Route: AIR FREIGHT

Conf No:

Billing Information

Bill To: SENDER

Department: NML

Account No:

Special Information

Biological Material Desc.: DIAGNOSTIC SPECIME

Dangerous: TDG Document Required: For Specimen Receiving:

Existing Memos

created	memo
2018-12-31 10:34 AM	RECOMBINANT PROTEIN - DELIVERED TO SPECIMEN RECEIVING - 3rd party TEMP TAIL IN PACKAGE, TO BE RETURNED TO 3rd party UPON RECEIPT BY SPECIMEN RECEIVING



SHIPPER'S DECLARATION FOR DANGEROUS GOODS

Shipper Dr. Xiangguo Qiu (204-784-7548) Public Health Agency of Canada - NML 1015 Arlington St. Winnipeg, Manitoba, Canada, R3E 3R2				Air Waybill No. Page 1 of 1 Pages Shipper's Reference No. (optional)		
Consignee <div style="background-color: black; width: 100px; height: 15px; margin-bottom: 5px;"></div> Chinese Academy of Sciences - Wuhan Institute of Virology Xiao Hong Shan No.44 Wuhan, Hubei, China, 430071						
<i>Two completed and signed copies of this Declaration must be handed to the operator.</i>				WARNING Failure to comply in all respects with the applicable Dangerous Goods Regulations may be in breach of the applicable law, subject to legal penalties.		
TRANSPORT DETAILS This shipment is within the limitations prescribed for: (delete non-applicable)						
Airport of Departure (optional):		<input type="checkbox"/> PASSENGER AND CARGO AIRCRAFT		<input checked="" type="checkbox"/> CARGO AIRCRAFT ONLY		
Airport of Destination (optional):		Shipment type: (delete non-applicable)		<input type="checkbox"/> NON-RADIOACTIVE		
				<input checked="" type="checkbox"/> RADIOACTIVE		
NATURE AND QUANTITY OF DANGEROUS GOODS						
Dangerous Goods Identification						
UN or ID No.	Proper Shipping Name	Class or Division (subsidiary hazard)	Packing Group	Quantity and Type of Packing	Packing Inst.	Authorization
UN 2814	Infectious substance, affecting humans (Ebola virus, Henipah virus)	6.2		30 vials x 0.5 ml	620	
Additional Handling Information 1-888-CAN-UTEC (226-8832), 613-996-6666 PHAC NML EOC Director: 1-866-262-8433						
I hereby declare that the contents of this consignment are fully and accurately described above by the proper shipping name, and are classified, packaged, marked and labelled/placarded, and are in all respects in proper condition for transport according to applicable international and national governmental regulations. I declare that all of the applicable air transport requirements have been met.				Name of Signatory Date Signature (See warning above)		

Burrows, Andrea (HC/SC)

From: Robertson, Catherine (PHAC/ASPC)
Sent: 2018-09-14 12:19 PM
To: Safronetz, David (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC)
Cc: Drebot, Mike (PHAC/ASPC); Guercio, Steven (PHAC/ASPC)
Subject: Re: viruses to be exported to China

Sorry guys,

I just got to this.

Tracy is off [REDACTED] and I just got back. I'll go over the request and put together a package of what we need from the requesting lab. We usually ask for evidence of certification or a statement from the lab director.

Cathy

Sent from my BlackBerry 10 smartphone on the Bell network.

From: Safronetz, David (PHAC/ASPC)
Sent: Friday, September 14, 2018 9:59 AM
To: Gilmour, Matthew (PHAC/ASPC); Robertson, Catherine (PHAC/ASPC)
Cc: Drebot, Mike (PHAC/ASPC); Guercio, Steven (PHAC/ASPC)
Subject: Re: viruses to be exported to China

We would of course not send anything out without appropriate paper work, MTAs, certifications , letters from BSOs etc. They are requesting material from us due to collaboration with dr. Qiu. Historically it's also been easier to obtain material from us as opposed to US labs. I don't think other , closer labs have the ability to ship these materials. We can certainly ask about their stocks and see if we can get some.

Dave

Sent from my Samsung Galaxy smartphone.

----- Original message -----

From: "Gilmour, Matthew (PHAC/ASPC)" <matthew.gilmour@canada.ca>
Date: 2018-09-14 9:17 AM (GMT-06:00)
To: "Safronetz, David (PHAC/ASPC)" <david.safronetz@canada.ca>, "Robertson, Catherine (PHAC/ASPC)" <catherine.robertson@canada.ca>
Cc: "Drebot, Mike (PHAC/ASPC)" <mike.drebot@canada.ca>, "Guercio, Steven (PHAC/ASPC)" <steven.guercio@canada.ca>
Subject: RE: viruses to be exported to China

Hi Dave,

I have some concerns here.

- No certifications are provided, they simply cite they have them.
- What is the nature of the work, and why are our materials required? (ie. these are surely available from other, more local labs).
- MTA's would be required, not generic 'guarantees' on their storage and usage.
- Are there materials that they have that we would benefit from receiving? Other VHF? High path flu?
- Good to know that you trust this group. How did we get connected with them?

Matt

From: Safronetz, David (PHAC/ASPC)
Sent: 2018-09-12 2:13 PM
To: Robertson, Catherine (PHAC/ASPC)
Cc: Drebot, Mike (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)
Subject: FW: viruses to be exported to China

Hi Cathy,

We haven't heard back from Tracey regarding this. Is there any issues from your perspective to send out these isolates? I trust the lab and would be personally fine to sign off for SP.

Dave

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2018-09-10 2:36 PM
To: Drew, Tracy (PHAC/ASPC)
Cc: Safronetz, David (PHAC/ASPC); Leung, Anders (PHAC/ASPC)
Subject: viruses to be exported to China

Hi Tracy,

Pls see attached for the request letter from Wuhan Institute of Virology, Chinese Academy of Sciences and let me know if there are any concerns/questions.

Dave, we had discussed this some time ago and you are agreed to send the viruses once all the documents are in place.

Thanks!

Qiu

Burrows, Andrea (HC/SC)

From: Robertson, Catherine (PHAC/ASPC)
Sent: 2019-01-24 11:59 AM
To: Guercio, Steven (PHAC/ASPC)
Subject: FW: RG4 viral culture export to CL4 lab in China

I am in the process of putting together an email regarding our first conversation.

Maybe we can have a meeting later to discuss.

Cathy

Catherine Robertson

Director, Biorisk and Occupational Safety Services
 Public Health Agency of Canada
 National Microbiology Laboratory
 1015 Arlington Street
 Winnipeg
 Manitoba R3E 3P6
 Tel: 204 789-6079 (office)
 204-229-8275 (cellphone)
 Fax: 204 789-2069
 e-mail: catherine.robertson@canada.ca

From: Lau, Allan (PHAC/ASPC)
Sent: 2019-01-24 10:57 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: Robertson, Catherine (PHAC/ASPC); Krishnan, Jay (PHAC/ASPC)
Subject: RE: RG4 viral culture export to CL4 lab in China

Hi Qiu,

To send something to China (or any country), you will need to complete SES-F-052 which includes signatures from the recipient and their facility BSO. You as the importer (or Dave as the Section Chief) will also need to sign off on it. You will also need to obtain the country's import permit and/or laboratory certification for verification that they are approved to work with the material you are sending them.

Once you have the completed application and the import permit/certification, please bring it to me for review. I will give you a Transfer Authorization (TA) that will need to be reviewed and signed off by Mike Drebot (divisional policy) before you can send the package. Include the TA along with China's import permit, and other relevant shipment documentation (NML requisition, TDG paperwork, courier waybill, etc) when you send it out.

As a FYI, make sure you notify the NML OCD that you will be sending out a package containing a RG4 pathogen for ERAP purposes as soon as you have details on when you will be sending it and the route the package will be taking.

Feel free to drop by if you have any questions about any of this.

Allan

From: Krishnan, Jay (PHAC/ASPC)
Sent: 2019-01-24 10:37 AM
To: Lau, Allan (PHAC/ASPC)
Cc: Qiu, Xiangguo (PHAC/ASPC); Robertson, Catherine (PHAC/ASPC)
Subject: RG4 viral culture export to CL4 lab in China

Hi Allan,

Qiu is planning to send cultures to a CL4 lab in China; could you let her know all the required docs please?

Cathy, do you have the phrase “ the crown doesn’t regulate the crown” in writing from the Foreign affairs please? Qiu seem to remember something like was included in previous exports from our CL4, thanks

-Jay

Burrows, Andrea (HC/SC)

From: Robertson, Catherine (PHAC/ASPC)
Sent: 2019-01-24 2:25 PM
To: Qiu, Xiangguo (PHAC/ASPC); Krishnan, Jay (PHAC/ASPC); Lau, Allan (PHAC/ASPC)
Subject: RE: RG4 viral culture export to CL4 lab in China

We don't have anything in writing but when we try to get an export permit, we are told we don't need one.

Cathy

Catherine Robertson

Director, Biorisk and Occupational Safety Services
 Public Health Agency of Canada
 National Microbiology Laboratory
 1015 Arlington Street
 Winnipeg
 Manitoba R3E 3P6
 Tel: 204 789-6079 (office)
 204-229-8275 (cellphone)
 Fax: 204 789-2069
 e-mail: catherine.robertson@canada.ca

From: Qiu, Xiangguo (PHAC/ASPC)
Sent: 2019-01-24 10:48 AM
To: Krishnan, Jay (PHAC/ASPC); Lau, Allan (PHAC/ASPC)
Cc: Robertson, Catherine (PHAC/ASPC)
Subject: RE: RG4 viral culture export to CL4 lab in China

Thanks! Jay.

Cathy, I thought you said something like that" the crown doesn't regulate the crown" and we should include a sentence like that somewhere(I forgot where) when the shipment to be sent out during our discussion in the hallway(outside Jay's office) sometime ago.

Thanks a lot everyone!

Qiu

From: Krishnan, Jay (PHAC/ASPC)
Sent: 2019-01-24 10:37 AM
To: Lau, Allan (PHAC/ASPC)
Cc: Qiu, Xiangguo (PHAC/ASPC); Robertson, Catherine (PHAC/ASPC)
Subject: RG4 viral culture export to CL4 lab in China

Hi Allan,

Qiu is planning to send cultures to a CL4 lab in China; could you let her know all the required docs please?

Cathy, do you have the phrase " the crown doesn't regulate the crown" in writing from the Foreign affairs please? Qiu seem to remember something like was included in previous exports from our CL4, thanks

-Jay

From: [Drebot, Mike \(PHAC/ASPC\)](#)
To: [Leung, Anders \(PHAC/ASPC\)](#); [Lau, Allan \(PHAC/ASPC\)](#); [Krishnan, Jay \(PHAC/ASPC\)](#)
Cc: [Safronetz, David \(PHAC/ASPC\)](#); [Strong, Jim \(PHAC/ASPC\)](#); [Qiu, Xiangguo \(PHAC/ASPC\)](#); [Gilmour, Matthew \(PHAC/ASPC\)](#); [Guercio, Steven \(PHAC/ASPC\)](#); [Robertson, Catherine \(PHAC/ASPC\)](#)
Subject: RE: Paperwork for Special Pathogens pathogen transfers to China
Date: 2019-03-18 12:19:04 PM

Thanks Anders et al, I think we are good for documentation on this May shipment.
Michael

From: Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>
Sent: 2019-03-18 12:09 PM
To: Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; Krishnan, Jay (PHAC/ASPC) <jay.krishnan@canada.ca>
Cc: Safronetz, David (PHAC/ASPC) <david.safronetz@canada.ca>; Strong, Jim (PHAC/ASPC) <jim.strong@canada.ca>; Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Robertson, Catherine (PHAC/ASPC) <catherine.robertson@canada.ca>
Subject: RE: Paperwork for Special Pathogens pathogen transfers to China

Hi Mike,

I wasn't part of the initial conversation for the shipment but I have the original request letter from China and the NML forms, attached in email.

Anders

From: Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>
Sent: 2019-03-18 12:04 PM
To: Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; Krishnan, Jay (PHAC/ASPC) <jay.krishnan@canada.ca>
Cc: Safronetz, David (PHAC/ASPC) <david.safronetz@canada.ca>; Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; Strong, Jim (PHAC/ASPC) <jim.strong@canada.ca>; Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Robertson, Catherine (PHAC/ASPC) <catherine.robertson@canada.ca>
Subject: Paperwork for Special Pathogens pathogen transfers to China

Thanks Allan, I have cc'd Qiu and Jim as well. To what agency or institution are the Ebola, etc. cultures / materials going to ?

Have also informed Matt and Steve so they are in the loop.

Thanks again,

Michael

Mike Drebot, PhD, ARMCCM

Director, Zoonotic Diseases and Special Pathogens
National Microbiology Laboratory, Public Health Agency of Canada
1015 Arlington Street
Winnipeg, Manitoba R3E 3R2

Associate Professor
Department of Medical Microbiology
University of Manitoba

E-Mail: Mike.Drebot@canada.ca
Phone: (204) 789-6059
Fax: (204) 789-2082

From: Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>
Sent: 2019-03-18 11:56 AM
To: Krishnan, Jay (PHAC/ASPC) <jay.krishnan@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>
Cc: Safronetz, David (PHAC/ASPC) <david.safronetz@canada.ca>; Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>
Subject: RE: Paperwork for path transfers to China

Hi all,

Anders came to see me and I did not realize that this process was started back in October of last year while I was [REDACTED]. We do have all the proper documentation from China and the Transfer Authorization (NML-TA-18-0480) was issued on Oct. 29, 2018.

As a note, the expiry date of the Transfer Authorization is 2019-08-10, which coincides with the expiry date of our RG4 license. If the shipment is not completed by that date, a new Transfer Authorization will need to be issued with the new RG4 license number and expiry date before the samples are transferred.

Allan

From: Krishnan, Jay (PHAC/ASPC) <jay.krishnan@canada.ca>
Sent: 2019-03-18 11:41 AM
To: Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>
Cc: Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; Safronetz, David (PHAC/ASPC) <david.safronetz@canada.ca>; Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>
Subject: Paperwork for path transfers to China

Hi Mike,

Allan has not received any paperwork yet for the transfer to China; there is a paperwork he initiated this morning to temporarily store viral cultures in NCFAD CL4. He and Anders will make sure no

cultures leave the building without all the paperwork and your final sign off as usual, thanks

-Jay

From: [Lau, Allan \(PHAC/ASPC\)](#)
To: [Drebot, Mike \(PHAC/ASPC\)](#); [Krishnan, Jay \(PHAC/ASPC\)](#)
Cc: [Safronetz, David \(PHAC/ASPC\)](#); [Leung, Anders \(PHAC/ASPC\)](#); [Strong, Jim \(PHAC/ASPC\)](#); [Qiu, Xiangguo \(PHAC/ASPC\)](#); [Gilmour, Matthew \(PHAC/ASPC\)](#); [Guercio, Steven \(PHAC/ASPC\)](#); [Robertson, Catherine \(PHAC/ASPC\)](#)
Subject: RE: Paperwork for Special Pathogens pathogen transfers to China
Date: 2019-03-18 12:07:00 PM

Hi Mike,

They're going to the Wuhan Institute of Virology, Chinese Academy of Science.

Allan

From: Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>
Sent: 2019-03-18 12:04 PM
To: Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; Krishnan, Jay (PHAC/ASPC) <jay.krishnan@canada.ca>
Cc: Safronetz, David (PHAC/ASPC) <david.safronetz@canada.ca>; Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; Strong, Jim (PHAC/ASPC) <jim.strong@canada.ca>; Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Robertson, Catherine (PHAC/ASPC) <catherine.robertson@canada.ca>
Subject: Paperwork for Special Pathogens pathogen transfers to China

Thanks Allan, I have cc'd Qiu and Jim as well. To what agency or institution are the Ebola, etc. cultures / materials going to ?

Have also informed Matt and Steve so they are in the loop.

Thanks again,

Michael

Mike Drebot, PhD, ARMCCM
 Director, Zoonotic Diseases and Special Pathogens
 National Microbiology Laboratory, Public Health Agency of Canada
 1015 Arlington Street
 Winnipeg, Manitoba R3E 3R2

Associate Professor
 Department of Medical Microbiology
 University of Manitoba

E-Mail: Mike.Drebot@canada.ca
 Phone: (204) 789-6059
 Fax: (204) 789-2082

From: Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>
Sent: 2019-03-18 11:56 AM

To: Krishnan, Jay (PHAC/ASPC) <jay.krishnan@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>
Cc: Safronetz, David (PHAC/ASPC) <david.safronetz@canada.ca>; Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>
Subject: RE: Paperwork for path transfers to China

Hi all,

Anders came to see me and I did not realize that this process was started back in October of last year while I was [REDACTED]. We do have all the proper documentation from China and the Transfer Authorization (NML-TA-18-0480) was issued on Oct. 29, 2018.

As a note, the expiry date of the Transfer Authorization is 2019-08-10, which coincides with the expiry date of our RG4 license. If the shipment is not completed by that date, a new Transfer Authorization will need to be issued with the new RG4 license number and expiry date before the samples are transferred.

Allan

From: Krishnan, Jay (PHAC/ASPC) <jay.krishnan@canada.ca>
Sent: 2019-03-18 11:41 AM
To: Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>
Cc: Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; Safronetz, David (PHAC/ASPC) <david.safronetz@canada.ca>; Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>
Subject: Paperwork for path transfers to China

Hi Mike,

Allan has not received any paperwork yet for the transfer to China; there is a paperwork he initiated this morning to temporarily store viral cultures in NCFAD CL4. He and Anders will make sure no cultures leave the building without all the paperwork and your final sign off as usual, thanks

-Jay

From: [Leung, Anders \(PHAC/ASPC\)](#)
To: [OC NML-Dir-LNM CO, PHAC-ASPC \(PHAC/ASPC\)](#)
Cc: [Fernando, Lisa \(PHAC/ASPC\)](#); [Drebot, Mike \(PHAC/ASPC\)](#); [Qiu, Xiangguo \(PHAC/ASPC\)](#); [NML Specimen Receiving \(PHAC/ASPC\)](#); [Pushka, Mike \(PHAC/ASPC\)](#); [Letkeman, Paul \(PHAC/ASPC\)](#); [Ashley, Don \(PHAC/ASPC\)](#); [Gilmour, Matthew \(PHAC/ASPC\)](#); [Guercio, Steven \(PHAC/ASPC\)](#); [Lau, Allan \(PHAC/ASPC\)](#)
Subject: CL-4 Shipment to China Thursday/Friday
Date: 2019-03-26 5:38:31 PM

Hi,

I just wanted to give the EOC an heads up that we are potentially sending out a RG4 shipment to China on Thursday or Friday this week. Once details are confirmed with [REDACTED] I will let you know.

Thanks!

Anders Leung

National Microbiology Laboratory | Laboratoire national de microbiologie

Public Health Agency of Canada | Agence de la santé publique du Canada

Canadian Science Centre for Human and Animal Health | Centre scientifique canadien de la santé humaine et animale

Winnipeg, Canada R3E 3R2

anders.leung@canada.ca

Telephone | Téléphone 204-789-7665 / Facsimile | Télécopieur 204-789-2140

Government of Canada | Gouvernement du Canada

From: [Qiu, Xiangguo \(PHAC/ASPC\)](#)
To: [Lau, Allan \(PHAC/ASPC\)](#); [Jay Krishnan](#)
Subject: RE: China shipment
Date: 2019-03-26 11:34:27 AM

That's right.
Thanks!

Qiu

From: Lau, Allan (PHAC/ASPC)
Sent: 2019-03-26 11:33 AM
To: Qiu, Xiangguo (PHAC/ASPC); Jay Krishnan
Subject: RE: China shipment

Hi Qiu,

Are you sending two vials of each of these?

Allan

From: Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>
Sent: 2019-03-26 11:15 AM
To: Jay Krishnan <[REDACTED]>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>
Subject: FW: China shipment

Fyi...

From: Leung, Anders (PHAC/ASPC)
Sent: 2019-03-26 10:12 AM
To: Qiu, Xiangguo (PHAC/ASPC)
Cc: He, Shihua (PHAC/ASPC)
Subject: RE: China shipment

Hi Shihua,

Can you please send me the locations of the mouse and guinea pig adapted viruses from this list? So I can collect the viruses today.

Thanks!
Anders

From: Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>
Sent: 2019-03-26 9:53 AM
To: Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>
Subject: China shipment
Importance: High

Hi Anders,

Pls find me when you are done your meeting with Mike to dis cuss the potential shipment to China by Friday.

Thanks!

Qiu

Commercial Invoice								
Date of Export: March 28 2019				Export References (i.e. order no., invoice no., etc):				
Shipper/Exporter (complete name and address): Dr. Xiangguo Qiu (+1-204-784-7548) Public Health Agency of Canada - NML 1015 Arlington Street Winnipeg, Manitoba, Canada R3E 3R2				Recipient (complete name and address): Chinese Academy of Sciences - Wuhan Institute of Virology Xiao Hong Shan No.44 Wuhan, Hubei, China, 430071				
Country of export: Canada				Importer - if other than recipient (complete name and address):				
Country of manufacture: Canada								
Country of ultimate destination: China								
International Air Waybill Number: [REDACTED]				Currency: CAD				
Marks/Nos	No. of pkgs	Type of packaging	Full Description of goods	Qty	Units of measure	Weight	Unit value	Total Value
	1	2 ml cryovial containing 0.5ml	Infectious substance, affecting humans (Ebola virus)	24	vials	0.5 kg	\$2.50	\$60.00
		2 ml cryovial containing 0.5ml	Infectious substance, affecting humans (henipah virus)	6	vials	0.5 kg	\$2.50	\$15.00
		Overpack	Dry Ice	1	kg	15 kg	\$0.00	\$0.00
Total No. of Pkgs		1		Total Weight		16 kg		Total Invoice Value
								\$75.00

I declare all the information contained in this invoice to be true and correct		Check One	
Signature of shipper/exporter (type name and title and sign) Dr. Xiangguo Qiu Research Scientist, Special Pathogens		Date: 27/Mar/2019	FOB
			C&F
			CIF

Fleury, Teresa (PHAC/ASPC)

From: Audette, Luc (PHAC/ASPC)
Sent: 2019-03-27 2:32 PM
To: OCNML DIR / LNMCO (PHAC/ASPC)
Cc: Gordon, Kristina (PHAC/ASPC); OCNML Doc / LNMCO (PHAC/ASPC)
Subject: ERAP 2019-02, ERAP Notification - Pending Shipment

Hi Heidi, you can prefix your ERAP e-mails for this shipment with ERAP 2019-02. I will need the tracking#, who is sending it out, the consignee information and what they are shipping out. If you end up getting any documentation for this shipment, you can drop it off at my desk and I will scan it into the folder as well. No rush, thanks.

Luc

From: OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>
Sent: 2019-03-27 1:31 PM
To: Semanowich, Gene (PHAC/ASPC) <gene.semanowich@canada.ca>; Fleury, Teresa (PHAC/ASPC) <teresa.fleury@canada.ca>; Audette, Luc (PHAC/ASPC) <luc.audette@canada.ca>; Gordon, Kristina (PHAC/ASPC) <kristina.gordon@canada.ca>; Zozman, Grant (PHAC/ASPC) <grant.zozman@canada.ca>
Subject: FW: ERAP Notification - Pending Shipment

From: Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)
Sent: Wednesday, March 27, 2019 2:30:34 PM (UTC-05:00) Eastern Time (US & Canada)
To: Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); [REDACTED]@gov.mb.ca; PHAC.F OC_NML_OCD_Group F.ASPC; NML Specimen Receiving (PHAC/ASPC)
Cc: HPOC-COPS, PHAC-ASPC (PHAC/ASPC)
Subject: ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28th. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch
 Canadian Science Centre for Human and Animal Health
 Public Health Agency of Canada - Government of Canada
 Telephone (866)262-8433
 ****new e-mail PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA *****

Directeur du centre des opérations
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses
 Centre scientifique canadien de la santé humaine et animale
 Agence de la santé publique du Canada
 Téléphone (866)262-8433
 **** nouveau courriel PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA *****

1015 Arlington Street, Emergency Operations Centre
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Government
of Canada

Gouvernement
du Canada

Canada



SHIPPER'S DECLARATION FOR DANGEROUS GOODS

Shipper Dr. Xiangguo Qiu (204-784-7548) Public Health Agency of Canada - NML 1015 Arlington St. Winnipeg, Manitoba, Canada, R3E 3R2				Air Waybill No. [REDACTED] Page 1 of 1 Pages Shipper's Reference No. (optional)		
Consignee [REDACTED] Chinese Academy of Sciences - Wuhan Institute of Virology Xiao Hong Shan No.44 Wuhan, Hubei, China, 430071						
<i>Two completed and signed copies of this Declaration must be handed to the operator</i>				WARNING Failure to comply in all respects with the applicable Dangerous Goods Regulations may be in breach of the applicable law, subject to legal penalties.		
TRANSPORT DETAILS This shipment is within the limitations prescribed for (delete non-applicable)						
Airport of Departure (optional):		Airport of Destination (optional):		Shipment type: (delete non-applicable)		
<input type="checkbox"/> PASSENGER AND CARGO AIRCRAFT		<input checked="" type="checkbox"/> HAZARDOUS ONLY		<input type="checkbox"/> NON-RADIOACTIVE <input checked="" type="checkbox"/> RADIOACTIVE		
NATURE AND QUANTITY OF DANGEROUS GOODS						
Dangerous Goods Identification						
UN or ID No.	Proper Shipping Name	Class or Division (subsidiary hazard)	Packing Group	Quantity and Type of Packing	Packing Inst.	Authorization
UN 2814	Infectious substance, affecting humans (Ebola virus, Henipah virus)	6.2		30 vials x 0.5 ml	620	
UN1845	Dry Ice	9		15 kg Overpack Used	954	
Additional Handling Information 1-888-CAN-UTEC (226-8832), 613-996-6666 24HR EMERGENCY CONTACT PHAC NML EOC Director: 1-866-262-8433 PERSON RESPONSIBLE						
I hereby declare that the contents of this consignment are fully and accurately described above by the proper shipping name, and are classified, packaged, marked and labelled/placarded, and are in all respects in proper condition for transport according to applicable international and national governmental regulations. I declare that all of the applicable air transport requirements have been met.				Name of Signatory <i>Xiangguo Qiu</i> Date <i>Mar 27/2019</i> Signature (See warning above)		

From: [Guercio, Steven \(PHAC/ASPC\)](#)
To: [Gilmour, Matthew \(PHAC/ASPC\)](#)
Subject: Re: ERAP Notification - Pending Shipment
Date: 2019-03-27 7:31:57 PM

Ok. I had looked at this before and saw the paperwork. It all appeared to check out.

Sent from my Bell Samsung device over Canada's largest network.

----- Original message -----

From: "Gilmour, Matthew (PHAC/ASPC)" <matthew.gilmour@canada.ca>
Date: 2019-03-27 5:20 PM (GMT-06:00)
To: "Guercio, Steven (PHAC/ASPC)" <steven.guercio@canada.ca>
Subject: Fwd: ERAP Notification - Pending Shipment

Hi Steve

I'd like you to be comfortable with this before it goes.

Matt

(via mobile)

Begin forwarded message:

From: "OCNML DIR / LNMCO (PHAC/ASPC)" <PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA>
Date: March 27, 2019 at 1:30:34 PM CDT
To: "Gilmour, Matthew (PHAC/ASPC)" <matthew.gilmour@canada.ca>, "Guercio, Steven (PHAC/ASPC)" <steven.guercio@canada.ca>, "Drebot, Mike (PHAC/ASPC)" <mike.drebot@canada.ca>, NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.asp.aspc@canada.ca>, "CSCHAH SES (PHAC/ASPC)" <phac.cschah.ses.aspc@canada.ca>, "OCNML Logistics / Logistique LNMCO (PHAC/ASPC)" <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>, "OCNML Support / Soutien LNMCO (PHAC/ASPC)" <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>, [REDACTED]@gov.mb.ca" <[REDACTED]@gov.mb.ca>, PHAC.F OC_NML_OCD_Group F.ASPC <OC_NML_OCD_Group@canada.ca>, "NML Specimen Receiving (PHAC/ASPC)" <phac.nml.specimen.receiving.aspc@canada.ca>
Cc: "HPOC-COPS, PHAC-ASPC (PHAC/ASPC)" <phac-aspc.hpoc-cops@canada.ca>
Subject: ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg

th

on Thursday, March 28 . The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch
Canadian Science Centre for Human and Animal Health
Public Health Agency of Canada - Government of Canada
Telephone (866)262-8433

****new e-mail PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

Directeur du centre des opérations
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses
Centre scientifique canadien de la santé humaine et animale
Agence de la santé publique du Canada
Téléphone (866)262-8433

**** nouveau courriel PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA ****

1015 Arlington Street, Emergency Operations Centre
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.

<image001.png>

From: [Hartigan, Maureen \(PHAC/ASPC\)](#)
To: [Guercio, Steven \(PHAC/ASPC\)](#); [Gilmour, Matthew \(PHAC/ASPC\)](#)
Subject: FW: Urgent - clarification please
Date: 2019-03-28 7:47:29 AM

Hi Folks,

Any additional information you can share?

I have told them that shipping samples for research purposes is not uncommon and part of regular NML business. I suspect they will still want more information...

Maureen

~~~~~  
Maureen Hartigan  
Senior Policy Advisor / Conseillère principale en politiques  
Infectious Disease Prevention and Control Branch | Direction générale de la prévention et du contrôle des maladies infectieuses  
Public Health Agency of Canada | Agence de la santé publique du Canada  
Tel.: (613) 797-5082

---

**From:** Lefebvre, Christine (PHAC/ASPC) <christine.lefebvre@canada.ca>  
**Sent:** 2019-03-28 8:39 AM  
**To:** Hartigan, Maureen (PHAC/ASPC) <maureen.hartigan@canada.ca>  
**Subject:** Urgent - clarification please

Hi Maureen,

Good morning. CEPR has our daily issues meeting at 8:45, and we have the following in our daily report – can you please confirm what RG4 sample is being shipped, why it's being shipped to China, etc.

Thank you!

**ERAP Notification - Pending Shipment**

- A Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China.
- Routing information is still pending for this shipment and will be provided when available.

Thank you,

-----  
Christine Lefebvre-Johnston, MSc.

Senior Advisor, CENTRE FOR EMERGENCY PREPAREDNESS AND RESPONSE  
HEALTH SECURITY INFRASTRUCTURE BRANCH | Public Health Agency of Canada | Government of  
Canada

Conseillère principale, CENTRE DE MESURES ET INTERVENTIONS D'URGENCE  
DIRECTION GÉNÉRALE DE L'INFRASTRUCTURE DE SÉCURITÉ SANITAIRE | Agence de la santé publique  
du Canada | Gouvernement du Canada  
[Christine.lefebvre@canada.ca](mailto:Christine.lefebvre@canada.ca) | Tel: 613-407-4300

**Drebot, Mike (PHAC/ASPC)**

---

**From:** Drebot, Mike (PHAC/ASPC)  
**Sent:** 2019-03-28 8:15 AM  
**To:** Drebot, Mike (PHAC/ASPC)  
**Subject:** FW: Shipping Req. for China Shipment Anders March 27 documents

See [L Drive Anders Folder](#) for several March 27 docs

**From:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>  
**Sent:** 2019-03-27 12:19 PM  
**To:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Letkeman, Paul (PHAC/ASPC) <paul.letkeman@canada.ca>; Pushka, Mike (PHAC/ASPC) <mike.pushka@canada.ca>; Ashley, Don (PHAC/ASPC) <don.ashley@canada.ca>  
**Cc:** Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>  
**Subject:** Shipping Req. for China Shipment

Hi Mike/Paul/Don,

Please see attached shipping requisition, sorry for filling everyone's mailbox with these files again.

Thanks!

Anders Leung  
National Microbiology Laboratory | Laboratoire national de microbiologie  
Public Health Agency of Canada | Agence de la santé publique du Canada  
Canadian Science Centre for Human and Animal Health | Centre scientifique canadien de la santé humaine et animale  
Winnipeg, Canada R3E 3R2  
[anders.leung@canada.ca](mailto:anders.leung@canada.ca)  
Telephone | Téléphone 204-789-7665 / Facsimile | Télécopieur 204-789-2140  
Government of Canada | Gouvernement du Canada

**Drebot, Mike (PHAC/ASPC)**

---

**From:** Drebot, Mike (PHAC/ASPC)  
**Sent:** 2019-03-28 8:11 AM  
**To:** Drebot, Mike (PHAC/ASPC)  
**Subject:** Anders March 27 [REDACTED] - packaging required

See L drive Anders folder for 2 docs Shippers Declaration 2 and Commercial Invoice.xls

**From:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>  
**Sent:** 2019-03-27 12:00 PM  
**To:** [REDACTED]; Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached customs invoice and revised shippers declaration. The shipment will be ready for pickup tomorrow morning at 10:00, again can you please provide us with the route info so we can activate the ERAP teams.

Thanks!  
 Anders

**From:** [REDACTED]  
**Sent:** 2019-03-27 10:59 AM  
**To:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED]; Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo



Please provide a customs invoice with the following information (if applicable):

Shipper: (company name, address, contact person, tel)  
 Consignee: (company name, address, contact person, tel)  
 Incoterms: EXW  
 Cargo description: (please confirm with Shipper for below)  
 Ebola virus// 24vial(500ul/vial)// unit price:  
 Nipah virus//6vial(500ul/vial)// unit price:  
 Total value:  
 Package in dry ice:

Please send us the invoice at your earliest convenience.

If you have any questions please feel free to contact our office.

Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

---

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 27 March 2019 12:03 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** Re: [REDACTED] - packaging required

Hi [REDACTED]

Can you please send me the flight route for the package so we can activate the provincial ERAP teams?

Thanks!  
Anders

Sent from my BlackBerry 10 smartphone on the Bell network.

---

**From:** [REDACTED]  
**Sent:** Tuesday, March 26, 2019 7:58 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hello Andres,

Well received.

Thank you

[REDACTED]

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

---

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 March 2019 18:44  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached documents (signed copy will accompany the shipment), please let me know if I am missing any documents. Again please let us know if Thursday or Friday will work for sample pickup.

Thanks!  
Anders

**From:** Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>  
**Sent:** 2019-03-26 1:01 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hi Anders,

Pls can you send what paper work required for us to [REDACTED] ?

Thanks!

Qiu

---

**From:** Leung, Anders (PHAC/ASPC)  
**Sent:** 2019-03-26 11:46 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

If we can schedule this for Thursday or Friday morning that would be great.

Thanks!

**From:** [REDACTED]  
**Sent:** 2019-03-26 10:56 AM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please advise when shipment will be ready for pick up as requested by our [REDACTED] office they would like this to arrive before April 1<sup>st</sup>. Please forward all paperwork at your earliest convenience in order for us to get the ok to send.

Regards,

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

---

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 27 February 2019 6:34 PM  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

I think that the best contact would be the company that produces the packaging Saf-T-Pak Inc., they should be able to provide you some standards testing/certificates.

<http://www.saftpak.com/StpPack/ProductDetail.aspx?ID=3>

Anders

**From:** Qiu, Xiangguo (PHAC/ASPC)  
**Sent:** 2019-02-27 5:28 PM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

My colleague Anders will assist the shipping and he is confused about the request from your side. He will try to help with your request but may need your clarification.

Best regards,

Qiu

---

**From:** [REDACTED]  
**Sent:** 2019-02-27 5:15 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hello,

Client has requested you provide certificate approval since inner DG package provide by you, template now attached.

Best Regards,

[REDACTED]



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 February 2019 11:53  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

That is correct, it should be PI620. How in-depth would you like for the pick up process I don't really think we can make a video, maybe pictures?

Thanks!  
Anders

**From:** [REDACTED]  
**Sent:** 2019-02-20 7:22 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Andre,

Client is asking the PI should be 620 instead of 650, please advise if this ok, They are also requesting to take picture or video of whole pick-up process.

Regards





Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

---

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 05 February 2019 16:51  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

The package will be sent via UN2814 (P650 packaging) and the shipping description and pictures are in the link. The package will be overpacked in dry ice (PI 954) probably around 10-15 kgs depending on where the sample is going to and how long transit will be so I would guess around 20 kgs. The dimensions should be 15 3/8 x 13 5/8 x 12 3/4".

<https://www.tc.gc.ca/eng/tdg/page-1296.html>

<https://www.saftpak.com/STPPack/ProductDetail.aspx?ID=11>

Thanks!  
Anders

---

**From:** Qiu, Xiangguo (PHAC/ASPC)  
**Sent:** 2019-02-01 10:39 AM  
**To:** [REDACTED]  
**Cc:** Leung, Anders (PHAC/ASPC); NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

The shipment will contain RG4 agents (Ebola and Nipha viruses).

I cc'd my colleagues Anders and people from our shipping and receiving and they can answer your questions properly.

Best,

Qiu


---

**From:** [REDACTED]  
**Sent:** 2019-01-31 10:39 AM  
**To:** Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hi Qiu,

See below

|                                     |                                       |
|-------------------------------------|---------------------------------------|
| National Microbiology Laborato      | CONSG: Wuhan Institute of Virology, C |
| FROM : Xiangguo Qiu, M.D [REDACTED] |                                       |
| : Public Health Agency of Canada    | : Chinese Academy of Sciences         |
| : 1015 Arlington Street H2410       | : Xiao Hong Shan 44, Wuhan            |
| (YWG): WINNIPEG MB CAN              | (WUH): WUHAN CHN                      |



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

---

**From:** Qiu, Xiangguo (PHAC/ASPC) [<mailto:xiangguo.qiu@canada.ca>]  
**Sent:** January 31, 2019 11:37 AM  
**To:** [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hi There,

Which Shipment we are talking about here? Pls can you specify?

Best regards,

Xiangguo Qiu, M.D  
Research Scientist  
Head, Vaccine Development & Antiviral Therapy  
Special Pathogens Program  
National Microbiology Laboratory  
Public Health Agency of Canada  
1015 Arlington Street H2410  
Winnipeg, MB R3E 3R2

Adjunct Professor  
Dept. of Medical Microbiology  
University of Manitoba

email: [xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)

---

**From:** [REDACTED]  
**Sent:** 2019-01-31 10:25 AM  
**To:** Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** [REDACTED]  
**Subject:** [REDACTED] - packaging required

Hi there,

Can you please confirm if you require UN2814 packaging for your shipment. Also if you are providing packaging can you provide the below.

1. Pictures of the UN2814 packaging
2. dimensions
3. weight of product

Thanks,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**Fleury, Teresa (PHAC/ASPC)**

---

**From:** Audette, Luc (PHAC/ASPC)  
**Sent:** 2019-03-28 7:05 AM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Subject:** RE: ERAP 2019-02 Shipping Req. for China Shipment

Thanks Heidi.

**From:** Wood, Heidi (PHAC/ASPC) <[heidi.wood@canada.ca](mailto:heidi.wood@canada.ca)> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-27 2:47 PM  
**To:** Audette, Luc (PHAC/ASPC) <[luc.audette@canada.ca](mailto:luc.audette@canada.ca)>  
**Subject:** FW: ERAP 2019-02 Shipping Req. for China Shipment

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-27 2:37 PM  
**To:** OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>  
**Cc:** OCNML Doc / LNMCO (PHAC/ASPC) <[phac.ocnml.doc.lnmco.aspc@canada.ca](mailto:phac.ocnml.doc.lnmco.aspc@canada.ca)>  
**Subject:** ERAP 2019-02 Shipping Req. for China Shipment

Hi Luc,

This is what Anders has sent so far – I think this has everything you're looking for.

Thanks,  
 Heidi

**From:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>  
**Sent:** 2019-03-27 12:19 PM  
**To:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Letkeman, Paul (PHAC/ASPC) <[paul.letkeman@canada.ca](mailto:paul.letkeman@canada.ca)>; Pushka, Mike (PHAC/ASPC) <[mike.pushka@canada.ca](mailto:mike.pushka@canada.ca)>; Ashley, Don (PHAC/ASPC) <[don.ashley@canada.ca](mailto:don.ashley@canada.ca)>  
**Cc:** Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>  
**Subject:** Shipping Req. for China Shipment

Hi Mike/Paul/Don,

Please see attached shipping requisition, sorry for filling everyone's mailbox with these files again.

Thanks!

Anders Leung  
 National Microbiology Laboratory | Laboratoire national de microbiologie  
 Public Health Agency of Canada | Agence de la santé publique du Canada  
 Canadian Science Centre for Human and Animal Health | Centre scientifique canadien de la santé humaine et animale

Winnipeg, Canada R3E 3R2

[anders.leung@canada.ca](mailto:anders.leung@canada.ca)

Telephone | Téléphone 204-789-7665 / Facsimile | Télécopieur 204-789-2140

Government of Canada | Gouvernement du Canada

**Fleury, Teresa (PHAC/ASPC)**

---

**From:** [REDACTED]  
**Sent:** 2019-03-28 9:13 AM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) [REDACTED]  
**Subject:** 回复:[REDACTED] - packaging required

Dear [REDACTED]  
 Thank you for your information.

We hope that the shipment can be started on Thursday morning as planned, because all relevant departments and personnel in China have been prepared for the shipment on Thursday, and it is better not to change the time.

In addition, taking photos or video is not a necessary requirement. We have discussed this matter with Anders before, and everything will be executed according to the regulations of PHAC.

Most importantly, we hope to know the flight routing and time information as soon as possible, thank you!

Please cc all the following email to [REDACTED] who is the general coordinator in charge of the transportation in China. Thank you very much!

Best wishes,  
 [REDACTED]

Wuhan Institute of Virology, CAS

----- 原始邮件 -----

主题：RE: [REDACTED] - packaging required

发件人：[REDACTED]

收件人：[REDACTED], "Leung, Anders (PHAC/ASPC)" , "Qiu, Xiangguo (PHAC/ASPC)" [REDACTED]


抄送： "NML Specimen Receiving (PHAC/ASPC)" , "Drebot, Mike (PHAC/ASPC)" , "Fernando, Lisa (PHAC/ASPC)" , "OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)" "

Good morning,

We have received the ok to send for this shipment. Please confirm if we can pickup the shipment on Friday morning? We would have to send the dry ice data logger to our agent today so they can have it in place for tomorrow.

Also, our China office has asked that you take pictures/video during the packing of the shipment. Is this possible?

Please confirm.



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [REDACTED]  
**Sent:** 27 March 2019 17:32  
**To:** 'Leung, Anders (PHAC/ASPC)'; [REDACTED] 'Qiu, Xiangguo (PHAC/ASPC)'; [REDACTED]  
**Cc:** 'NML Specimen Receiving (PHAC/ASPC)'; 'Drebot, Mike (PHAC/ASPC)'; 'Fernando, Lisa (PHAC/ASPC)'; 'OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)'  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders

Thank you for the paperwork. Once the paperwork has been approved we will contact you to confirm a pick up date and time. We will also advise the routing.

Regards,



**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 27 March 2019 1:00 PM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached customs invoice and revised shippers declaration. The shipment will be ready for pickup tomorrow morning at 10:00, again can you please provide us with the route info so we can activate the ERAP teams.

Thanks!  
Anders

**From:** [REDACTED]  
**Sent:** 2019-03-27 10:59 AM  
**To:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drobot, Mike (PHAC/ASPC) <mike.drobot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please provide a customs invoice with the following information (if applicable):

- Shipper: (company name, address, contact person, tel)
- Consignee: (company name, address, contact person, tel)
- Incoterms: EXW
- Cargo description: (please confirm with Shipper for below)
- Ebola virus// 24vial(500ul/vial)// unit price:
- Nipah virus//6vial(500ul/vial)// unit price:
- Total value:
- Package in dry ice:

Please send us the invoice at your earliest convenience.

If you have any questions please feel free to contact our office.

Regards,

[REDACTED]

[REDACTED]



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:[anders.leung@canada.ca](mailto:anders.leung@canada.ca)]  
**Sent:** 27 March 2019 12:03 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** Re: [REDACTED] - packaging required

Hi [REDACTED]

Can you please send me the flight route for the package so we can activate the provincial ERAP teams?

Thanks!  
Anders

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** [REDACTED]  
**Sent:** Tuesday, March 26, 2019 7:58 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hello Andres,

Well received.

Thank you  
[REDACTED]



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 March 2019 18:44  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached documents (signed copy will accompany the shipment), please let me know if I am missing any documents. Again please let us know if Thursday or Friday will work for sample pickup.

Thanks!  
 Anders

**From:** Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>  
**Sent:** 2019-03-26 1:01 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hi Anders,

Pls can you send what paper work required for us to [REDACTED]?

Thanks!

Qiu

**From:** Leung, Anders (PHAC/ASPC)  
**Sent:** 2019-03-26 11:46 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

If we can schedule this for Thursday or Friday morning that would be great.

Thanks!

**From:** [REDACTED]  
**Sent:** 2019-03-26 10:56 AM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]


Cc: NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

Subject: RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please advise when shipment will be ready for pick up as requested by our [REDACTED] office they would like this to arrive before April 1<sup>st</sup>. Please forward all paperwork at your earliest convenience in order for us to get the ok to send.

Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]

**Sent:** 27 February 2019 6:34 PM

**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC)

**Subject:** RE: [REDACTED] - packaging required

Hi,

I think that the best contact would be the company that produces the packaging Saf-T-Pak Inc., they should be able to provide you some standards testing/certificates.

<http://www.saftpak.com/StpPack/ProductDetail.aspx?ID=3>

Anders

**From:** Qiu, Xiangguo (PHAC/ASPC)

**Sent:** 2019-02-27 5:28 PM

**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)> [REDACTED]

[Redacted]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Subject:** RE: [Redacted] - packaging required

Hi [Redacted]

My colleague Anders will assist the shipping and he is confused about the request from your side. He will try to help with your request but may need your clarification.

Best regards,

Qiu

**From:** [Redacted]

**Sent:** 2019-02-27 5:15 PM

**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)

**Cc:** NML Specimen Receiving (PHAC/ASPC); [Redacted]

**Subject:** RE: [Redacted] - packaging required

Hello,

Client has requested you provide certificate approval since inner DG package provide by you, template now attached.

Best Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]

**Sent:** 26 February 2019 11:53

**To:** [Redacted]; Qiu, Xiangguo (PHAC/ASPC)

**Cc:** NML Specimen Receiving (PHAC/ASPC)

**Subject:** RE: [Redacted] - packaging required

Hi,

That is correct, it should be PI620. How in-depth would you like for the pick up process I don't really think we can make a video, maybe pictures?

Thanks!  
Anders

**From:** [REDACTED]  
**Sent:** 2019-02-20 7:22 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Andre,

Client is asking the PI should be 620 instead of 650, please advise if this ok, They are also requesting to take picture or video of whole pick-up process.

Regards

[REDACTED]

[REDACTED]

**Fleury, Teresa (PHAC/ASPC)**

---

**From:** Lau, Allan (PHAC/ASPC)  
**Sent:** 2019-03-28 9:39 AM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Subject:** RE: ERAP Notification 2019-02 - Pending Shipment

Hey Heidi,

I know it's a new process so in case the package is going through Toronto airport, don't forget to add their hazmat team to the notifications. [REDACTED] said he set up a group email so it should be easy to add them.

Allan

**From:** Wood, Heidi (PHAC/ASPC) <heidi.wood@canada.ca> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-28 9:34 AM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC) <PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA>; Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.asp.aspc@canada.ca>; CSCHAH SES (PHAC/ASPC) <phac.cschah.ses.aspc@canada.ca>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca>; PHAC.F OC\_NML\_OCD\_Group F.ASPC <OC\_NML\_OCD\_Group@canada.ca>; NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>  
**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>  
**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood


Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433  
 \*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433  
 \*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.aspc@canada.ca](mailto:phac.nml.sp-lnm.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca; oc\_nml\_ocd\_group@phac-aspc.gc.ca; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**Fleury, Teresa (PHAC/ASPC)**

---

**From:** Lau, Allan (PHAC/ASPC)  
**Sent:** 2019-03-28 9:42 AM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Subject:** RE: ERAP Notification 2019-02 - Pending Shipment

Fingers crossed!

**From:** Wood, Heidi (PHAC/ASPC) <heidi.wood@canada.ca> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-28 9:42 AM  
**To:** Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>  
**Subject:** RE: ERAP Notification 2019-02 - Pending Shipment

I'm just really hoping that this goes through Vancouver....

**From:** Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>  
**Sent:** 2019-03-28 9:39 AM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC) <PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA>  
**Subject:** RE: ERAP Notification 2019-02 - Pending Shipment

Hey Heidi,

I know it's a new process so in case the package is going through Toronto airport, don't forget to add their hazmat team to the notifications. [REDACTED] said he set up a group email so it should be easy to add them.

Allan

**From:** Wood, Heidi (PHAC/ASPC) <heidi.wood@canada.ca> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-28 9:34 AM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC) <PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA>; Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.asp.aspc@canada.ca>; CSCHAH SES (PHAC/ASPC) <phac.cschah.ses.aspc@canada.ca>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca>; PHAC.F OC\_NML\_OCD\_Group F.ASPC <OC\_NML\_OCD\_Group@canada.ca>; NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>  
**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>  
**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health


Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433  
 \*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433  
 \*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca; oc\_nml\_ocd\_group@phac-aspc.gc.ca; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood


Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433  
 \*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433  
 \*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

**IMPORTANT:** This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

**IMPORTANT :** Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



**From:** [Leung, Anders \(PHAC/ASPC\)](#)  
**To:** [Lau, Allan \(PHAC/ASPC\)](#); [Gharib, Marie \(CFIA/ACIA\)](#); [Laverdiere, Amanda \(CFIA/ACIA\)](#)  
**Cc:** [Drebot, Mike \(PHAC/ASPC\)](#); [Fernando, Lisa \(PHAC/ASPC\)](#)  
**Subject:** RE: Import permit numbers?  
**Date:** 2019-03-28 10:21:58 AM

---

Hi Marie,

Thanks for getting back to us. Here are the answers to the questions;

1. Not sure where the A-2001-00241-4 permit came from but if its for RG2/3 agents then please keep it off the letter
2. A-2008-00395-4 is the Uganda strain and the new name is Bundibugyo. Sorry for the confusion.
3. Mayinga - A-1999-00979-4, Makona/Guinea - A-2014-01842-4, Kikwit - A-1999-00979-4, MA-EBOV - A-2000-01262-4, GP-Sudan was generated in house so the parental virus import should be A-2000-01262-4, Nipah Malaysia - A-2000-01951-4 and Nipah Bangladesh was generated from reverse genetics.

Since there seems to be changes to names of viruses over the past 20 years and just to get ensure that my records match the official import permits issued by CFIA would it be possible to get a copy of all the CFIA import permits issued to the PHAC CL-4 program as well? I think this should also expedite future requests.

Thanks!  
Anders

---

**From:** Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>  
**Sent:** 2019-03-27 11:27 AM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>  
**Subject:** Import permit numbers?

FYI

---

**From:** Gharib, Marie (CFIA/ACIA) <[marie.gharib@canada.ca](mailto:marie.gharib@canada.ca)>  
**Sent:** 2019-03-27 11:10 AM  
**To:** Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>  
**Cc:** Safronetz, David (PHAC/ASPC) <[david.safronetz@canada.ca](mailto:david.safronetz@canada.ca)>; Laverdiere, Amanda (CFIA/ACIA) <[amanda.laverdiere@canada.ca](mailto:amanda.laverdiere@canada.ca)>  
**Subject:** RE: New OBCS permit manager

Hi Allan,

After reviewing the transfer request form and all of the original permits, a few clarifications are required in order to proceed with the completion of your transfer request.

1. A-2001-00241-4 – This permit is for RG3 and RG2 pathogens. (Mopeia virus, Mobala virus, Oliveros virus and Lymphocytic choriomeningitis virus [Lab-Adapted Armstrong and We strains])  
Would you like to include these products on the transfer letter?
2. A-2008-00395-4 – We'd like to confirm that the "Ebola Uganda Strain" as listed on the original permit is the "Bundbugyo" strain that is outlined in the description of the transfer request form.
3. The following are not listed in any of the original permit numbers that were indicated on the transfer request form:  
Ebola strains: Mayinga, Makona, Kikwit, Bundibugyo, MA-EBOV, guinea pig adapted EBOV, GP-adapted Sudan  
Henipavirus strains: Malaysia/Bangladesh  
  
Were these strains imported? If so, please provide the original permit numbers of the permits used to import them.

Once we receive the missing information, we will proceed to process your request.

Thank you,  
Marie

---

**From:** Lau, Allan (PHAC/ASPC)  
**Sent:** 2019-03-27 9:01 AM  
**To:** Gharib, Marie (CFIA/ACIA)  
**Subject:** RE: New OBCS permit manager

Thanks, Marie! ☺

---

**From:** Gharib, Marie (CFIA/ACIA) <[marie.gharib@canada.ca](mailto:marie.gharib@canada.ca)>  
**Sent:** 2019-03-27 6:29 AM  
**To:** Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>  
**Subject:** RE: New OBCS permit manager

Good morning Allan,

We are currently working on your transfer request (assorted strains of Ebola viruses, etc.) and hope to get it out to you before this Friday.

If you have any further questions, do not hesitate to contact me.

Marie

---

**From:** Lau, Allan (PHAC/ASPC)  
**Sent:** 2019-03-26 2:06 PM

**To:** Gharib, Marie (CFIA/ACIA)  
**Subject:** RE: New OBCS permit manager

Hi Marie,

Just so you don't have to scroll all the way down the email chain, our Special Pathogens unit is planning on sending RG4 samples to China in the summer. However, by the time China's lab is able [REDACTED] we won't be able to access the samples due to a shutdown of our CL4 lab. [REDACTED] Therefore, our plan is to transfer these samples over to NCFAD for temporary storage until we can ship. Our CL4 manager, Anders Leung, filed the application last Monday, so I was following up in the hopes we could have the Transfer Permit before we shutdown at the end of this week. We're much appreciative of any assistance you could offer with this.

Regards,  
Allan

**Allan Lau**

Biorisk Officer | Agent de biorisque  
Safety and Environmental Services | Services de sécurité et Services environnementaux  
National Microbiology Laboratory at the | Laboratoire national de microbiologie au  
Canadian Science Centre for Human and Animal Health | Centre scientifique canadien de la santé humaine et animale  
Public Health Agency of Canada | Agence de la santé publique du Canada  
1015 Arlington Street, Winnipeg, MB, Canada, R3E 3P6  
**NEW:** [Allan.Lau@canada.ca](mailto:Allan.Lau@canada.ca)  
Telephone | Téléphone 204-784-5986 / Facsimile | Télécopieur 204-789-2069  
Government of Canada | Gouvernement du Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

---

**From:** Falardeau, Émilie (PHAC/ASPC) <[emilie.falardeau@canada.ca](mailto:emilie.falardeau@canada.ca)>  
**Sent:** 2019-03-26 12:05 PM  
**To:** Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>  
**Cc:** Gharib, Marie (CFIA/ACIA) <[marie.gharib@canada.ca](mailto:marie.gharib@canada.ca)>  
**Subject:** RE: New OBCS permit manager

Hi Allain,


Marie Gharib, is the one who replaced me. I have cced her on this email so that you can connect.

Cheers!

Émilie Falardeau

Manager, Compliance and Enforcement  
 Centre for Biosecurity  
 Public Health Agency of Canada / Government of Canada  
[Emilie.Falardeau@Canada.ca](mailto:Emilie.Falardeau@Canada.ca) / Tel.: 343-542-3098

Gestionnaire, conformité et application de la loi  
 Centre de biosécurité  
 Agence de la santé publique du Canada / Gouvernement du Canada  
[Emilie.Falardeau@Canada.ca](mailto:Emilie.Falardeau@Canada.ca) / Tél.: 343-542-3098




---

**From:** Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>  
**Sent:** 2019-03-26 12:32 PM  
**To:** Falardeau, Émilie (PHAC/ASPC) <[emilie.falardeau@canada.ca](mailto:emilie.falardeau@canada.ca)>  
**Subject:** New OBCS permit manager

Hi Emilie,

Would you happen to know who replaced you in OBCS? We submitted a CFIA transfer permit application last Monday and I wanted to follow up on it. Our CL4 is shutting down Friday so we were hoping to get the transfer permit in time to transfer samples over to NCFAD.

Thanks and best regards,  
 Allan

**Allan Lau**

Biorisk Officer | Agent de biorisque  
 Safety and Environmental Services | Services de sécurité et Services environnementaux  
 National Microbiology Laboratory at the | Laboratoire national de microbiologie au  
 Canadian Science Centre for Human and Animal Health | Centre scientifique canadien de la santé humaine et animale  
 Public Health Agency of Canada | Agence de la santé publique du Canada  
 1015 Arlington Street, Winnipeg, MB, Canada, R3E 3P6

**NEW:** [Allan.Lau@canada.ca](mailto:Allan.Lau@canada.ca)

Telephone | Téléphone 204-784-5986 / Facsimile | Télécopieur 204-789-2069  
 Government of Canada | Gouvernement du Canada

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Le présent courriel est réservé à l'usage du destinataire visé et peut contenir des renseignements privés et

confidentiels. Si vous n'êtes pas le destinataire visé ou une personne chargée de transmettre le courriel au destinataire visé, vous n'avez aucun droit de diffuser cette communication, de la copier ou de la distribuer, ni de prendre toute mesure en fonction de l'information qu'elle contient. Si cette communication vous a été transmise par erreur, veuillez en aviser l'expéditeur immédiatement par courriel et la supprimer de votre ordinateur, sans oublier toute pièce jointe. Merci

**Fleury, Teresa (PHAC/ASPC)**

---

**From:** [REDACTED]  
**Sent:** 2019-03-29 12:28 AM  
**To:** Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC)  
**Subject:** Re: RE: [REDACTED] - packaging required

Dear Anders and [REDACTED] is ready to wait, and [REDACTED] will help to handle cargo then. So when you have the information of flight itinerary, please inform us ASAP.

Thank you all and with best wishes,  
 [REDACTED]

[REDACTED]  
 Virus Resource and Bioinformation Center,  
 Wuhan Institute of Virology, Chinese Academy of Sciences.  
 [REDACTED]

**From:** Leung, Anders (PHAC/ASPC)  
**Date:** 2019-03-29 03:30  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**CC:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required  
 Perfect! Can you please send me the flight itinerary?

**From:** [REDACTED]  
**Sent:** 2019-03-28 12:38 PM  
**To:** [REDACTED]; Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca> [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

We can pickup Friday at 10am.

**From:** [REDACTED]  
**Sent:** 28 March 2019 10:40  
**To:** Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** 回复: [REDACTED] - packaging required

Dear Anders and dear [REDACTED]

Ok, we will make corresponding preparations for shipment start on Friday.

Best wishes,

[REDACTED]

来自我的华为手机

----- 原始邮件 -----

主题：RE: [REDACTED] - packaging required

发件人："Leung, Anders (PHAC/ASPC)"

收件人：[REDACTED] "Qiu, Xiangguo (PHAC/ASPC) ", [REDACTED]

抄送："NML Specimen Receiving (PHAC/ASPC) ", "Drebot, Mike (PHAC/ASPC) ", "Fernando, Lisa (PHAC/ASPC) ", "OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) ", "Lau, Allan (PHAC/ASPC) "

Hi [REDACTED]

The shipment will be ready for tomorrow morning. Please confirm the pick up time and provide an update for the routing of flights. Unfortunately there is a strict no video/picture policy for this building so this is a no-go.

Thanks!

Anders

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [REDACTED]  
**Sent:** 2019-03-28 8:24 AM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC)  
<[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]


**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Good morning,

We have received the ok to send for this shipment. Please confirm if we can pickup the shipment on Friday morning? We would have to send the dry ice data logger to our agent today so they can have it in place for tomorrow.

Also, our China office has asked that you take pictures/video during the packing of the shipment. Is this possible?

Please confirm.



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [REDACTED]  
**Sent:** 27 March 2019 17:32  
**To:** 'Leung, Anders (PHAC/ASPC)'; [REDACTED] 'Qiu, Xiangguo (PHAC/ASPC)'; [REDACTED]  
**Cc:** 'NML Specimen Receiving (PHAC/ASPC)'; 'Drebot, Mike (PHAC/ASPC)'; 'Fernando, Lisa (PHAC/ASPC)'; 'OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)'  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders

Thank you for the paperwork. Once the paperwork has been approved we will contact you to confirm a pick up date and time. We will also advise the routing.

Regards,

**From:** Leung, Anders (PHAC/ASPC) [mailto:[anders.leung@canada.ca](mailto:anders.leung@canada.ca)]

**Sent:** 27 March 2019 1:00 PM

**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)

**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached customs invoice and revised shippers declaration. The shipment will be ready for pickup tomorrow morning at 10:00, again can you please provide us with the route info so we can activate the ERAP teams.

Thanks!  
Anders

**From:** [REDACTED]

**Sent:** 2019-03-27 10:59 AM

**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]  
[REDACTED] Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>

**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please provide a customs invoice with the following information (if applicable):


Shipper: (company name, address, contact person, tel)  
Consignee: (company name, address, contact person, tel)  
Incoterms: EXW  
Cargo description: (please confirm with Shipper for below)  
Ebola virus// 24vial(500ul/vial)// unit price:  
Nipah virus//6vial(500ul/vial)// unit price:

Total value:  
Package in dry ice:

Please send us the invoice at your earliest convenience.

If you have any questions please feel free to contact our office.

Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]

**Sent:** 27 March 2019 12:03 AM

**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)

**Subject:** Re: [REDACTED] - packaging required

Hi [REDACTED]

Can you please send me the flight route for the package so we can activate the provincial ERAP teams?

Thanks!  
Anders

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** [REDACTED]

**Sent:** Tuesday, March 26, 2019 7:58 PM

**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)

**Subject:** RE: [REDACTED] - packaging required

Hello Andres,

Well received.

Thank you

[Redacted]

[Redacted]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 March 2019 18:44  
**To:** Qiu, Xiangguo (PHAC/ASPC); [Redacted]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [Redacted] - packaging required

Hi,

Please see attached documents (signed copy will accompany the shipment), please let me know if I am missing any documents. Again please let us know if Thursday or Friday will work for sample pickup.

Thanks!  
Anders

**From:** Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>  
**Sent:** 2019-03-26 1:01 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [Redacted]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [Redacted] - packaging required

Hi Anders,

Pls can you send what paper work required for us to [Redacted]?

Thanks!

Qiu

**From:** Leung, Anders (PHAC/ASPC)  
**Sent:** 2019-03-26 11:46 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

If we can schedule this for Thursday or Friday morning that would be great.

Thanks!

**From:** [REDACTED]  
**Sent:** 2019-03-26 10:56 AM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please advise when shipment will be ready for pick up as requested by our [REDACTED] office they would like this to arrive before April 1<sup>st</sup>. Please forward all paperwork at your earliest convenience in order for us to get the ok to send.

Regards,

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 27 February 2019 6:34 PM  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

I think that the best contact would be the company that produces the packaging Saf-T-Pak Inc., they should be able to provide you some standards testing/certificates.

<http://www.saftpak.com/StpPack/ProductDetail.aspx?ID=3>

Anders

**From:** Qiu, Xiangguo (PHAC/ASPC)  
**Sent:** 2019-02-27 5:28 PM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC)  
<[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

My colleague Anders will assist the shipping and he is confused about the request from your side. He will try to help with your request but may need your clarification.

Best regards,


Qiu

**From:** [REDACTED]  
**Sent:** 2019-02-27 5:15 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hello,

Client has requested you provide certificate approval since inner DG package provide by you, template now attached.

Best Regards,





Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 February 2019 11:53  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

That is correct, it should be PI620. How in-depth would you like for the pick up process I don't really think we can make a video, maybe pictures?


Thanks!  
Anders

**From:** [REDACTED]  
**Sent:** 2019-02-20 7:22 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Andre,

Client is asking the PI should be 620 instead of 650, please advise if this ok, They are also requesting to take picture or video of whole pick-up process.

Regards





**Fleury, Teresa (PHAC/ASPC)**

---

**From:** Krishnan, Jay (PHAC/ASPC)  
**Sent:** 2019-03-29 7:55 AM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Cc:** Anderson, Kelly (PHAC/ASPC)  
**Subject:** RE: ERAP deactivation

Please make sure you cc the Toronto airport Hazmat team; Kelly has forwarded this info to EOC a couple of weeks ago, thanks

**From:** Wood, Heidi (PHAC/ASPC) <[heidi.wood@canada.ca](mailto:heidi.wood@canada.ca)> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-29 7:53 AM  
**To:** Krishnan, Jay (PHAC/ASPC) <[jay.krishnan@canada.ca](mailto:jay.krishnan@canada.ca)>; OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; [REDACTED]@[gov.mb.ca](mailto:gov.mb.ca)>  
**Subject:** RE: ERAP deactivation

Just a quick update - it looks like [REDACTED] is going to route this shipment through Toronto.

**From:** Krishnan, Jay (PHAC/ASPC) <[jay.krishnan@canada.ca](mailto:jay.krishnan@canada.ca)>  
**Sent:** 2019-03-29 7:51 AM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; [REDACTED]@[gov.mb.ca](mailto:gov.mb.ca)>  
**Subject:** RE: ERAP deactivation

Yes; this is correct, thanks

**From:** Wood, Heidi (PHAC/ASPC) <[heidi.wood@canada.ca](mailto:heidi.wood@canada.ca)> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-28 3:44 PM  
**To:** [REDACTED]@[gov.mb.ca](mailto:gov.mb.ca)>; OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; Krishnan, Jay (PHAC/ASPC) <[jay.krishnan@canada.ca](mailto:jay.krishnan@canada.ca)>  
**Subject:** RE: ERAP deactivation

Hi Jared,

I spoke to Jay Krishnan, our ERAP National Coordinator, about this today and Jay indicated that for this international shipment, the ERAP teams can stand down after the flight has left the airport in Vancouver (we are assuming that the RG4 shipment will be routed through Vancouver but this has not yet been confirmed by [REDACTED]).

Jay – can you confirm that this is the procedure we will follow?

Thanks,  
 Heidi

**From:** [REDACTED]@[gov.mb.ca](mailto:gov.mb.ca)>  
**Sent:** 2019-03-28 3:37 PM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>  
**Subject:** ERAP deactivation

At what geographical point does the ERAP get deactivated? I understood it to be when the shipment is received.  
Thanks.





Please be advised that the Risk group 4 shipment will be routed through Toronto and is scheduled to depart from the NML in Winnipeg today between 13:30-14:00. Further details will be provide when available.


Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433  
\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433  
\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-28 9:34 AM

**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca>; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433  
\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433

\*\*\*\* **nouveau courriel** [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)> [REDACTED]@gov.mb.ca; oc\_nml\_ocd\_group@phac-aspc.gc.ca; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433

\*\*\*\* **new e-mail** [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433

\*\*\*\* **nouveau courriel** [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

**IMPORTANT:** This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

**IMPORTANT :** Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



**Canada**

**Fleury, Teresa (PHAC/ASPC)**

---



**From:** [REDACTED]  
**Sent:** 2019-03-29 9:21 AM  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED] Leung, Anders (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hi Qiu,

Can you please ensure the dangerous goods declaration is revised.

The one we have on file for this shipment, doesn't show the dry ice quantity.

Thanks,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Qiu, Xiangguo (PHAC/ASPC) [mailto:xiangguo.qiu@canada.ca]  
**Sent:** 29 March 2019 09:44  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

1:30-2pm pick up should be fine for us. And the dry ice is needed for this shipment! Thanks for the inquiry. Anders and Paul/Don, pls correct me if there is an issue with the new pick -up time.

Thanks!

Qiu


**From:** [REDACTED]  
**Sent:** 2019-03-29 7:43 AM  
**To:** Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Good morning Xiangguo Qiu,

We will have to push the pickup back a little, because the temperature got bumped on the flight and will only arrive in Winnipeg at noon. We can pickup around 1:30-2pm. This doesn't affect the planned flight to Toronto.

Also, can you confirm if this shipment has dry ice? The DG Declaration doesn't show a dry ice quantity, so want to make sure its corrected if needed. Need to confirm this before booking the onward flight to Beijing.

Thanks,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 28 March 2019 15:30  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM

CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC) [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Perfect! Can you please send me the flight itinerary?

**From:** [REDACTED]

**Sent:** 2019-03-28 12:38 PM

**To:** [REDACTED]; Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED]

[REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>

**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

We can pickup Friday at 10am.

**From:** [REDACTED]

**Sent:** 28 March 2019 10:40

**To:** Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)

**Cc:** NML Specimen Receiving (PHAC/ASPC) ; Drebot, Mike (PHAC/ASPC) ; Fernando, Lisa (PHAC/ASPC) ; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) ; Lau, Allan (PHAC/ASPC) [REDACTED]

**Subject:** 回复 [REDACTED] - packaging required

Dear Anders and dear [REDACTED]

Ok, we will make corresponding preparations for shipment start on Friday.

Best wishes,

来自我的华为手机

----- 原始邮件 -----

**主题:** RE: [REDACTED] - packaging required

**发件人:** "Leung, Anders (PHAC/ASPC)"

**收件人:** [REDACTED], "Qiu, Xiangguo (PHAC/ASPC)" [REDACTED]


**抄送:** "NML Specimen Receiving (PHAC/ASPC)" , "Drebot, Mike (PHAC/ASPC)" , "Fernando, Lisa (PHAC/ASPC)" , "OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)" , "Lau, Allan (PHAC/ASPC)"

Hi [REDACTED]

The shipment will be ready for tomorrow morning. Please confirm the pick up time and provide an update for the routing of flights. Unfortunately there is a strict no video/picture policy for this building so this is a no-go.

Thanks!

Anders



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [REDACTED]  
**Sent:** 2019-03-28 8:24 AM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Good morning,

We have received the ok to send for this shipment. Please confirm if we can pickup the shipment on Friday morning? We would have to send the dry ice data logger to our agent today so they can have it in place for tomorrow.

Also, our China office has asked that you take pictures/video during the packing of the shipment. Is this possible?

Please confirm.



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [REDACTED]  
**Sent:** 27 March 2019 17:32  
**To:** 'Leung, Anders (PHAC/ASPC)'; [REDACTED] 'Qiu, Xiangguo (PHAC/ASPC)'; [REDACTED]  
**Cc:** 'NML Specimen Receiving (PHAC/ASPC)'; 'Drebot, Mike (PHAC/ASPC)'; 'Fernando, Lisa (PHAC/ASPC)'; 'OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)'  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders

Thank you for the paperwork. Once the paperwork has been approved we will contact you to confirm a pick up date and time. We will also advise the routing.

Regards,

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 27 March 2019 1:00 PM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached customs invoice and revised shippers declaration. The shipment will be ready for pickup tomorrow morning at 10:00, again can you please provide us with the route info so we can activate the ERAP teams.

Thanks!  
 Anders

**From:** [REDACTED]  
**Sent:** 2019-03-27 10:59 AM

**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please provide a customs invoice with the following information (if applicable):

Shipper: (company name, address, contact person, tel)  
Consignee: (company name, address, contact person, tel)  
Incoterms: EXW  
Cargo description: (please confirm with Shipper for below)  
Ebola virus// 24vial(500ul/vial)// unit price:  
Nipah virus//6vial(500ul/vial)// unit price:  
Total value:  
Package in dry ice:

Please send us the invoice at your earliest convenience.

If you have any questions please feel free to contact our office.

Regards,

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 27 March 2019 12:03 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** Re: [REDACTED] - packaging required

Hi [REDACTED]

Can you please send me the flight route for the package so we can activate the provincial ERAP teams?

Thanks!  
Anders



Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** [REDACTED]  
**Sent:** Tuesday, March 26, 2019 7:58 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hello Andres,

Well received.

Thank you  
[REDACTED]



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 March 2019 18:44  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached documents (signed copy will accompany the shipment), please let me know if I am missing any documents. Again please let us know if Thursday or Friday will work for sample pickup.

Thanks!  
Anders

**From:** Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>  
**Sent:** 2019-03-26 1:01 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hi Anders,

Pls can you send what paper work required for us to [REDACTED]?

Thanks!

Qiu

**From:** Leung, Anders (PHAC/ASPC)  
**Sent:** 2019-03-26 11:46 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

If we can schedule this for Thursday or Friday morning that would be great.


Thanks!

**From:** [REDACTED]  
**Sent:** 2019-03-26 10:56 AM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please advise when shipment will be ready for pick up as requested by our [REDACTED] office they would like this to arrive before April 1<sup>st</sup>. Please forward all paperwork at your earliest convenience in order for us to get the ok to send.

Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 27 February 2019 6:34 PM  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

I think that the best contact would be the company that produces the packaging Saf-T-Pak Inc., they should be able to provide you some standards testing/certificates.

<http://www.saftpak.com/StpPack/ProductDetail.aspx?ID=3>

Anders

**From:** Qiu, Xiangguo (PHAC/ASPC)  
**Sent:** 2019-02-27 5:28 PM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

My colleague Anders will assist the shipping and he is confused about the request from your side. He will try to help with your request but may need your clarification.

Best regards,

Qiu

**From:** [REDACTED]  
**Sent:** 2019-02-27 5:15 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hello,

Client has requested you provide certificate approval since inner DG package provide by you, template now attached.

Best Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 February 2019 11:53  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

That is correct, it should be PI620. How in-depth would you like for the pick up process I don't really think we can make a video, maybe pictures?


Thanks!  
Anders

**From:** [REDACTED]  
**Sent:** 2019-02-20 7:22 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>;  
[REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Andre,

Client is asking the PI should be 620 instead of 650, please advise if this ok, They are also requesting to take picture or video of whole pick-up process.

Regards



**Fleury, Teresa (PHAC/ASPC)**

---

**From:** Leung, Anders (PHAC/ASPC)  
**Sent:** 2019-03-29 11:36 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

Have you figured out the flight schedules yet? The ERAP teams will need this information.

Thanks!  
Anders

**From:** [REDACTED]  
**Sent:** 2019-03-29 9:49 AM  
**To:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Thank you,

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]

**Sent:** 29 March 2019 10:43

**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Revised version attached.

**From:** [REDACTED]

**Sent:** 2019-03-29 9:29 AM

**To:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]

[REDACTED]

**Subject:** RE: [REDACTED] - packaging required


Hi Anders,

On the declaration (see snapshot below), you need to add a few things:

- "24HR EMERGENCY CONTACT" (before the Canutec #)
- "PERSON RESPONSIBLE" (before the PHAC #)

**Additional Handling Information**

1-888-CAN-UTEC (226-8832), 613-996-6666  
PHAC NML EOC Director: 1-866-262-8433





Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]

**Sent:** 29 March 2019 10:23

**To:** [REDACTED]; Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

We will have the dry ice in the package.

**From:** [REDACTED]

**Sent:** 2019-03-29 9:22 AM


**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>; Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>; [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Perfect. Thank you Anders.

And just to confirm; is [REDACTED] providing the dry ice for you?



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]

**Sent:** 29 March 2019 10:20

**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Hi Lorraine,

Attached is the revised and final signed copy of the shippers declaration and the commercial invoice, which includes the dry ice (15kg). We will have the shipment ready for the scheduled 1:30.

Thanks!

Anders

**From:** Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>

**Sent:** 2019-03-29 8:44 AM

**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Hi Lorraine,

1:30-2pm pick up should be fine for us. And the dry ice is needed for this shipment! Thanks for the inquiry. Anders and Paul/Don, pls correct me if there is an issue with the new pick -up time.

Thanks!

Qiu

**From:** [REDACTED]

**Sent:** 2019-03-29 7:43 AM

**To:** Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]



**Subject:** RE: [REDACTED] - packaging required

Good morning Xiangguo Qiu,

We will have to push the pickup back a little, because the temperature got bumped on the flight and will only arrive in Winnipeg at noon. We can pickup around 1:30-2pm. This doesn't affect the planned flight to Toronto.

Also, can you confirm if this shipment has dry ice? The DG Declaration doesn't show a dry ice quantity, so want to make sure its corrected if needed. Need to confirm this before booking the onward flight to Beijing.

Thanks,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:[anders.leung@canada.ca](mailto:anders.leung@canada.ca)]

**Sent:** 28 March 2019 15:30

**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Perfect! Can you please send me the flight itinerary?

**From:** [REDACTED]

**Sent:** 2019-03-28 12:38 PM

**To:** [REDACTED]; Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]

[REDACTED] Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>; Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>; [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

We can pickup Friday at 10am.

**From:** [REDACTED]

**Sent:** 28 March 2019 10:40

**To:** Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]

**Subject:** 回复: [REDACTED] - packaging required

Dear Anders and dear [REDACTED]

Ok, we will make corresponding preparations for shipment start on Friday.

Best wishes,

来自我的华为手机

----- 原始邮件 -----

主题：RE: [REDACTED] - packaging required

发件人："Leung, Anders (PHAC/ASPC)"



收件人：[REDACTED]; "Qiu, Xiangguo (PHAC/ASPC)" [REDACTED]

抄送："NML Specimen Receiving (PHAC/ASPC)", "Drebot, Mike (PHAC/ASPC)", "Fernando, Lisa (PHAC/ASPC)", "OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)", "Lau, Allan (PHAC/ASPC)"

Hi [REDACTED]

The shipment will be ready for tomorrow morning. Please confirm the pick up time and provide an update for the routing of flights. Unfortunately there is a strict no video/picture policy for this building so this is a no-go.

Thanks!  
Anders



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

From: [REDACTED]

Sent: 2019-03-28 8:24 AM

To: [REDACTED]; Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]

Cc: NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC)

<mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>



**Subject:** RE: [REDACTED] - packaging required

Good morning,

We have received the ok to send for this shipment. Please confirm if we can pickup the shipment on Friday morning? We would have to send the dry ice data logger to our agent today so they can have it in place for tomorrow.

Also, our China office has asked that you take pictures/video during the packing of the shipment. Is this possible?

Please confirm.



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [REDACTED]

**Sent:** 27 March 2019 17:32

**To:** 'Leung, Anders (PHAC/ASPC)'; [REDACTED] 'Qiu, Xiangguo (PHAC/ASPC)'; [REDACTED]

**Cc:** 'NML Specimen Receiving (PHAC/ASPC)'; 'Drebot, Mike (PHAC/ASPC)'; 'Fernando, Lisa (PHAC/ASPC)'; 'OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)'

**Subject:** RE: [REDACTED] - packaging required

Hello Anders

Thank you for the paperwork. Once the paperwork has been approved we will contact you to confirm a pick up date and time. We will also advise the routing.

Regards,



**From:** Leung, Anders (PHAC/ASPC) [mailto:[anders.leung@canada.ca](mailto:anders.leung@canada.ca)]

**Sent:** 27 March 2019 1:00 PM

**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)

**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached customs invoice and revised shippers declaration. The shipment will be ready for pickup tomorrow morning at 10:00, again can you please provide us with the route info so we can activate the ERAP teams.

Thanks!  
Anders

**From:** [REDACTED]

**Sent:** 2019-03-27 10:59 AM

**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>

**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please provide a customs invoice with the following information (if applicable):

Shipper: (company name, address, contact person, tel)

Consignee: (company name, address, contact person, tel)

Incoterms: EXW

Cargo description: (please confirm with Shipper for below)

Ebola virus// 24vial(500ul/vial)// unit price:

Nipah virus//6vial(500ul/vial)// unit price:


Total value:

Package in dry ice:

Please send us the invoice at your earliest convenience.

If you have any questions please feel free to contact our office.

Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]

**Sent:** 27 March 2019 12:03 AM

**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)

**Subject:** Re: [REDACTED] - packaging required

Hi [REDACTED]

Can you please send me the flight route for the package so we can activate the provincial ERAP teams?

Thanks!  
Anders

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** [REDACTED]

**Sent:** Tuesday, March 26, 2019 7:58 PM

**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); [REDACTED]


**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)

**Subject:** RE: [REDACTED] - packaging required

Hello Andres,

Well received.

Thank you  
[REDACTED]



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 March 2019 18:44  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached documents (signed copy will accompany the shipment), please let me know if I am missing any documents. Again please let us know if Thursday or Friday will work for sample pickup.

Thanks!  
Anders

**From:** Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>  
**Sent:** 2019-03-26 1:01 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]  
[REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hi Anders,

Pls can you send what paper work required for us to [REDACTED]?

Thanks!

Qiu

**From:** Leung, Anders (PHAC/ASPC)  
**Sent:** 2019-03-26 11:46 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

If we can schedule this for Thursday or Friday morning that would be great.

Thanks!

**From:** [REDACTED]  
**Sent:** 2019-03-26 10:56 AM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: job 7534 - packaging required

Hello Anders/Xiangguo

Please advise when shipment will be ready for pick up as requested by our [REDACTED] office they would like this to arrive before April 1<sup>st</sup>. Please forward all paperwork at your earliest convenience in order for us to get the ok to send.

Regards,

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:[anders.leung@canada.ca](mailto:anders.leung@canada.ca)]  
**Sent:** 27 February 2019 6:34 PM  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

I think that the best contact would be the company that produces the packaging Saf-T-Pak Inc., they should be able to provide you some standards testing/certificates.

<http://www.saftpak.com/StpPack/ProductDetail.aspx?ID=3>

Anders

**From:** Qiu, Xiangguo (PHAC/ASPC)  
**Sent:** 2019-02-27 5:28 PM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)> [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

My colleague Anders will assist the shipping and he is confused about the request from your side. He will try to help with your request but may need your clarification.

Best regards,

Qiu

**From:** [REDACTED]  
**Sent:** 2019-02-27 5:15 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hello,

Client has requested you provide certificate approval since inner DG package provide by you, template now attached.

Best Regards,

[REDACTED]

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 February 2019 11:53  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

That is correct, it should be PI620. How in-depth would you like for the pick up process I don't really think we can make a video, maybe pictures?

Thanks!  
Anders

**From:** [REDACTED]  
**Sent:** 2019-02-20 7:22 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Andre,

Client is asking the PI should be 620 instead of 650, please advise if this ok, They are also requesting to take picture or video of whole pick-up process.

Regards

[REDACTED]



**Fleury, Teresa (PHAC/ASPC)**

---

**From:** Wood, Heidi (PHAC/ASPC) on behalf of OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-29 3:01 PM  
**To:** Frost, Shelley (PHAC/ASPC)  
**Cc:** guelph, erap (PHAC/ASPC)  
**Subject:** RE: ERAP Notification 2019-02 - Pending Shipment

Hi Shelley,

Yes, we're still waiting for the pick-up – I just checked about 10 minutes ago and [REDACTED] has not arrived yet at the NML.

The tracking # for this shipment is [REDACTED] but I do not yet know the exact routing (other than that this shipment will travel first to Toronto).

Just FYI – I spoke to the ERAP National Coordinator (Jay Krishnan) yesterday and he indicated that the ERAP teams can stand-down once the shipment leaves the airport in Toronto.

I'll be sending another email as soon as I hear that the shipment is ready for departure from the NML.

Thanks,  
 Heidi

**From:** Frost, Shelley (PHAC/ASPC) <shelley.frost@canada.ca>  
**Sent:** 2019-03-29 2:58 PM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC) <PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA>  
**Cc:** guelph, erap (PHAC/ASPC) <phac.erap-guelph.aspc@canada.ca>  
**Subject:** RE: ERAP Notification 2019-02 - Pending Shipment

Hi again, Heidi,

I was just wondering if you still waiting for shipping details from [REDACTED]?

Shelley

**From:** Wood, Heidi (PHAC/ASPC) <heidi.wood@canada.ca> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-29 9:40 AM  
**To:** Frost, Shelley (PHAC/ASPC) <shelley.frost@canada.ca>  
**Subject:** RE: ERAP Notification 2019-02 - Pending Shipment

Yes, received.

Thanks,  
 Heidi

**From:** Frost, Shelley (PHAC/ASPC) <shelley.frost@canada.ca>  
**Sent:** 2019-03-29 8:39 AM

**To:** OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>

**Subject:** FW: ERAP Notification 2019-02 - Pending Shipment

Hi,

I received an acknowledgement from HPOC. Just wanted to make sure the message got through to the NML OC?

Thx!

Shelley

**From:** Frost, Shelley (PHAC/ASPC)

**Sent:** 2019-03-29 9:27 AM

**To:** OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>; 'OCNML.Doc (PHAC/ASPC)' <[phac.ocnml.doc.aspc@canada.ca](mailto:phac.ocnml.doc.aspc@canada.ca)>; HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Cc:** [guelph, erap \(PHAC/ASPC\) \(phac.erap-guelph.aspc@canada.ca\)](mailto:phac.erap-guelph.aspc@canada.ca) <[phac.erap-guelph.aspc@canada.ca](mailto:phac.erap-guelph.aspc@canada.ca)>; [Cornelisse, Mette \(PHAC/ASPC\) <mette.cornelisse@canada.ca>](mailto:mette.cornelisse@canada.ca); [Nichani, Anil \(PHAC/ASPC\) <anil.nichani@canada.ca>](mailto:anil.nichani@canada.ca); [Gilmour, Matthew \(PHAC/ASPC\) <matthew.gilmour@canada.ca>](mailto:matthew.gilmour@canada.ca); [Guercio, Steven \(PHAC/ASPC\) <steven.guercio@canada.ca>](mailto:steven.guercio@canada.ca); [Drebot, Mike \(PHAC/ASPC\) <mike.drebot@canada.ca>](mailto:mike.drebot@canada.ca); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nlm.sp-lnm.aspc@canada.ca](mailto:phac.nlm.sp-lnm.aspc@canada.ca)>; [Kernaghan, Shaun \(PHAC/ASPC\) <shaun.kernaghan@canada.ca>](mailto:shaun.kernaghan@canada.ca); [Cook, Matthew \(PHAC/ASPC\) <matthew.cook@canada.ca>](mailto:matthew.cook@canada.ca)

**Subject:** RE: ERAP Notification 2019-02 - Pending Shipment

Hi,

Shawn Kernaghan and Matt Cook from the Ontario ERAP team will be on standby for this shipment. Contact details below.

|                 |                                                                              |                                                                                                                                         |
|-----------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Shaun Kernaghan | Research Technologist<br>PHAC-LFZ<br>110 Stone Road W<br>Guelph, ON, N1G 3W4 | Work: 519 826-2618<br>Cell: [REDACTED]<br>Fax: 519 822-2280<br><a href="mailto:shaun.kernaghan@canada.ca">shaun.kernaghan@canada.ca</a> |
| Matthew Cook    | Research Technologist<br>PHAC-LFZ<br>110 Stone Road W<br>Guelph, ON, N1G 3W4 | Work: 519 826-2648<br>Cell: [REDACTED]<br>Fax: 519 822-2280<br><a href="mailto:matthew.cook@canada.ca">matthew.cook@canada.ca</a>       |

Shelley Frost

Safety Manager, IDPC  
Public Health Agency of Canada, Government of Canada  
[Shelley.Frost@canada.ca](mailto:Shelley.Frost@canada.ca) / 519-826-2604

Gestionnaire de sécurité, PCMI  
Agence de la santé publique du Canada, Gouvernement du Canada  
[Shelley.Frost@canada.ca](mailto:Shelley.Frost@canada.ca) / 519-826-2604

**From:** [guelph, erap \(PHAC/ASPC\) <phac.erap-guelph.aspc@canada.ca>](mailto:phac.erap-guelph.aspc@canada.ca)

**Sent:** 2019-03-29 9:03 AM

**To:** Frost, Shelley (PHAC/ASPC) <[shelley.frost@canada.ca](mailto:shelley.frost@canada.ca)>; Gill, Chad (PHAC/ASPC) <[chad.gill@canada.ca](mailto:chad.gill@canada.ca)>; Ziebell, Kim

(PHAC/ASPC) <[kim.ziebell@canada.ca](mailto:kim.ziebell@canada.ca)>

**Subject:** FW: ERAP Notification 2019-02 - Pending Shipment

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** Friday, March 29, 2019 9:02:42 AM (UTC-05:00) Eastern Time (US & Canada)

**To:** Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); [REDACTED]@gov.mb.ca'; PHAC.F OC\_NML\_OCD\_Group F.ASPC; NML Specimen Receiving (PHAC/ASPC); guelph, erap (PHAC/ASPC); [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC)

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment will be routed through Toronto and is scheduled to depart from the NML in Winnipeg today between 13:30-14:00. Further details will be provide when available.

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-28 9:34 AM

**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca'; [REDACTED]@gov.mb.ca'; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML

Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

Cc: HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

Subject: ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.aspc@canada.ca](mailto:phac.nml.sp-lnm.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)> [REDACTED]@gov.mb.ca; oc\_nml\_ocd\_group@phac-aspc.gc.ca; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433

\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**Fleury, Teresa (PHAC/ASPC)**

**From:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC)  
**Sent:** 2019-03-29 3:43 PM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Cc:** Obenauf, Alison (PHAC/ASPC)  
**Subject:** RE: ERAP Notification 2019-02 - Shipment Ready for Departure

We acknowledge receipt. Thank you.

**NEW – Unsubscribe feature below**

Regards | Sincères salutations

Health Portfolio Operations Centre  
 Public Health Agency of Canada | Government of Canada  
 PHAC-ASPC.HPOC-COPS@canada.ca | Tel: 613-952-7940  
 Centre des opérations du portefeuille de la santé  
 Agence de la santé publique du Canada | Gouvernement du Canada  
 PHAC-ASPC.HPOC-COPS@canada.ca | Tél : 613-952-7940

Confidentiality Notice: This e-mail communication and any attachments may contain confidential and privileged information for the use of the designated recipients. If you are not the intended recipient, or authorized to receive for the recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please destroy all copies of this communication and any attachments and contact the sender by reply e-mail or telephone (613) 952-7940.

*If you no longer wish to receive these notifications, please click [manage](#) or [unsubscribe](#) to update your subscription.*

Avis de confidentialité: Le présent courriel et les pièces qui y sont jointes peuvent contenir des renseignements confidentiels ou privilégiés destinés uniquement aux personnes désignées. Si vous n'êtes pas le destinataire visé, ou une personne autorisée à recevoir sa correspondance, vous êtes par la présente avisé que cette communication vous a été transmise par erreur et qu'il est interdit d'en prendre connaissance, d'en divulguer le contenu, de la distribuer et de la reproduire en tout ou en partie. Si vous avez reçu le présent courriel par erreur, veuillez détruire toutes ses copies et tout dossier joint et communiquer avec l'expéditeur par courriel ou par téléphone, au 613-952-7940.

*Si vous ne souhaitez plus recevoir ces notifications, veuillez cliquer sur [gérer](#) ou vous [désabonner](#) pour mettre à jour votre abonnement.*

**From:** Wood, Heidi (PHAC/ASPC) <heidi.wood@canada.ca> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-03-29 4:38 PM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC) <PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA>; Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.asp.aspc@canada.ca>; CSCHAH SES (PHAC/ASPC) <phac.cschah.ses.aspc@canada.ca>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca>; PHAC.F OC\_NML\_OCD\_Group F.ASPC <OC\_NML\_OCD\_Group@canada.ca>; NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; guelph, erap (PHAC/ASPC) <phac.erap-guelph.aspc@canada.ca>; [REDACTED]@gtaa.com' <[REDACTED]@gtaa.com>; Kernaghan, Shaun (PHAC/ASPC) <shaun.kernaghan@canada.ca>; Cook, Matthew (PHAC/ASPC) <matthew.cook@canada.ca>; [REDACTED]@gov.mb.ca  
**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>  
**Subject:** ERAP Notification 2019-02 - Shipment Ready for Departure

The Risk Group 4 shipment has been picked up by [REDACTED] from the NML in Winnipeg.

The tracking number for this shipment is [REDACTED]. This shipment is en-route to China via Toronto.

Please note - once this shipment departs from the airport in Toronto, ERAP teams can stand down.


Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433  
\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433  
\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-29 8:03 AM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca>; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; [erap.guelph@canada.ca](mailto:erap.guelph@canada.ca) [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment will be routed through Toronto and is scheduled to depart from the NML in Winnipeg today between 13:30-14:00. Further details will be provided when available.

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch

Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-28 9:34 AM

**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca'; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.aspc@canada.ca](mailto:phac.nml.sp-lnm.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca; [oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca); NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*

Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433


\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et


confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.





IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-29 8:03 AM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca; [REDACTED]@gov.mb.ca; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; [erap.guelph@canada.ca](mailto:erap.guelph@canada.ca); [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment will be routed through Toronto and is scheduled to depart from the NML in Winnipeg today between 13:30-14:00. Further details will be provided when available.

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-28 9:34 AM

**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca'; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-](mailto:phac.ocnml.logistics-)

[logistique.lnmco.aspc@canada.ca](mailto:logistique.lnmco.aspc@canada.ca); OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca; oc\_nml\_ocd\_group@phac-aspc.gc.ca; NML Specimen Receiving (PHAC/ASPC) <[phac.nlm.specimen.receiving.aspc@canada.ca](mailto:phac.nlm.specimen.receiving.aspc@canada.ca)>  
**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>  
**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433  
 \*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433  
 \*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Government  
of Canada

Gouvernement  
du Canada

Canada

**Fleury, Teresa (PHAC/ASPC)**

---

**From:** Leung, Anders (PHAC/ASPC)  
**Sent:** 2019-03-30 1:20 PM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** Re: job [REDACTED] - packaging required

Hi all,

Don went in and got the number but it is [REDACTED] Thanks Don, you're our hero!!

Thanks!  
Anders

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** YYZ-Ops  
**Sent:** Friday, March 29, 2019 5:08 PM  
**To:** YYZ-Ops; Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hello Leung/Andres,

All exports to china need shipper's exporter# on MAWB, please advise.

Regards

[REDACTED]

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [REDACTED]  
**Sent:** 29 March 2019 17:55  
**To:** 'Leung, Anders (PHAC/ASPC)'; [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hello Leung,

Its booked on Air Canada flight AC-031 Mar 31<sup>st</sup> from Toronto to Beijing under [REDACTED]

Regards  
 [REDACTED]

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 29 March 2019 17:36  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC) [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required


Mainly an update to our collaborators in China, but the package has left the NML about an hour ago. We will be tracking the package over the weekend and hopefully it arrives safely in Beijing. Thanks everyone for assisting in this package.

Anders

**From:** [REDACTED]  
**Sent:** 2019-03-29 9:49 AM  
**To:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Thank you,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 29 March 2019 10:43  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Revised version attached.

**From:** [REDACTED]  
**Sent:** 2019-03-29 9:29 AM  
**To:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required



Hi Anders,

On the declaration (see snapshot below), you need to add a few things:

- "24HR EMERGENCY CONTACT" (before the Canutec #)
- "PERSON RESPONSIBLE" (before the PHAC #)

Additional Handling Information

1-888-CAN-UTEC (226-8832), 613-996-6666  
PHAC NML EOC Director: 1-866-262-8433



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]

**Sent:** 29 March 2019 10:23

**To:** [REDACTED]; Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

We will have the dry ice in the package.

**From:** [REDACTED]

**Sent:** 2019-03-29 9:22 AM



**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>; Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>; [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Perfect. Thank you Anders.

And just to confirm; is [redacted] providing the dry ice for you?



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 29 March 2019 10:20  
**To:** Qiu, Xiangguo (PHAC/ASPC); [redacted]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC) [redacted]  
**Subject:** RE: [redacted] - packaging required

Hi Lorraine,

Attached is the revised and final signed copy of the shippers declaration and the commercial invoice, which includes the dry ice (15kg). We will have the shipment ready for the scheduled 1:30.

Thanks!  
Anders

**From:** Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>  
**Sent:** 2019-03-29 8:44 AM  
**To:** [redacted] Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [redacted]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [redacted]  
**Subject:** RE: [redacted] - packaging required

Hi [REDACTED]

1:30-2pm pick up should be fine for us. And the dry ice is needed for this shipment! Thanks for the inquiry. Anders and Paul/Don, pls correct me if there is an issue with the new pick-up time.

Thanks!

Qiu

**From:** [REDACTED]  
**Sent:** 2019-03-29 7:43 AM  
**To:** Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Good morning Xiangguo Qiu,

We will have to push the pickup back a little, because the temperature got bumped on the flight and will only arrive in Winnipeg at noon. We can pickup around 1:30-2pm. This doesn't affect the planned flight to Toronto.

Also, can you confirm if this shipment has dry ice? The DG Declaration doesn't show a dry ice quantity, so want to make sure its corrected if needed. Need to confirm this before booking the onward flight to Beijing.

Thanks,

[REDACTED]

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 28 March 2019 15:30  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM

CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Perfect! Can you please send me the flight itinerary?

**From:** [REDACTED]  
**Sent:** 2019-03-28 12:38 PM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED]  
 [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

We can pickup Friday at 10am.

**From:** [REDACTED]  
**Sent:** 28 March 2019 10:40  
**To:** Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC) ; Drebot, Mike (PHAC/ASPC) ; Fernando, Lisa (PHAC/ASPC) ; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) ; Lau, Allan (PHAC/ASPC) ; [REDACTED]  
**Subject:** 回复: [REDACTED] - packaging required

Dear Anders and dear [REDACTED]

Ok, we will make corresponding preparations for shipment start on Friday.

Best wishes,  
 [REDACTED]

来自我的华为手机

----- 原始邮件 -----


**主题:** RE: [REDACTED] - packaging required  
**发件人:** "Leung, Anders (PHAC/ASPC)"  
**收件人:** [REDACTED] "Qiu, Xiangguo (PHAC/ASPC)" [REDACTED]  
**抄送:** "NML Specimen Receiving (PHAC/ASPC)" , "Drebot, Mike (PHAC/ASPC)" , "Fernando, Lisa (PHAC/ASPC)" , "OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)" , "Lau, Allan (PHAC/ASPC)"

Hi [REDACTED]

The shipment will be ready for tomorrow morning. Please confirm the pick up time and provide an update for the routing of flights. Unfortunately there is a strict no video/picture policy for this building so this is a no-go.

Thanks!  
 Anders

[REDACTED]



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary


**From:** [Redacted]  
**Sent:** 2019-03-28 8:24 AM  
**To:** [Redacted] Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [Redacted]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>  
**Subject:** RE: [Redacted] - packaging required

Good morning,

We have received the ok to send for this shipment. Please confirm if we can pickup the shipment on Friday morning? We would have to send the dry ice data logger to our agent today so they can have it in place for tomorrow.

Also, our China office has asked that you take pictures/video during the packing of the shipment. Is this possible?

Please confirm.



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [REDACTED]  
**Sent:** 27 March 2019 17:32  
**To:** 'Leung, Anders (PHAC/ASPC)'; [REDACTED] 'Qiu, Xiangguo (PHAC/ASPC)' [REDACTED]  
**Cc:** 'NML Specimen Receiving (PHAC/ASPC)'; 'Drebot, Mike (PHAC/ASPC)'; 'Fernando, Lisa (PHAC/ASPC)'; 'OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)'  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders

Thank you for the paperwork. Once the paperwork has been approved we will contact you to confirm a pick up date and time. We will also advise the routing.

Regards,

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 27 March 2019 1:00 PM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached customs invoice and revised shippers declaration. The shipment will be ready for pickup tomorrow morning at 10:00, again can you please provide us with the route info so we can activate the ERAP teams.

Thanks!  
 Anders

**From:** [REDACTED]  
**Sent:** 2019-03-27 10:59 AM

**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please provide a customs invoice with the following information (if applicable):

Shipper: (company name, address, contact person, tel)  
Consignee: (company name, address, contact person, tel)  
Incoterms: EXW  
Cargo description: (please confirm with Shipper for below)  
Ebola virus// 24vial(500ul/vial)// unit price:  
Nipah virus//6vial(500ul/vial)// unit price:  
Total value:  
Package in dry ice:

Please send us the invoice at your earliest convenience.

If you have any questions please feel free to contact our office.

Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 27 March 2019 12:03 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** Re: [REDACTED] - packaging required

Hi [REDACTED]

Can you please send me the flight route for the package so we can activate the provincial ERAP teams?

Thanks!  
Anders


Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** [REDACTED]  
**Sent:** Tuesday, March 26, 2019 7:58 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hello Andres,

Well received.

Thank you  
[REDACTED]



*[Faint, illegible text, likely bleed-through from the reverse side of the page]*

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 March 2019 18:44  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

Please see attached documents (signed copy will accompany the shipment), please let me know if I am missing any documents. Again please let us know if Thursday or Friday will work for sample pickup.

Thanks!  
Anders

**From:** Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>  
**Sent:** 2019-03-26 1:01 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hi Anders,

Pls can you send what paper work required for us to [REDACTED]?

Thanks!

Qiu

**From:** Leung, Anders (PHAC/ASPC)  
**Sent:** 2019-03-26 11:46 AM  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC) [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

If we can schedule this for Thursday or Friday morning that would be great.



Thanks!

**From:** [REDACTED]  
**Sent:** 2019-03-26 10:56 AM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Anders/Xiangguo

Please advise when shipment will be ready for pick up as requested by our [REDACTED] office they would like this to arrive before April 1<sup>st</sup>. Please forward all paperwork at your earliest convenience in order for us to get the ok to send.

Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [mailto:anders.leung@canada.ca]  
**Sent:** 27 February 2019 6:34 PM  
**To:** Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

I think that the best contact would be the company that produces the packaging Saf-T-Pak Inc., they should be able to provide you some standards testing/certificates.

<http://www.saftpak.com/StdPack/ProductDetail.aspx?ID=3>

Anders

**From:** Qiu, Xiangguo (PHAC/ASPC)  
**Sent:** 2019-02-27 5:28 PM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca> [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>  
**Subject:** RE: [REDACTED] - packaging required

Hi [REDACTED]

My colleague Anders will assist the shipping and he is confused about the request from your side. He will try to help with your request but may need your clarification.

Best regards,

Qiu

**From:** [REDACTED]  
**Sent:** 2019-02-27 5:15 PM  
**To:** Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hello,

Client has requested you provide certificate approval since inner DG package provide by you, template now attached.

Best Regards,



Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]  
**Sent:** 26 February 2019 11:53  
**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC)  
**Subject:** RE: [REDACTED] - packaging required

Hi,

That is correct, it should be PI620. How in-depth would you like for the pick up process I don't really think we can make a video, maybe pictures?


Thanks!  
Anders

**From:** [REDACTED]  
**Sent:** 2019-02-20 7:22 PM  
**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>  
**Subject:** RE: [REDACTED] - packaging required

Hello Andre,

Client is asking the PI should be 620 instead of 650, please advise if this ok, They are also requesting to take picture or video of whole pick-up process.

Regards





Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** Friday, March 29, 2019 3:38 PM

**To:** OCNML DIR / LNMCO (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); [REDACTED]@gov.mb.ca'; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca'; NML Specimen Receiving (PHAC/ASPC); 'erap.guelph@canada.ca'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC); [REDACTED]@gov.mb.ca

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC)

**Subject:** ERAP Notification 2019-02 - Shipment Ready for Departure

The Risk Group 4 shipment has been picked up by [REDACTED] from the NML in Winnipeg.

The tracking number for this shipment is [REDACTED]. This shipment is en-route to China via Toronto.

Please note - once this shipment departs from the airport in Toronto, ERAP teams can stand down.

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*


Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-29 8:03 AM

**To:** Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.asp.aspc@canada.ca>; CSCHAH SES (PHAC/ASPC) <phac.cschah.ses.aspc@canada.ca>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <phac.ocnml.logistics-

logistique.lnmco.aspc@canada.ca>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca>; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <oc\_nml\_ocd\_group@phac-aspc.gc.ca>; NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; erap.guelph@canada.ca; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment will be routed through Toronto and is scheduled to depart from the NML in Winnipeg today between 13:30-14:00. Further details will be provided when available.

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

**IMPORTANT:** This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

**IMPORTANT :** Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-28 9:34 AM

**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.aspc@canada.ca](mailto:phac.nml.sp-lnm.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca>; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood


Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433  
\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433  
\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nlm.sp-lnm.asp.aspc@canada.ca](mailto:phac.nlm.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca; [oc\\_nml\\_oed\\_group@phac-aspc.gc.ca](mailto:oc_nml_oed_group@phac-aspc.gc.ca); NML Specimen Receiving (PHAC/ASPC) <[phac.nlm.specimen.receiving.aspc@canada.ca](mailto:phac.nlm.specimen.receiving.aspc@canada.ca)>  
**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>  
**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health


Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433  
 \*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433  
 \*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**Fleury, Teresa (PHAC/ASPC)**

---

**From:** guelph, erap (PHAC/ASPC)  
**Sent:** 2019-03-31 3:20 PM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Cc:** Cornelisse, Mette (PHAC/ASPC); Nichani, Anil (PHAC/ASPC); Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC)  
**Subject:** Re: ERAP Notification 2019-02 - Shipment Ready for Departure

Acknowledged. Thankyou.

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** Sunday, March 31, 2019 4:08 PM  
**To:** Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); [REDACTED]@gov.mb.ca'; PHAC.F OC\_NML\_OCD\_Group F.ASPC; NML Specimen Receiving (PHAC/ASPC); guelph, erap (PHAC/ASPC); [REDACTED]@gtaa.com'; Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC); [REDACTED]@gov.mb.ca  
**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC)  
**Subject:** Re: ERAP Notification 2019-02 - Shipment Ready for Departure

Please be advised that the RG4 shipment has departed Toronto for Beijing on flight AC031.

ERAP teams can now stand down.

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** Friday, March 29, 2019 6:16 PM  
**To:** Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); [REDACTED]@gov.mb.ca'; PHAC.F OC\_NML\_OCD\_Group F.ASPC; NML Specimen Receiving (PHAC/ASPC); guelph, erap (PHAC/ASPC); [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC); [REDACTED]@gov.mb.ca  
**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC)  
**Subject:** Re: ERAP Notification 2019-02 - Shipment Ready for Departure

The RG4 shipment is scheduled to depart Toronto for Beijing on Air Canada Flight AC 031 on March 31 at 14:45 EDT.

The Air Canada Cargo air waybill tracking number for this shipment is [REDACTED]

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** Friday, March 29, 2019 3:38 PM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike

(PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); [REDACTED]@gov.mb.ca'; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca'; NML Specimen Receiving (PHAC/ASPC); 'erap.guelph@canada.ca'; [REDACTED]@gtaa.com'; Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC); [REDACTED]@gov.mb.ca  
**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC)  
**Subject:** ERAP Notification 2019-02 - Shipment Ready for Departure

The Risk Group 4 shipment has been picked up by [REDACTED] from the NML in Winnipeg.

The tracking number for this shipment is [REDACTED]. This shipment is en-route to China via Toronto.

Please note - once this shipment departs from the airport in Toronto, ERAP teams can stand down.

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433  
 \*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433  
 \*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Government of Canada  
 Gouvernement du Canada

Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-29 8:03 AM

**To:** Gilmour, Matthew (PHAC/ASPC) <matthew.gilmour@canada.ca>; Guercio, Steven (PHAC/ASPC) <steven.guercio@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <phac.nml.sp-lnm.aspc@canada.ca>; CSCHAH SES (PHAC/ASPC) <phac.cschah.ses.aspc@canada.ca>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <phac.ocnml.support-soutien.lnmco.aspc@canada.ca>; [REDACTED]@gov.mb.ca'; [REDACTED]@gov.mb.ca'; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <oc\_nml\_ocd\_group@phac-aspc.gc.ca>; NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; erap.guelph@canada.ca; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com;

██████████@gtaa.com; ██████████@gtaa.com; ██████████@gtaa.com; ██████████@gtaa.com;  
 ██████████@gtaa.com

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment will be routed through Toronto and is scheduled to depart from the NML in Winnipeg today between 13:30-14:00. Further details will be provided when available.


Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433  
 \*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433  
 \*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) On Behalf Of OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-28 9:34 AM

**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.asp.aspc@canada.ca](mailto:phac.nml.sp-lnm.asp.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; ██████████@gov.mb.ca' ██████████@gov.mb.ca>; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <phac-aspc.hpoc-cops@canada.ca>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood

Operations Centre Director

National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.aspc@canada.ca](mailto:phac.nml.sp-lnm.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca; [oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca); NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*


Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**Fleury, Teresa (PHAC/ASPC)**

**From:** Fernando, Lisa (PHAC/ASPC)  
**Sent:** 2019-04-01 1:45 PM  
**To:** OCNML DIR / LNMCO (PHAC/ASPC); [REDACTED] Leung, Anders (PHAC/ASPC); [REDACTED] Qiu, Xiangguo (PHAC/ASPC)  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Thank you to everyone who was involved in this shipment. We very much appreciate everyone's work.  
 Lisa

**From:** Tschetter, Lorelee (PHAC/ASPC) <lorelee.tschetter@canada.ca> **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)  
**Sent:** 2019-04-01 1:25 PM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Thanks so much for letting us know everything has safely arrived.  
 Have a wonderful week!  
 Lore

**Lorelee Tschetter**

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433  
 \*\*\*\***new e-mail** [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (204) 789-2021 / Cellulaire: (204) 292-0827  
 \*\*\*\* **nouveau courriel** [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne

pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.

**From:** [REDACTED]  
**Sent:** 2019-04-01 12:56 PM  
**To:** Leung, Anders (PHAC/ASPC) <anders.leung@canada.ca>; [REDACTED]; Qiu, Xiangguo (PHAC/ASPC) <xiangguo.qiu@canada.ca>  
**Cc:** NML Specimen Receiving (PHAC/ASPC) <phac.nml.specimen.receiving.aspc@canada.ca>; Drebot, Mike (PHAC/ASPC) <mike.drebot@canada.ca>; Fernando, Lisa (PHAC/ASPC) <lisa.fernando@canada.ca>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <phac-aspc.ocnml-dir-lnmco@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>; [REDACTED]  
**Subject:** 回复: [REDACTED] - packaging required

DEAR ALL,

The package has just arrived in Wuhan safely.

We would like to express our sincere gratitude to you all for the continuous support, especially Dr. Qiu and Anders! Thanks a lot!! Looking forward to our further cooperation in the future.

Best wishes,  
 [REDACTED]

----- 原始邮件 -----

主题 : Re: [REDACTED] - packaging required

发件人 : "Leung, Anders (PHAC/ASPC)"

收件人 : [REDACTED], "Qiu, Xiangguo (PHAC/ASPC) ", [REDACTED]

抄送 : "NML Specimen Receiving (PHAC/ASPC) ", "Drebot, Mike (PHAC/ASPC) ", "Fernando, Lisa (PHAC/ASPC) ", "OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) ", "Lau, Allan (PHAC/ASPC) " [REDACTED]

Hi all,

Don went in and got the number but it is [REDACTED] Thanks Don, you're our hero!!

Thanks!

Anders

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** [REDACTED]  
**Sent:** Friday, March 29, 2019 5:08 PM  
**To:** [REDACTED] Leung, Anders (PHAC/ASPC); Qiu, Xiangguo (PHAC/ASPC); [REDACTED]  
**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]  
**Subject:** RE: [REDACTED] - packaging required

Hello Leung/Andres,

All exports to china need shipper's exporter# on MAWB, please advise.

Regards

[Redacted]

[Redacted]

[Redacted]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** [Redacted]

**Sent:** 29 March 2019 17:55

**To:** 'Leung, Anders (PHAC/ASPC)'; [Redacted] Qiu, Xiangguo (PHAC/ASPC); [Redacted]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [Redacted]

**Subject:** RE: [Redacted] - packaging required

Hello Leung,

Its booked on Air Canada flight AC-031 Mar 31<sup>st</sup> from Toronto to Beijing under AWB# [Redacted]

Regards

[Redacted]

[Redacted]

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]

**Sent:** 29 March 2019 17:36

**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Mainly an update to our collaborators in China, but the package has left the NML about an hour ago. We will be tracking the package over the weekend and hopefully it arrives safely in Beijing. Thanks everyone for assisting in this package.

Anders

**From:** [REDACTED]

**Sent:** 2019-03-29 9:49 AM

**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED] Qiu, Xiangguo (PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; Fernando, Lisa (PHAC/ASPC) <[lisa.fernando@canada.ca](mailto:lisa.fernando@canada.ca)>; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.ocnml-dir-lnmco@canada.ca](mailto:phac-aspc.ocnml-dir-lnmco@canada.ca)>; Lau, Allan (PHAC/ASPC) <[allan.lau@canada.ca](mailto:allan.lau@canada.ca)>; [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Thank you,

[REDACTED]

Play your part in saving the environment - please do not print this e-mail unless absolutely necessary

**From:** Leung, Anders (PHAC/ASPC) [<mailto:anders.leung@canada.ca>]

**Sent:** 29 March 2019 10:43

**To:** [REDACTED] Qiu, Xiangguo (PHAC/ASPC); [REDACTED]

**Cc:** NML Specimen Receiving (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); Fernando, Lisa (PHAC/ASPC); OC NML-Dir-LNM

CO, PHAC-ASPC (PHAC/ASPC); Lau, Allan (PHAC/ASPC); [REDACTED]

**Subject:** RE: [REDACTED] - packaging required

Revised version attached.

**From:** [REDACTED]

**Sent:** 2019-03-29 9:29 AM

**To:** Leung, Anders (PHAC/ASPC) <[anders.leung@canada.ca](mailto:anders.leung@canada.ca)>; [REDACTED]; Qiu, Xiangguo

(PHAC/ASPC) <[xiangguo.qiu@canada.ca](mailto:xiangguo.qiu@canada.ca)>; [REDACTED] <<span lang="EN-CA" style="color:#



(PHAC/ASPC); guelph, erap (PHAC/ASPC); [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com';  
 [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com';  
 [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com'; [REDACTED]@gtaa.com';  
 [REDACTED]@gtaa.com'; Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC);  
 [REDACTED]@gov.mb.ca

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC)

**Subject:** Re: ERAP Notification 2019-02 - Shipment Ready for Departure

The RG4 shipment is scheduled to depart Toronto for Beijing on Air Canada Flight AC 031 on March 31 at 14:45 EDT.

The Air Canada Cargo air waybill tracking number for this shipment is [REDACTED]

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** Friday, March 29, 2019 3:38 PM

**To:** OCNML DIR / LNMCO (PHAC/ASPC); Gilmour, Matthew (PHAC/ASPC); Guercio, Steven (PHAC/ASPC); Drebot, Mike (PHAC/ASPC); NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC); CSCHAH SES (PHAC/ASPC); OCNML Logistics / Logistique LNMCO (PHAC/ASPC); OCNML Support / Soutien LNMCO (PHAC/ASPC); [REDACTED]@gov.mb.ca'; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca'; NML Specimen Receiving (PHAC/ASPC); 'erap.guelph@canada.ca'; [REDACTED]@gtaa.com'; Kernaghan, Shaun (PHAC/ASPC); Cook, Matthew (PHAC/ASPC); [REDACTED]@gov.mb.ca

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC)

**Subject:** ERAP Notification 2019-02 - Shipment Ready for Departure

The Risk Group 4 shipment has been picked up by [REDACTED] from the NML in Winnipeg.

The tracking number for this shipment is [REDACTED]. This shipment is en-route to China via Toronto.

Please note - once this shipment departs from the airport in Toronto, ERAP teams can stand down.

Operations Centre Director  
 National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
 Canadian Science Centre for Human and Animal Health  
 Public Health Agency of Canada - Government of Canada  
 Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*

Directeur du centre des opérations  
 Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
 Centre scientifique canadien de la santé humaine et animale  
 Agence de la santé publique du Canada  
 Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
 Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential

information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Government  
of Canada

Gouvernement  
du Canada

Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-29 8:03 AM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.aspc@canada.ca](mailto:phac.nml.sp-lnm.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca [REDACTED]@gov.mb.ca>; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>; [erap.guelph@canada.ca](mailto:erap.guelph@canada.ca); [REDACTED]@gtaa.com; [REDACTED]@gtaa.com [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com [REDACTED]@gtaa.com; [REDACTED]@gtaa.com; [REDACTED]@gtaa.com

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment will be routed through Toronto and is scheduled to depart from the NML in Winnipeg today between 13:30-14:00. Further details will be provided when available.

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* nouveau courriel [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre

Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Government  
of Canada

Gouvernement  
du Canada

Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-28 9:34 AM

**To:** OCNML DIR / LNMCO (PHAC/ASPC) <[PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA)>; Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.aspc@canada.ca](mailto:phac.nml.sp-lnm.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca' [REDACTED]@gov.mb.ca>; 'oc\_nml\_ocd\_group@phac-aspc.gc.ca' <[oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca)>; NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification 2019-02 - Pending Shipment

Please be advised that the Risk group 4 shipment is now scheduled to depart from the NML in Winnipeg on Friday, March 29<sup>th</sup>. Further details will be forwarded once the courier has provided the routing information and tracking number for this shipment.

Heidi Wood

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\*new e-mail [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*

Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses  
Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada

Téléphone (866)262-8433

\*\*\*\* **nouveau courriel** [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Canada

**From:** Wood, Heidi (PHAC/ASPC) **On Behalf Of** OCNML DIR / LNMCO (PHAC/ASPC)

**Sent:** 2019-03-27 1:31 PM

**To:** Gilmour, Matthew (PHAC/ASPC) <[matthew.gilmour@canada.ca](mailto:matthew.gilmour@canada.ca)>; Guercio, Steven (PHAC/ASPC) <[steven.guercio@canada.ca](mailto:steven.guercio@canada.ca)>; Drebot, Mike (PHAC/ASPC) <[mike.drebot@canada.ca](mailto:mike.drebot@canada.ca)>; NML Special Pathogens / LNM Agents Pathogènes spéciaux (PHAC/ASPC) <[phac.nml.sp-lnm.aspc@canada.ca](mailto:phac.nml.sp-lnm.aspc@canada.ca)>; CSCHAH SES (PHAC/ASPC) <[phac.cschah.ses.aspc@canada.ca](mailto:phac.cschah.ses.aspc@canada.ca)>; OCNML Logistics / Logistique LNMCO (PHAC/ASPC) <[phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca](mailto:phac.ocnml.logistics-logistique.lnmco.aspc@canada.ca)>; OCNML Support / Soutien LNMCO (PHAC/ASPC) <[phac.ocnml.support-soutien.lnmco.aspc@canada.ca](mailto:phac.ocnml.support-soutien.lnmco.aspc@canada.ca)>; [REDACTED]@gov.mb.ca; [oc\\_nml\\_ocd\\_group@phac-aspc.gc.ca](mailto:oc_nml_ocd_group@phac-aspc.gc.ca); NML Specimen Receiving (PHAC/ASPC) <[phac.nml.specimen.receiving.aspc@canada.ca](mailto:phac.nml.specimen.receiving.aspc@canada.ca)>

**Cc:** HPOC-COPS, PHAC-ASPC (PHAC/ASPC) <[phac-aspc.hpoc-cops@canada.ca](mailto:phac-aspc.hpoc-cops@canada.ca)>

**Subject:** ERAP Notification - Pending Shipment

Please be advised that a Risk group 4 shipment will depart from the NML in Winnipeg on Thursday, March 28<sup>th</sup>. The shipment will be transported by [REDACTED] to China. Routing information is still pending for this shipment and will be provided when available.

Heidi Wood

Operations Centre Director  
National Microbiology Laboratory/ Infectious Disease Prevention and Control Branch  
Canadian Science Centre for Human and Animal Health  
Public Health Agency of Canada - Government of Canada  
Telephone (866)262-8433

\*\*\*\* **new e-mail** [PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNML-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

Directeur du centre des opérations  
Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses

Centre scientifique canadien de la santé humaine et animale  
Agence de la santé publique du Canada  
Téléphone (866)262-8433

\*\*\*\* **nouveau courriel** [PHAC.OCNMI-DIR-LNMCO.ASPC@CANADA.CA](mailto:PHAC.OCNMI-DIR-LNMCO.ASPC@CANADA.CA) \*\*\*\*\*

1015 Arlington Street, Emergency Operations Centre  
Winnipeg, Canada R3E 3R2

IMPORTANT: This email transmission is for use by the intended recipient and it may contain private and confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy, or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please contact the sender immediately by return email and then immediately delete this email including all attachments. Thank you.

IMPORTANT : Cette transmission de courriel électronique est pour l'usage par le bénéficiaire voulu et il peut contenir des informations privées et confidentielles. Si vous n'êtes pas le bénéficiaire voulu ou une personne responsable de livrer cette transmission au bénéficiaire voulu, vous ne pouvez pas dévoiler, copier, ou distribuer cette transmission ou prendre de l'action dans la confiance dessus. Si vous avez reçu cette transmission dans l'erreur, s'il vous plaît contacter l'expéditeur immédiatement par le courriel électronique de retour et immédiatement effacer alors ce courriel y compris tous attachements. Merci.



Government  
of Canada

Gouvernement  
du Canada

Canada

**From:** [Robertson, Catherine \(PHAC/ASPC\)](#)  
**To:** [Lau, Allan \(PHAC/ASPC\)](#)  
**Cc:** [Krishnan, Jay \(PHAC/ASPC\)](#)  
**Subject:** Re: Latest ERAP  
**Date:** 2019-04-03 2:48:18 PM

---

Thanks Allan,

I figured that. Apparently hPOC contacted them to let them know about ERAP.

Sent from my BlackBerry 10 smartphone on the Bell network.

---

**From:** Lau, Allan (PHAC/ASPC)  
**Sent:** Wednesday, April 3, 2019 1:24 PM  
**To:** Robertson, Catherine (PHAC/ASPC)  
**Cc:** Krishnan, Jay (PHAC/ASPC)  
**Subject:** RE: Latest ERAP

---

Hi Cathy,

I just phoned Andr anne and let her know some details about the shipment. She was wondering what was sent, where the samples went, if there was proper paperwork, if Matt and Steve knew about it, etc.

We didn't do anything wrong... just that because of the nature of the pathogens and where it was going they (the higher ups in PHAC) wanted to know if we did our due diligence.

Allan

---

**From:** Robertson, Catherine (PHAC/ASPC) <catherine.robertson@canada.ca>  
**Sent:** 2019-04-03 12:44 PM  
**To:** Krishnan, Jay (PHAC/ASPC) <jay.krishnan@canada.ca>; Lau, Allan (PHAC/ASPC) <allan.lau@canada.ca>  
**Cc:** Bonhomme, Andr anne (PHAC/ASPC) <andreeanne.bonhomme@canada.ca>  
**Subject:** Latest ERAP

Hi,

Can you ease give Andr anne a call regarding the recent ERAP shipment. She would like some information regarding our process and the pathogen.

Cathy

Sent from my BlackBerry 10 smartphone on the Bell network.

**From:** [Ashley, Don \(PHAC/ASPC\)](#)  
**To:** [Siddiqi, Shafquat \(PHAC/ASPC\)](#)  
**Subject:** FW: Shipping Req. for China Shipment  
**Date:** 2019-08-01 11:50:34 AM  
**Attachments:** [Certification of Biological Safety Laboratory Assurance-20180628.pdf](#)  
[request letter-20180628.pdf](#)  
[NML-TA-18-0480 Signed.pdf](#)  
[Commercial Invoice.xls](#)  
[Shippers-Declaration-Column-Format-Fillable.pdf](#)  
[Shipping Contents.docx](#)  
[NML Shipping Req.pdf](#)

---

**From:** Leung, Anders (PHAC/ASPC)

**Sent:** 2019-03-27 12:19 PM

**To:** NML Specimen Receiving (PHAC/ASPC) ; Letkeman, Paul (PHAC/ASPC) ; Pushka, Mike (PHAC/ASPC) ; Ashley, Don (PHAC/ASPC)

**Cc:** Drebot, Mike (PHAC/ASPC) ; Fernando, Lisa (PHAC/ASPC) ; Qiu, Xiangguo (PHAC/ASPC) ; OC NML-Dir-LNM CO, PHAC-ASPC (PHAC/ASPC)

**Subject:** Shipping Req. for China Shipment

Hi Mike/Paul/Don,

Please see attached shipping requisition, sorry for filling everyone's mailbox with these files again.

Thanks!

Anders Leung

National Microbiology Laboratory | Laboratoire national de microbiologie

Public Health Agency of Canada | Agence de la santé publique du Canada

Canadian Science Centre for Human and Animal Health | Centre scientifique canadien de la santé humaine et animale

Winnipeg, Canada R3E 3R2

[anders.leung@canada.ca](mailto:anders.leung@canada.ca)

Telephone | Téléphone 204-789-7665 / Facsimile | Télécopieur 204-789-2140

Government of Canada | Gouvernement du Canada








| Date of Export: March 28 2019                                                                                                                                                              |                          | Export References (i.e. order no., invoice no., etc.):                                                                                                                   |                  |             |            |                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-------------|------------|-----------------------------|
| Shipper/Exporter (complete name and address):<br>Dr. Xiangguo Qiu (204-784-7548)<br>Public Health Agency of Canada - NML<br>1015 Arlington Street<br>Winnipeg, Manitoba, Canada<br>R3E 3R2 |                          | Recipient (complete name and address):<br>[Redacted]<br>Chinese Academy of Sciences - Wuhan Institute of Virology<br>Xiao Hong Shan No.44<br>Wuhan, Hubei, China, 430071 |                  |             |            |                             |
| Country of export:                                                                                                                                                                         | Canada                   | Importer - if other than recipient (complete name and address):                                                                                                          |                  |             |            |                             |
| Country of manufacture:                                                                                                                                                                    | Canada                   | Country of ultimate destination:                                                                                                                                         |                  |             |            |                             |
| China                                                                                                                                                                                      |                          | International Air Waybill Number: [Redacted]                                                                                                                             |                  |             |            |                             |
| Currency: CAD                                                                                                                                                                              |                          | Full Description of goods                                                                                                                                                |                  |             |            |                             |
| Marks/Nos                                                                                                                                                                                  | No. of Type of packaging | Qty                                                                                                                                                                      | Units of measure | Weight      | Unit value | Total Value                 |
|                                                                                                                                                                                            | 1                        | 24                                                                                                                                                                       | vials            | 0.5 kg      | \$2.50     | \$60.00                     |
|                                                                                                                                                                                            |                          | 6                                                                                                                                                                        | vials            | 1 kg        |            |                             |
|                                                                                                                                                                                            |                          |                                                                                                                                                                          |                  | 0.5 kg      | \$2.50     | \$15.00                     |
|                                                                                                                                                                                            |                          |                                                                                                                                                                          |                  | 15 kg       | \$0.00     | \$0.00                      |
|                                                                                                                                                                                            |                          |                                                                                                                                                                          |                  | Total 16 kg |            | Total Invoice Value \$75.00 |

I declare all the information contained in this invoice to be true and correct

Signature of shipper/exporter (type name and title and sign)  Date: 27-Mar-2019

Research Scientist, Special Pathogens  
 Dr. Xiangguo Qiu

Check One  
 FOB  
 C&F  
 CIF

|                                                                                                                                                                                  |                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                              |               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| <b>Shipper</b><br>Dr. Xiangguo Qiu (204-784-7548)<br>Public Health Agency of Canada - NML<br>1015 Arlington St.<br>Winnipeg, Manitoba, Canada, R3E 3R2                           |                                                                     | <b>Consignee</b><br>Chinese Academy of Sciences - Wuhan Institute of Virology<br>Xiao Hong Shan No. 44<br>Wuhan, Hubei, China, 430071                                                                                                                                                                                                                                                                        |               |
| Air Waybill No. [REDACTED]<br>Page 1 of 1 Pages<br>Shipper's Reference No. (optional)                                                                                            |                                                                     | Two completed and signed copies of this Declaration must be handed to the operator.                                                                                                                                                                                                                                                                                                                          |               |
| <b>TRANSPORT DETAILS</b><br>This shipment is within the limitations prescribed for:<br>PASSENGER AND CARGO AIRCRAFT <b>XXX</b><br>(delete non-applicable)                        |                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                              |               |
| <b>WARNING</b><br>Failure to comply in all respects with the applicable Dangerous Goods Regulations may be in breach of the applicable law, subject to legal penalties.          |                                                                     | Airport of Departure (optional):<br>Airport of Destination (optional):                                                                                                                                                                                                                                                                                                                                       |               |
| <b>NATURE AND QUANTITY OF DANGEROUS GOODS</b>                                                                                                                                    |                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                              |               |
| Shipment type: (delete non-applicable)<br>NON-RADIOACTIVE <b>X</b> <del>HAZARDOUS</del>                                                                                          |                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                              |               |
| <b>Dangerous Goods Identification</b>                                                                                                                                            |                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                              |               |
| UN or ID No.                                                                                                                                                                     | Proper Shipping Name                                                | Class or Division (subsidiary hazard)                                                                                                                                                                                                                                                                                                                                                                        | Packing Group |
| UN 2814                                                                                                                                                                          | Infectious substance, affecting humans (Ebola virus, Henipah virus) | 6.2                                                                                                                                                                                                                                                                                                                                                                                                          |               |
| UN1845                                                                                                                                                                           | Dry Ice                                                             | 9                                                                                                                                                                                                                                                                                                                                                                                                            |               |
| 620                                                                                                                                                                              | 30 vials x 0.5 ml<br>TOTAL 15 ml<br>1 fibreboard box                | 9 kg                                                                                                                                                                                                                                                                                                                                                                                                         | Overpack used |
| 954                                                                                                                                                                              |                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                              |               |
| Additional Handling Information ERP#: ERP2-0000 1<br>24 Hr Number CANUTEC: 613-996-6666 ERAP Duty Officer: 1-866-262-8433<br>Person Responsible: Dr. Xiangguo Qiu (204-784-7548) |                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                              |               |
| Name of Signatory<br>Dr. Xiangguo Qiu<br>Date March 29, 2019<br>Signature (See warning above)                                                                                    |                                                                     | I hereby declare that the contents of this consignment are fully and accurately described above by the proper shipping name, and are classed, packaged, marked and labelled/placarded, and are in all respects in proper condition for transport according to applicable international and national governmental regulations. I declare that all of the applicable air transport requirements have been met. |               |

SHIPPER'S DECLARATION FOR DANGEROUS GOODS



Shipping Contents (2 vials of each virus ~500 ul per vial total ~15 ml)

1. Ebola Makona

C05

C07

C15

2. Mayinga

3. Kikwit

4. Ivory Coast

5. Bundibugyo

6. Sudan Boniface

7. Sudan Gulu

8. MA-Ebov

9. GP-Ebov

10. GP-Sudan

11. Hendra

12. Nipah Malaysia

13. Nipah Bangladesh

|                                       |                               |
|---------------------------------------|-------------------------------|
| Technical Name                        | Ebola virus and Henipah virus |
| Quantity/Volume per Primary Container | 0.5mL                         |
| Number of Primary Containers          | 30 vials                      |

**Complete inventory of items being shipped:** Please attach list if not enough space  
 Include any and all chemical solutions, their concentration as well as related MSDS from the manufacturer or MSDS Online Database

**Origin of Biological Pathogen or Toxin:**  
 Domestic  International  
*Note: Refer to SES-WI-052 Obtain Transfer Letter or Complete SES-F-052A*

**Description of Material:** Please select all that apply

Chemical  Radiological  Proficiency Panel  
 Toxins  Other  
 Culture  Nucleic Acids  Recombinant Material  Tissue  
 Antibody  Antigen  Blood Product  Cells  
 RG2\*  RG3\*\*  RG4\*\*  Bacteria  Virus  Prion  Non-infectious

**Preferred Courier:**  
 Account Number: [Redacted]  
 Originator Acting as Courier:

Telephone Number: [Redacted] Email: [Redacted]

Prov./State: Hubei Country: China Postal/Zip Code: [Redacted]  
 Address: [Redacted] City: Wuhan

Receiving Lab Name: Chinese Academy of Sciences  
 Name of Receiver: [Redacted]

**Recipient:**  
 C12 Laboratory  C13/4 Laboratory\*\*  
 \*Compliance Letter No. [Redacted] \*\*Certification ID No. NML-TA-18-0480  
 Domestic  International  
*Note: Refer to item 3.4 of SES-WI-068*

**NOTE: Person Responsible must have knowledge and expertise related to contents and would be contacted in case of emergency relating to the shipment**

Room Number: [Redacted] Telephone Number: [Redacted]  
 Name: [Redacted] Title: [Redacted]

**Person Responsible:** Please check box if same as Originator

Room Number: H2140 Telephone Number: (204) 784-7548  
 Name: Dr. Xiangguo Qiu Department: Special Pathogens

**Originator Information:**  
 Requested Ship Date: (YYYY-MM-DD) 2019-03-29

**NML Shipping Requisition** DELIVERED APR 02 2019

ALL FIELDS IN RED BOXES ARE REQUIRED

Public Health Agency of Canada / Agence de la santé publique du Canada

Internal Use Only

SHIPPED MAR 29 2019

Shipping Request Form

Form# MED-F-013A-1

Issue Date: 2014-12-02

1. Has your supervisor been notified and agreed to the outgoing shipment?  YES  NO
2. For biological pathogens or toxins, is a transfer letter required?  
(See SES-WI-068 for information)  YES (please attach)  NO
3. Are other special permits required?  
(See SES-WI-068 for information)  YES (please attach)  NO
4. Is the material being sent under (as part of) an agreement?  
(If unsure, please contact the Office of Business Development and Intellectual Property at Ext. 2120)  YES (please attach)  NO
5. Is a commercial invoice or B13A required?  
(If unsure, please contact Shipping and Receiving at Ext. 2046)  YES (please attach)  NO

## 6. Special handling Instructions?

 Dry Ice Cold Packs Room Temp. Other:

7. For items from CL3 and CL4: Please describe the method of physical or chemical treatment used to decontaminate the inside and outside of the sealed container (Provide SOP number if applicable)

## Other comments or important information:

Originator signature (not required if emailed)

Date (YYYY-MM-DD)

**ALL SPECIMENS MUST BE IN SPECIMEN SHIPPING ROOM (R1130) BY NOON**All biological material sent via Specimen Shipping must:

- Be in appropriate leak-proof primary containers. Example, O-ring cryovials, tubes must be wrapped with Parafilm
- Include an inventory list and all required documentation.

Completed Shipping Requisitions Required:

48 hours for Domestic shipment  
5 business days for International shipments  
5 business days for Proficiency Panels

Room Temp: Thursday at noon  
Domestic:  
Dry Ice: Wednesday at noon  
Cold Pack: Thursday at noon

Cut off for shipping specimens:

Within the City: Daily by 2 pm  
International:  
Dry Ice: Monday at noon  
Cold Pack: Tuesday at noon

In case of an emergency shipment, please contact Ext. 6091 and we will do our best to accommodate.

Please use "EMAIL" button to send COMPLETED FORM TO SPECIMEN SHIPPING if you wish to use their service for packaging and labelling.

If you have any questions in regard to shipping specimens, please contact Specimen Shipping at EXT. 6091/6096 or via email at [nml.specimen.receiving@phac-aspc.gc.ca](mailto:nml.specimen.receiving@phac-aspc.gc.ca)Important Disclaimers:**Please note that obtaining transfer letters or any other special permits will be responsibility of the Originator.****A copy of the Shipping Requisition must be left with Specimen Shipping or Shipping and Receiving for ALL shipments regardless of if the originator is acting as the courier**

NML-TA-18-0480

ENTERED OCT 26 2018

Title: NML Transfer Application for Pathogens and Toxins  
Date Issued: 2017-02-08

Form #: SES-F-052A-8

| TRANSFEROR                                                                 |                                                                                                                                                                 |
|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Section Head/<br>Designate:                                                | David Safronetz                                                                                                                                                 |
| Contact Person:                                                            | Xiangguo Qiu                                                                                                                                                    |
| NML Location:                                                              | <input checked="" type="checkbox"/> CSCHAH<br>1015 Arlington St. Winnipeg, MB, R3E 3R2                                                                          |
|                                                                            | <input type="checkbox"/> Guelph<br>110 Stone Rd West, Guelph, ON, N1G 3W4                                                                                       |
|                                                                            | <input type="checkbox"/> Lethbridge<br>225089 Township Road 9-1, Lethbridge, AB,<br>T1J 3Z4                                                                     |
|                                                                            | <input type="checkbox"/> JCWIDRC<br>745 Logan Ave, Winnipeg, MB, R3E 3L5                                                                                        |
|                                                                            | <input type="checkbox"/> St. Hyacinthe<br>3400 boul Casavant Ouest, St. Hyacinthe, QC, J2S 8E3                                                                  |
|                                                                            | <input type="checkbox"/> Other: <a href="#">Click here to enter text</a>                                                                                        |
| Department/Unit:                                                           | Special Pathogens Program                                                                                                                                       |
| Telephone:                                                                 | 204-784-7548                                                                                                                                                    |
| Origin of Material                                                         | <input checked="" type="checkbox"/> Domestic                                                                                                                    |
|                                                                            | <input checked="" type="checkbox"/> Imported                                                                                                                    |
| Import Permit or<br>Transfer Letter No.:                                   | P14-3865 (Makona), P05670 (MA-Zebov) P-05100 (ass.<br>Ebola), P15000 (Bebov), P05978 (Hendra), P05671 (Nipah)                                                   |
| Risk Group / Material<br>(select all that apply)                           | <input type="checkbox"/> RG2 <input type="checkbox"/> RG3 <input checked="" type="checkbox"/> RG4 <input type="checkbox"/> SSBA <input type="checkbox"/> Prions |
| Pathogen/Toxin and<br>description of<br>material(s)* to be<br>transferred: | Ebola and Henipah viruses                                                                                                                                       |

| RECIPIENT LABORATORY                                                                                 |                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Recipient Name:                                                                                      | [REDACTED]                                                                                                                                                                                                   |
| Biosafety Officer (BSO):                                                                             | [REDACTED]                                                                                                                                                                                                   |
| BSO Email:                                                                                           | [REDACTED]                                                                                                                                                                                                   |
| BSO Telephone No.:                                                                                   | [REDACTED]                                                                                                                                                                                                   |
| Organization Name:                                                                                   | Chinese Academy of Sciences                                                                                                                                                                                  |
| Department:                                                                                          | Wuhan Institute of Virology                                                                                                                                                                                  |
| Street Address:                                                                                      | Xiao Hong Shan No.44                                                                                                                                                                                         |
| City:                                                                                                | Wuhan                                                                                                                                                                                                        |
| Prov/State:                                                                                          | Hubei                                                                                                                                                                                                        |
| Country:                                                                                             | China                                                                                                                                                                                                        |
| Postal/Zip Code:                                                                                     | [REDACTED]                                                                                                                                                                                                   |
| Telephone:                                                                                           | [REDACTED]                                                                                                                                                                                                   |
| Fax:                                                                                                 | [REDACTED]                                                                                                                                                                                                   |
| For Canadian Labs: Room number(s) where Prions, RG3, RG4 or SSBA<br>material will be used or stored: | <a href="#">Click here to enter text</a>                                                                                                                                                                     |
| Work Intent:                                                                                         | Stock virus culturing                                                                                                                                                                                        |
| <input type="checkbox"/> Canadian<br>Laboratory                                                      | <input type="checkbox"/> CL2 <input type="checkbox"/> CL2+ <input type="checkbox"/> CL3 <input type="checkbox"/> CL4                                                                                         |
| PHAC Licence No.:                                                                                    | <a href="#">Click here to enter text</a>                                                                                                                                                                     |
| Expiry Date:                                                                                         | <a href="#">Click here to enter text</a>                                                                                                                                                                     |
| <input type="checkbox"/> Exempt***                                                                   |                                                                                                                                                                                                              |
| <input checked="" type="checkbox"/> International<br>Laboratory**                                    | Include one or more of the following documentation                                                                                                                                                           |
|                                                                                                      | <input checked="" type="checkbox"/> Recipient Import Permit <input checked="" type="checkbox"/> Laboratory Certification Letter                                                                              |
|                                                                                                      | <input checked="" type="checkbox"/> Documentation from Institute Director or Biosafety Officer indicating they meet the biosafety and biosecurity requirements<br>to work safely with the exported material. |

Examples of materials include (but are not exclusive): cultures, various infected specimens (serum, blood, tissue, etc), toxins, etc.

\*\* For international laboratories: an import permit, certification letter, or documentation from the institute's Director or Biosafety Officer indicating they meet the biosafety and biosecurity requirements to work safely with the exported material is required.

\*\*\* Canadian laboratories receiving proficiency panels with RG2 or RG3 samples that mimic primary specimens for instrument calibration, performance determination of a laboratory's tests or measurements, and/or monitoring a laboratory's continuing performance may be exempt from PHAC licencing requirements.

## Recipient acknowledgement:

1. PHAC makes no representations and gives no warranties of any nature, expressed or implied, with respect to the Materials.
2. The material shall be used only on the Recipient's premises and under suitable containment conditions.
3. [REDACTED] shall have no liability to the Recipient.

|                                                         |                   |                                              |                   |
|---------------------------------------------------------|-------------------|----------------------------------------------|-------------------|
| [REDACTED]                                              | 2018-10-18        | [REDACTED]                                   | 2018-10-26        |
| Recipient Signature                                     | Date (YYYY-MM-DD) | Transferor Signature                         | Date (YYYY-MM-DD) |
| [REDACTED]                                              | 2018-10-18        | [REDACTED]                                   | 2018-10-26        |
| Recipient's BSO / Director/<br>Licence Holder Signature | Date (YYYY-MM-DD) | Transferring BSO (or<br>designate) Signature | Date (YYYY-MM-DD) |

RECEIVED OCT 26 2018